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Invariant natural killer (iNKT) cells are a small subset of innate cells which express 
an invariant T cell receptor and NK surface molecules and recognize glycolipid 
antigen presented by CD1. iNKT cells have shown potent anti-tumour properties 
when stimulated with the iNKT cell agonist α-galactosylceramide (αGalCer) in 
murine models. However iNKT cell based immunotherapies have proved 
disappointing in phase I and II clinical trials to date. Humans have a wider 
repertoire of CD1-restricted T cells compared to mice. These CD1 restricted T cells 
are poorly defined in healthy human blood. In this study we investigated the 
reactivity of CD1 in human blood, we identified in healthy donors the majority of 
CD1 reactive T cells were identified as iNKT cells. We optimized a method to 
readily isolate and expand iNKT from human peripheral blood. 
iNKT stimulated with synthetic analogues of αGalCer have shown the potential as 
tailored adjuvants for dendritic cell (DC) based immunotherapy. We established a 
system to test the immunostimulatory ability of iNKT cell analogues on DC 
maturation and function. A novel αGalCer analogue α-S-GalCer stimulated iNKT 
cell line to produce a Th1 biased cytokine response and lyse tumour cells. α-S-
GalCer stimulated iNKT cells also induced maturation of monocyte derived DC, 
and stimulated DC to produce Th1 biased cytokines. Furthermore DC matured by 
α-S-GalCer stimulated iNKT cells proliferated allogeneic T cell and induced Th1 
cytokine production by the same. 
This data shows that the novel iNKT agonist α-S-GalCer stimulates iNKT cell lines 
in a Th1 biased fashion and induces DC maturation. Results suggests that α-S-
GalCer may possibly be an attractive adjuvant for iNKT/DC based cell 
immunotherapy for malignancies and viruses. 
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1.1 Overview of innate and adaptive immunity 
 
The human body has evolved a highly complex group of defence mechanisms that are 
collectively termed the immune system. The function of the immune system is to 
protect the host from a vast array of micro-organisms such as viruses, bacteria, fungi, 
large parasitic eukaryotes known generally as parasites, and cancer. Classically the 
immune system has been divided into two separate but interlinked sections; the innate 
and adaptive immune systems. The innate immune system recognizes conserved 
components of pathogens using germ-line encoded receptors and responds rapidly. The 
adaptive immune system discriminates individual antigens using rearranged antigen 
receptors and elicits a specific response resulting in memory. In no way is this 
separation of the two systems literal. The innate and adaptive arms coexist and in many 
ways are complementary to each other, each relying on many shared response 
mediators (Rouse & Sehrawat, 2010, Einsenbarth & Flavell, 2009). 
 
The immune system provides defence on a number of levels and is composed of a 
number of important organs and several different cell types. All cellular components of 
the blood including the cells of the immune system develop from pluripotent 
haematopoietic stem cells in the bone marrow. White blood cell or leukocyte 
production proceeds along two main pathways of differentiation. The myeloid lineage 
produces polymorphonuclear leucocytes and monocytes as well as other elements of 
the blood such as erythrocytes and platelets.  The lymphoid lineage develops from a 
common lymphoid progenitor stem cell and gives rise to the lymphocytes; T 
lymphocytes, B lymphocytes, and natural killer cells (NK cells). 
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1.2 Pathogen recognition by the innate immune system 
 
The outstanding feature of innate immunity is its direct recognition of molecular 
structures that signify danger. These include conserved motifs on microbes known as 
pattern associated molecular patterns (PAMPs) and host molecules which are induced 
or released in response to infection, damage or tumour transformation. Cells of the 
innate immune system use a restricted set of germ-line-encoded pattern recognition 
receptors (PRRs) such as Toll-like receptors (TLR), scavenger receptors, collectins & 
ficolins, RIG I like receptors (RLRs) and proteins containing nucleotide 
oligomerization domains (NOD) (Einsenbarth & Flavell, 2009). These receptors 
recognize PAMPs but recognition is not pathogen specific. Unlike the adaptive immune 
response, activation of innate cells is immediate and of relatively short duration. There 
is no immunological memory associated with the innate immune response (Pichlmair & 
Reise de Sousa, 2007, Iwasaki & Medzhitov, 2004). 
 
Collectins and ficolins are C-type lectin containing molecules which recognise a 
variety of PAMPs and act as opsonins, ultimately leading to complement assisted 
phagocytosis (Holmskov et al, 2003). Scavenger receptors such as mannose receptor 
allow phagocytes to bind directly to microbes; they consist of a similar C-type lectin 
domain to that found in collectins & ficolins. Mannose receptors recognise mannan in 
bacterial cell walls and are expressed by mononuclear phagocytes. NOD like receptors 
(NLRs) are intracellular receptors for PAMPs such as microbial wall degradation 
products. Ligation of these receptors induces the production of pro-inflammatory 
cytokines from cells such as the macrophage. 
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The TLR family of receptors are a group of PRRs which upon binding by a PAMP can 
activate the innate immune response. Transmembrane protein Toll was first identified 
in studies examining development in the fruit fly, Drosophila melanogaster. It was 
noted that mutants lacking Toll were very susceptible to infection by gram positive 
bacteria and fungi (Lemaitre et al, 1996). Subsequent studies identified the presence of 
Toll like receptors in mammals. There are at least 11 identified TLRs to date in humans 
(Garantziotis et al 2008). Cellular expression of TLR repertoires varies and TLRs can 
be surface expressed (TLR 1, 2, 4, 5, 6 and 11) or intracellular (TLR 3, 7, 8 and 9). 
TLR expression levels can be modulated by inflammatory stimuli (interferons). The 
ligands recognised by TLRs range from lipopeptides (TLR 1, 2 and 6), double stranded 
RNA (TLR 3), lipopolysaccaride (TLR 4), flagellin (TLR 5), single stranded RNA 
(TLR 7 & 8), CpG (TLR 9), prokaryotic DNA (TLR 10) to profiling like protein (TLR 
11) (Table 1). Upon ligation, signaling through adaptor molecules and expression of 
transcription factors such as NFκB leads to cellular activation (O’Neill & Bowie, 2007) 
(Figure 1.1). 
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Table 1: Adapted from Garantziotis et al 2008. 
 
 
 
Human Toll like receptors are transmembrane proteins characterised by multiple copies 
of a leucine rich motif in their extracellular domains and a shared TIR (Toll IL-1 
receptor) motif in their cytoplasmic domain (O’Neill & Bowie, 2007). Cell activation 
via the transcription factor NFκB is initiated by the TIR domain. Upon TLR4 ligation, a 
conformational change occurs in the TIR domain allowing it to bind one of a family of 
five adaptor proteins which also contain TIR domains. This results in the activation of 
kinases and transcription factors, for example NFκB, is liberated from its inhibitor IκB 
and NFκB is rendered free to translocate to the nucleus (O’Neill & Bowie 2007).  
TLR4 signalling is detailed as an example of TLR signalling due to the presence of this 
pathway in dendritic cell (DCs) activation, detailed in later chapters (Figure 1.2). TLR4 
signalling utilizes the MyD88, TRIF, TRAM or Mal dependant pathway, which recruits 
IRAK-4 and TRAF-6, leading to the activation of TAK1. Activated transforming 
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growth factor-β kinase 1 (TAK1) activates the IKK complex which catalyses IκBs. 
IκBs are degraded allowing translocation of NFκB in the nucleus and the transcription 
of innate immune response genes such as those encoding pro-inflammatory cytokines. 
This is one of several TLR-4 pathways (Kawai and Akira, 2006). 
 
Figure 1.1: The TLR signalling pathways. Schematic outlining nine TLR signalling 
pathways. Diagrams shows pathways utilized by surface expressed TLRs 1, 2, 4, 5 
and 6 and intracellular TLRs 3, 7, 8 and 9. Reproduced from Bowie & O’Neill, Nat 
Imm 2007. 
Chapter 1: Introduction 
 
 7 
 
 
Figure 1.2: The TLR 4 signalling pathway. TLR4 utilizes the MyD88 dependant 
pathway, which recruits IRAK-4 and TRAF-6, leading to the activation of TAK1. 
Activated transforming growth factor-β kinase 1 (TAK1) activates IKK complex 
which catalyses IκBs. IκBs are degraded allowing translocation of NFκB in the 
nucleus. Adapted from Kawai and Akira, 2006. 
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1.3 Physical barriers and defensins  
 
The first line of defence is provided by a physical barrier to the outside world and 
invading micro-organisms provided by the epithelia. Epithelial cells are held together 
in tight junctions which effectively form a tight seal against the external environment. 
Epithelia make up the skin, and the linings of the gastrointestinal, respiratory and 
urogenital tracts. The internal epithelia are known as the mucosal epithelia, due to their 
secretion of a thick viscous fluid called mucus. This mucus contains many 
glycoproteins called mucins. Mucus lines the epithelia and prevents micro-organisms 
binding to the surfaces. Mucus also aids in the expulsion of invading micro-organisms 
via the mucus flow driven by the beating of the epithelial cilia. Epithelial cells also 
produce several microbicidal chemicals such as histatins, cryptdins and defensins. 
Defensins are secreted in the small intestine in the form of α-defensins, and in the 
respiratory, urogenital tracts and skin in the form of β-defensins. Defensins’ mode of 
function is cationic which disrupts the cell walls of invading micro-organisms (Metz-
Boutigue et al, 2010). 
 
1.4 Effector cells of the innate immune system 
 
The principle cells of the innate immune system include cytotoxic lymphocytes (NK 
cells and some T cells), toxin releasing cells of myeloid origin such as mast cells, 
basophils and eosinophils, and the phagocytic cells of the monocyte/macrophage 
lineage, neutrophils and myeloid dendritic cells (DCs). 
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1.4.1 Phagocytes - Neutrophils and Macrophages 
 
Macrophages are long lived tissue resident phagocytes that mature from circulating 
monocytes before migrating to tissues. In contrast, neutrophils are released from bone 
marrow in response to infection and abundantly found in the blood.  
 
1.4.2 Eosinophils, basophils and mast cells 
 
Eosinophils and basophils have noted importance in defence against parasitic infection 
and are recruited to sites of allergic inflammation. Tissue resident mast cells at these 
sites release many chemical mediators, triggering local inflammation and blood vessel 
dilation in response to allergens. 
 
1.4.3 Natural killer cells 
 
NK cells are bone marrow derived lymphocytes which share a common progenitor with 
T cells. They play key roles in the recognition and destruction of virus infected and 
tumour cells, and in early cytokine secretion (Lanier 1998). NK cells are potent 
cytotoxic effector cells, and have been shown to lyse target cells in vitro and in vivo. 
NK cells also rapidly produce cytokines (e.g IFN-γ) which promote Th1 biased 
immune responses. Various stimuli are required to activate NK cell functions and this 
process is tightly regulated by inhibitory receptors and cytokines that control and 
potentially terminate the NK response. NK function is therefore regulated by a balance 
of signals which are stimulatory or inhibitory. Virus infected and tumour cells are 
identified by changes in MHC class I expression and NK cells can recognise and kill 
cells with altered MHC class I expression (Karre et al 1986), (Ljunggren & Karre, 
1990). 
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NK cells have several families of receptors which provide the activatory/inhibitory 
signals that control NK function. NK1.1 is a member of C-type lectin superfamily 
found on the surface of murine NK cells. Ligation of NK1.1 activates cytokine 
production and cytotoxicity by some NK cells. Murine NK cells also express the Ly49 
family of receptors which recognise MHC class I (human homologue called HLA) and 
activate or inhibit NK cell cytotoxicity. Another stimulatory/inhibitory receptor found 
on murine and also human NK cells is the CD94/NKG2 receptor complex which 
recognise the non-classical MHC class I molecule HLA-E. Mice and humans have four 
NKG2 receptors which can recognise HLA class I molecules and some associate with 
CD94 which acts as a chaperone for the surface expression of NKG2A and NKG2C. 
NKG2D and NKG2C have been reported to have stimulatory function, whereas the 
CD94/NKG2A complex is inhibitory (Lanier, 1998).  
 
Killer cell immunoglobulin like cell receptor (KIRs) genes encode glycoproteins of the 
Ig superfamily which bind HLA class I ligands in humans. There are 2 subsets of KIRs 
based on the number of domains in the extracellular region. KIR3D and KIR2D have 3 
and 2 domains respectively. The intracellular cytoplasmic tail can be long or short 
(KIR3DL or KIR3DS) and signals through these resulting in inhibition or stimulation, 
respectively, of the NK cell (Lanier, 1998). 
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1.4.5 Dendritic cells 
 
Dendritic cells (DCs) are professional antigen presentation cells (APC) and unique in 
their ability to induce a primary immune response resulting in immunological memory 
(Figure 1.4) (Banchereau & Steinman, 1998). DCs are considered the professional 
antigen presenting cells, because they possess the ability to carry a large antigen load. 
This ability to capture and process large quantities of antigen is paired with low rates of 
antigen degradation. DCs can induce qualitatively different adaptive immune responses 
(Palucka et al, 2007). 
 
 
Figure 1.4: Dendritic Cell: Electron microscope picture showing a mature dendritic 
cell interacting with a lymphocyte. Reproduced from University of California, San 
Diego. 
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Several subsets of DC exist in humans; plasmacytoid, thymic, LN resident, skin 
resident Langerhans cells and myeloid DCs (the focus of this work). Plasmacytoid DC 
arise from a lymphoid origin and are CD14 negative CD11c negative cells. They 
express intracellular TLRs 7 and 9 and are potent producers of type I interferons. DC 
progenitors are found in bone marrow and give rise to blood circulating precursors 
which home to the tissues where they reside as immature DCs (iDC) with high 
phagocytic capacities. Chemokines at sites of inflammation draw tissue resident iDC to 
the site of antigen (Ag) deposition. The dendritic cell proceeds to capture antigen by 
one of several methods; phagocytosis, receptor mediated endocytosis or 
macropinocytosis. PRR ligation and antigen capture by the iDC induces maturation of 
the cell; this involves the phenotypic and functional change from tissue resident Ag 
capture cell to APC (Banchereau & Steinman, 1998).  
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1.5 Effector cells of the adaptive immune system 
 
The adaptive immune response is mediated by T and B lymphocytes that express 
antigen specific receptors and display immunological memory. T lymphocytes and B 
lymphocytes derive from the bone marrow and undergo genetic rearrangement during 
development in order to select cells with diversity of receptors that are specific for 
antigen. T lymphocytes are distinguished from B lymphocytes firstly by their place of 
maturation during development. Both types originate in the bone marrow but T 
lymphocytes mature in the thymus where they are differentiate into CD4+ and CD8+ 
cells and are selected on the basis of their ability to recognize self HLA and to remain 
unreactive with self antigen. B cells on the other hand mature in the bone marrow and 
are stimulated by T cells, specifically CD4+ T helper cells to proliferate and secrete 
antibodies. Self-reactive B and  T cells, die by apoptosis and thereby the body prevents 
the development of autoimmune disorders. 
 
In the event that a pathogen or tumour successfully evades the innate immune defences, 
inflammation is not resolved and an adaptive immune response is initiated. Professional 
antigen presenting cells (APCs) such as dendritic cells are the important link between 
the innate and adaptive immune systems. Upon presentation of foreign antigen to 
complementary antigen receptors on T and B lymphocytes, they initiate clonal 
expansion and differentiation into effector T and B cells, the beginning of an adaptive 
immune response. 
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Activation or priming of the adaptive immune response is slow to develop but once 
activated infection is usually resolved and a state of immunological memory is 
established. This memory may last a lifetime and is the result of the pre-existence of 
populations of clonally expanded antigen specific lymphocytes known as immune 
memory effector cells. Immunological memory along with antigen specificity is a 
defining feature of the adaptive immune response. 
 
 
1.5.5 B cells 
 
B cells express an antigen specific receptor on their surface, the B cell receptor (BCR). 
The BCR is a immunoglobulin, composed of 2 identical light chains and 2 identical 
heavy chains, the genes specifying them are found in the 'V' (variable) region and the 
'C' (constant) region. In the heavy-chain 'V' region there are three segments; V, D and J, 
which recombine randomly, giving a massive repertoire of unique BCRs (Tonegawa et 
al, 1983).  
 
Upon binding of BCR to specific antigen, the B cell becomes activated and with signals 
from the T helper cell (Th cell) differentiates into an antibody secreting plasma cells 
(Reth & Wienands, 1997). The secreted antibodies are truncated BCRs with the same 
antigen specificity and function by neutralizing, opsonisation of targets for removal by 
phagocytes and activation of the complement system. B cells also function as antigen 
processing and presenting cells, although not as efficiently as the “professional” APC; 
the dendritic cell.  
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1.5.6 T cells 
 
T cells function by killing virus infected or tumour cells, and activating or regulating 
other cells of the immune system via the secretion of cytokines. There are several 
forms of T cells; cytotoxic, helper and regulatory, all express a cell surface T cell 
receptor which is specific for antigen. Classical T cells can be divided into 2 separate 
groups depending on the accessory molecules expressed; CD4 T helper cells and CD8 
cytotoxic T cells. CD4 T helper cells recognize MHC II (HLA in humans) molecules 
and have been divided into several groups including Th1, Th2, Tregs, Th17 cells. Th1 
cells are mainly involved in immunity against intracellular pathogens and tumors, and 
secrete IFN-γ and IL-2 amongst others. Th1 cells can also induce the production of 
antibody involved in macrophage activation. Th2 cells secrete IL-4, IL-5, IL-10 and IL-
13 and are mainly involved in B cell, neutralizing antibody, mast cell and eosinophil 
opsonisation immune responses. Regulatory T cells were the third defined subset of T 
cells described; the main populations are CD4+ cells which also express CD25 and the 
transcriptional regulator FOX-P3. As the name suggests they have a regulatory role and 
are associated with IL-10 and TGF-β secretion which inhibits the classical Th1 and Th2 
profiles (Bluestone, 2009). 
 
From 2003 to 2005 several groups reported a new lineage of T cells defined by the 
production of IL-17 (Aggarwal et al, 2003, Langrish et al, 2005, Park et al, 2005).  
This Th17 T cell subset was characterized in many studies as being CD4+ T cells 
which produce IL-17A (a member of the IL-17 cytokine family). The factors required 
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for Th17 polarization were identified as IL-6 and TGF-β with IL-21, with IL-23 needed 
for expanding and sustaining Th17 T cells. 
 
1.5.7 Cytokines 
 
Interferons are well known for their anti-viral, anti-proliferative and 
immunomodulatory functions. IFN-γ is the classical Th1 cytokine and has antiviral, 
immunoregulatory, and anti-tumour properties. Amongst the effects are: suppression of 
Th2 cell differentiation, the upregulation of MHC class II expression, increased antigen 
presentation and lysosome activity of macrophages, and the activation of NK cells. 
Interleukins 4 and 13 are described as Th2 cytokines and promote proliferation and 
development of B cells and IgE class switching during parasitic infection. It also leads 
to the upregulation of MHC class II. IL-10 is classed as a regulatory cytokine which 
has anti inflammatory functions. IL-10 mainly secreted by monocytes, DCs and 
regulatory T cells. IL-17 produced by Th17 cells induces the release of chemotactic 
factors for neutrophils and inflammatory mediators. IL-17 is highly pathogenic during 
the inflammation process, with opposite effects to those of the developmentally linked 
regulatory T cells (Awasthi & Kuchroo, 2009). 
 
1.5.4 Antigen recognition by T cells 
The TCR is a hetrodimer composed of 2 transmembrane glycoprotein chains. Both 
TCR chains have 'V' (variable) region which interacts with antigen, a 'C' (constant) 
region and a short hinge region, each chain has transmembrane domain. The vast TCR 
repertoire is made using VDJ recombination; as a result each TCR is specific for a 
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unique Ag. The concentration of TCR diversity occurs in both the Vα and Vβ CDR3 
loops. Structural data confirms that the CDR3 loops sit largely over the centre of the 
antigenic peptides (Davis et al, 1998). The transmembrane domain, has positive 
charges and these play important roles in the association with the invariant signaling 
molecule CD3 (Clevers et al, 1988). CD3 is composed of 3 chains; CD3γ, CD3δ, and 
CD3ε which form the CD3 complex and associate with ζ chain which is disulfide-
linked homodimer (Janeway et al, 2008). The ζ chain contains 3 immunoreceptor 
tyrosine-based activation motif (ITAM) regions and function in signal transduction and 
activation of signaling kinases (Samelson & Klausner,1992).  
 
TCRs respond to major histocompatibility complex (MHC) proteins loaded with 
peptide fragments of protein Ag. The loading of peptide antigen onto MHC molecules 
has been shown to be a highly regulated process, MHC class I (York & Rock,1996) and 
MHC class II (Cresswell, 1997) molecules use different pathways for the processing 
and loading of antigen. TAP and tapasin facilitate the loading of cytosolic peptide onto 
MHC class I in the endoplasmic reticulum (ER). Invariant chain (Ii) and HLA-DM 
catalyze the loading of endogenously processed peptide derivatives from extracellular 
antigen onto MHC class II molecules in lysosome like multivesicular compartments 
(MIIC). To stabilize the interaction between the TCR and antigen loaded MHC 
molecules, T cells have accessory molecules, CD4 and CD8 and depending which 
molecule is expressed determines cell effector functions. Both molecules bind sites on 
the MHC molecule and are required for effective response. CD4 is a single chain 
molecule composed of four immunoglobulin like domains. The intracellular portion of 
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CD4 is linked to signaling kinase (discussed later). CD4 recognizes MHC class II 
molecules and is expressed by T helper set of T cells. CD8 is a disulfide linked dimer, 
composed of an α and a β immunoglobulin like domain expressed by cytotoxic T cells 
(Figure 1.3). CD8 recognizes MHC class I molecules. The intracellular portion of CD8 
is linked to the same signaling kinase as CD4.  
 
Figure 1.3: The T cell receptor complex: Diagrammatic representation of the TCR 
and accessory molecules CD3, CD4 & CD8. CD3 has extracellular domains 
(rectangles) and 2 transmembrane ζ domains. Immunoreceptor tyrosine based 
activating motifs (ITAMs) are denoted in yellow. CD4 has 4 extracellular domains, 
whilst CD8 has 2 extracellular domains. 
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1.6 Initiation of adaptive immune responses 
 
 
1.6.1 Dendritic cell maturation 
 
Maturation of DCs is associated with several co-ordinated events including; the loss of 
endocytic/phagocytic receptors and the upregulation of MHC and T & B cell co-
stimulatory molecules such as CD40, CD80 and CD86 (Banchereau & Steinman, 
1998). Maturation results in the changes in the Ag processing compartments such as 
MHC compartments (Cella et al, 1997). Maturation also results in the induction and 
upregulation of receptors for chemokines such as CCL-2 (MCP-1), CCL3 (MIP-1α), 
CCL4 (MIP-1β), CCL5 (RANTES) which regulate DC trafficking to the lymphoid 
tissues and recruitment of DC progenitors. Maturation also results in chemokine 
secretion which recruits effector cells to the site of Ag capture (CCR7, CCL19, and 
CCL21) (Sozzani et al, 2005). Finally they undergo a change in morphology to a 
mature cell expressing the classical dendrite projections which earn the DC its name. 
 
The maturing DC migrates via the lymphatics to the lymphoid organs where it presents 
and cross-presents antigen to specific CD8+ and CD4+ T cells via MHC class I & II 
molecules repectively. During migration, internalized capture antigen is directed to 
specific MHC compartments (Sallusto & Lanzavecchia, 1994) for processing and 
loading onto MHC molecules. These loaded MHC molecules are quickly trafficked to 
the cell surface and remain stable and ready for T cell interaction for days.  
 
Mature dendritic cells (mDCs) express a unique repertoire of functional surface 
expressed molecules. Some are constitutively expressed on the immature DCs and are 
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up-regulated upon activation, others are absent on the iDC and expressed only on the 
mature form. DC maturation signals the change from immature antigen capturing cell 
to the mature antigen presenting form, and begins with the upregulation of MHC class I 
and II expression. The MHC molecules present antigen on the dendritic cell surface to 
T helper cells. This interaction provides “signal 1” (TCR-MHC-Ag) to the effector T 
cell. The induction of co stimulatory molecule expression is the next step of the DC 
maturation process and co-stimulatory molecules are essential to fully activate a naïve 
T cell response. If the dendritic cell provides signal 1 but no signal 2 to the responding 
T cell, the T cell will go into a state of unresponsiveness known as anergy (Janeway et 
al, 2008). CD80 and CD86 are co stimulatory molecules found on DCs, which are also 
known as the B7 molecules. They bind to the same pair of receptors, CD28 and 
cytotoxic T lymphocyte antigen-4 (CTLA-4). CD28 is constitutively expressed on the 
surface of T cells whereas CTLA-4 is up-regulated following T cell activation. CTLA-
4 has a 10-100 fold higher affinity for the B7 molecules.  Signalling through CD28 
results in T cell activation, in contrast signalling through CTLA-4 results in the 
inhibition of the T cell response (Greenwald et al, 2005, Alegre et al, 2001).  
 
CD40 is a member of the TNF-receptor superfamily found on monocytes, dendritic 
cells and B cells. The binding of CD40L on T helper cells to CD40 activates antigen 
presenting cells and ultimately T helper responses. CD40 is essential in mediating a 
broad variety of immune and inflammatory responses including T cell-dependent 
immunoglobulin class switching, memory B cell development, and germinal center 
formation (Van Kooten & Banchereau, 2000).  CD40 ligation results in the production 
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and secretion of IL-1, IL-6, IL-10 and IL-12 by DCs, and the upregulation of; CD54, 
CD80 and CD86 (Banchereau & Steinman, 1998). Interupting CD40-CD40L 
interaction during T cell and DC co-cultures in vitro results in reduction in T cell 
proliferation (Van Kooten & Banchereau, 2000). 
 
Once a DC encounters an effector cell, adhesion molecules bind and result in cell to 
cell contact. CD54, also known as intracellular adhesion molecule 1 (ICAM-1), is an 
adhesion molecule found on most leukocytes including monocytes and DCs. During 
interaction between DCs and T cells, CD54 binds weakly to LFA-1 on the T cell, upon 
TCR signal the affinity increases and the contact is prolonged between the 2 cells. 
(Springer, 1990, Janeway et al, 2008). 
 
CD83 is a member of the immunoglobulin (Ig) super-family with one V type Ig 
domain. It is expressed by human circulating and tissue resident DCs (Zhou & Tedder, 
1995, Zhou et al, 1992). The function of CD83 is unclear and a number studies are 
aiming to elucidate a ligand (Prazma & Tedder, 2008). High density CD83 expression 
is however recognised as a marker of DC maturation and correlates with the 
upregulation of HLA class II expression (Zhou et al, 1992). Monocyte derived DC 
(generated using GM-CSF and IL-4) express low levels of CD83 on the cell surface but 
upon activation upregulate the protein (Zhou & Tedder, 1996). 
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1.6.2 DC based immunotherapy 
 
The DC system is designed to shape the recognition repertoire of T cells, consisting of 
billions of different lymphocytes, each with distinct but randomly arranged antigen 
receptors. This repertoire in turn represents a virtually infinite ‘drug library’ for 
specific therapies that increase or decrease T cell function (Steinman & Banchereau, 
2007).  Due to this powerful ability of initiating specific immune responses, DCs have 
been targeted for immunotherapy (Figure 1.5). 
 
As well as priming naïve T cells for maturation into effector cells, DCs also have 
regulatory role for antigen activated T cells. Tolergenic DCs induce regulatory CD4+ T 
cells, and are described as partial or semi matured DCs, whereas fully matured DC are 
immunogenic. The decisive signal is hypotheised to be the release of proinflammatory 
cytokines from DCs (Lutz & Schuler, 2002). These tolerogenic DCs have the ability to 
block or delete T cells by signalling through inhibitory receptors such as PD-1 and 
CTLA-4 interactions. If deletion is avoided the selected T cell clone undergoes 
differentiation and elicits a specific response (Probst et al, 2005).  
 
The importance of DC in resistance to infection has been demonstrated in studies, 
where microbial antigens were injected in association with DC into mice, and the 
animals acquire adaptive immune responses specific to the antigen (Steinman & 
Banchereau, 2007). Vaccination of healthy volunteers with ex-vivo generated DCs that 
were pulsed with either the keyhole limpet hemocyanin protein, tetanus toxin or 
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influenza matrix protein, then subsequently activated, can lead to Ag specific immune 
responses (Dhodapkar et al, 1999, Dhodapkar et al, 2000). 
 
One of the main targets of DC-based immunotherapy has been on tumour therapy 
(Figure 1.5).  Tumours contain many potential antigens which can be loaded onto DCs 
with the aim to generate an adaptive immune response (Figdor et al, 2004, Banchereau 
& Palucka, 2005). Several approaches have been investigated; the in-vivo targeting of 
DC with antigen and adjuvant, anti-DC antibodies conjugated with antigen, and the ex-
vivo generation of DC loaded with antigen and injected into patients (Palucka et al, 
2007). Several studies have focused on the approach consisting of adoptive transfer of 
tumour antigen pulsed DCs, in a range of human cancers including colorectal cancer 
(Rains et al, 2001), melonoma (Palucka et al, 2006, Butterfield et al, 2008) and 
hepatocellular carcinoma (Palmer et al, 2009).  
 
To date DC vaccinations for tumour therapy has been somewhat disappointing and 
resulted in a failure to generate anti-tumour immune responses due to T cell anergy or 
induction of specific response but without the regression of the tumour (6 trials are 
outlined in a review by Palucka et al, 2007). Three possible reasons offered for this 
include (1) the generation of a weak T cell responses, where tolerance or a non 
protective T cell response is initiated, (2) altered trafficking of T cells or (3) inhibition 
of T cell responses by elements in the tumour micro-enviroment such as vascular 
endothelial growth factor (VEG-F) and transforming growth factor beta (TGF-β), 
which inhibit DC maturation and function (Palucka et al, 2007, Steinman & 
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Banchereau, 2007).  However the use of dendritic cells in conjunction with or as an 
adjuvant remains an attractive target for therapy especially in human cancers. This will 
be discussed in detail in section 1.11. 
 
Figure 1.5: DC adoptive transfer strategy: Schematic detailing DC adoptive transfer 
therapy. Monocytes are taken from patient and induced to differentiate into immature 
DC. The tumour lysate and maturation stimuli such as LPS, are cultured with the iDC, 
which is then infused back into the patient. Reproduced from Steinman & Banchereau 
Nat Imm 2008 
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1.7 Innate T cells 
Innate T cells are a small proportion of CD3+ T cells which are MHC (HLA) 
unrestricted and recognise conserved Ag. Innate like rapid activation is a defining 
feature of these subsets. The various subsets of innate T cells will be discussed in the 
forthcoming sections. 
 
1.7.1 Mucosal associated invariant T cells  
Mucosal associated invariant T cells (MAIT cells) are gut resident innate T cells. They 
express a semi invariant TCR (Vα19 Jα33 in mice and Vα7.2 Jα33 in humans) which 
recognises the monomorphic MHC class Ib molecule MR1. MAIT cells express NK 
cell surface markers such as CD161 and can produce multiple cytokines such as IFN-γ, 
IL-4, IL-5 and IL-10 (Godfrey, 2010, Lantz, 2010). 
 
1.7.2 γδ T cells 
 
γδ T cells are a subset of T cells which express a TCR composed of γ and δ chains as 
opposed to the conventional αβ arrangement. They account for 1-5% of peripheral T 
cells and 25-60% of gut T cells (Hayday, 2000). γδ T cells are innate like effector T 
cells which express a limited repertoire of TCRs but which include a subset of memory 
cells, a function not normally associated with innate immunity. Antigen recognition by 
the γδ TCR seems to be direct or through a non MHC molecule, and it occurs in the 
tissue, as γδ T cells are generally absent from the lymph nodes (Hayday, 2000). γδ T 
cells are predominantly CD8+ in the tissues and double negative for CD4 and CD8 in 
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the periphery although a minority are CD4+. The CD8 molecule on γδ T cells is 
composed of a CD8α homodimer opposed to heterodimers found in most αβ T cells 
(Hayday, 2000). 
 
Human γδ T cells can be broadly divided into 3 groups based on the Vδ chain selection. 
Vδ1 cells are mostly tissue resident and express a naïve phenotype. Studies into their 
function suggest a role in tumour surveillance (Eberl et al 2006). Vδ2 cells are unique 
to higher primates and account for the majority of peripheral γδ T cells. They are 
activated in an MHC-independent manner by non-peptide antigens such as 
phosphoantigens. This subset expands in response to bacteria and tumors and release 
cytokine (IFN-γ, TNF-α) and can kill bacteria and tumour cells. Vδ2 cells have also 
been observed to have characteristics of professional APC (Brandes et al 2005). Vδ3 
cells are found mainly in the liver (Kenna et al 2004). The exact function of Vδ3+ T 
cells is unknown but they are thought to recognize cytomegalovirus (Dechanet et al 
1999). 
 
1.7.3 Natural Killer T cells 
Natural Killer T (NKT) cells are innate T cell subsets which express a TCR and NK 
cell receptors. NKT cells recognise glycolipid antigen presented by the MHC like 
molecules CD1.   
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1.7.4 CD1 
CD1 molecules are a family of glycoproteins resembling major histocompatibility 
complex class 1 (MHC I) in overall structure, consisting of a transmembrane heavy 
chain composed of 3 domains; α1, α2 and α3 which associate with β2-microglobulin 
(Gumperz Traffic 2006).  The binding sites of CD1 molecules are deep hydrophobic 
pockets which bind lipids and glycolipids and present them to T cells (Zeng et al 1997) 
(Figure 1.6 A-C). 
 
CD1 isotypes have been found in all mammals examined to date. Humans express 5 
isoforms of CD1, while mice and rats have lost their CD1a, CD1b, CD1c and CD1e 
isoforms but have duplicated CD1d genes, CD1d1 and CD1d2 (Dascher & Brenner, 
2003) (Figure 1.7). Studies in chickens led to the indentification of a CD1 orthologue 
which suggests CD1 is evolutionary ancient, predating the divergence of birds and 
mammals (Miller et al 2005, Salomonsen et al, 2005).  
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Figure 1.6: Structure of CD1: (A) Crystal structure of the CD1d molecule with bound 
αlpha galactoslyceramide (αGalCer) showing the 3 α domains (blue) paired with a 
β2Microglobulin domain (Yellow). (B) Molecule and Lipid shown from the point of 
view of T cell (Koch et al, 2005). (C) Schematic showing the structure of a CD1 
molecule, showing the 3 α domains paired with a β2-microglobulin domain, and a 
transmembrane cytoplasmic tail. Redproduced from Gumperz 2006. 
 
 
 
Figure 1.7: CD1 gene organisation in humans and mice: Schematic representation 
of the location and orientation of the 5 human CD1 genes; CD1a-e, on human 
chromosome 1 and the duplicated murine CD1d genes on mouse chromosome 3. The 
direction of transcription is indicated by arrows. 
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Human CD1a-d function in the presentation of lipid derived antigen to CD1 restricted 
T cells. CD1e differs in its location and function; being an intracellular chaperone 
molecule (Angenieux et al 2000). Human CD1 molecules are split, based on sequence 
homology, into 2 groups termed group 1 and 2.  Group 1 CD1  molecules include 
CD1a, b and c whilst group 2 contains CD1d. Group 1 molecules are widely 
distributed, and are commonly used as markers for human DCs. Langerhans cells 
express CD1a and low levels of CD1c, but not CD1c or CD1d. Dermal DCs express 
CD1b and CD1d detected (Brigl & Brenner, 2004, Pena-Cruz et al, 2003, Gerlini et al, 
2001). CD1c and CD1d are expressed by circulating B cells (Brigl & Brenner, 2004, 
Exley et al, 2000). CD1d is expressed on monocytes, iDC and mDCs at low but 
functional levels. The in-vivo generation of monocyte derived DC results in a reduction 
of CD1d expression but remain functional (Spada et al, 2000, Brigl & Brenner, 2004). 
CD1d is also found on epithelial, hepatocytes and some parenchymal cells (Bleicher et 
al, 1990).  
 
1.7.5 Antigen processing and presentation by CD1 
 
The intracellular pathway taken by a CD1 isoform will ultimately determine the lipid 
processing and loading. Studies into this processing and loading have shown the CD1 
heavy chains are folded and assembled with β2-microglobulin in the endoplasmic 
reticulum (Sugita et al, 1997), by a mechanism which is dependant on calnexin and 
calreticulin but independent of  transporter associated with antigen processing (TAP) 
(Kang et al, 2002). From the ER the molecules are transported via the Golgi to the cell 
surface using the secretory pathway. The surface expressed molecules are then re-
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internalised through clathrin-coated pits (Sugita et al, 1999) and the different isoforms 
undergo different intracellular trafficking and processing pathways (Dascher et al, 
2002) as shown in figure 1.8.  
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Figure 1.8: CD1 trafficking pathways: Schematic showing the different CD1 
trafficking pathways. (A) CD1a is trafficked to the surface via the endoplasmic 
reticulum (ER) and recycled through the early endosome (se and ee). (B) CD1b is 
trafficked to the surface via the ER and recycles through the late endosome (le) and 
the MIIC compartments with the aid of the adaptor proteins (AP) 2 and 3. (C) CD1c 
traffics to the surface via the ER and recycles with the aid of AP2 through the ee and 
the le. (D) CD1d traffics with the aid of AP1 to the surface and subsequently traffics 
with the aid of AP2 through the le and MIIC compartments. (Reproduced from Brigl 
and Brenner, 2003) 
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The intracellular pathway selected appears to depend on the cytoplasmic amino acid 
sequence of CD1 (Sugita et al, 1996). The cytoplasmic tails of most isoforms contain 
tyrosine-based motifs of the pattern YXXZ, where Y is tyrosine, X is any amino acid 
and Z is a bulky hydrophobic amino acid (Sugita et al, 2004, Gumprez, 2006). CD1a is 
truncated and lacks this motif. CD1a finds its way to the early endosome, and 
subsequently traffics through the recycling endosome. The YXXZ motif of the other 
molecules bind adaptor proteins (AP). AP-2 directs the CD1b, CD1c and CD1d 
molecules to the early and late endosomes. CD1b associates with AP-3 and results in 
the molecule trafficking to the lysosomal compartment (Sugita et al, 2004). CD1b is 
the only human CD1 isoform which associates with AP-3 but a point to note is that 
murine CD1d also associates with AP-3 and can traffic to the lysosome. The endocytic 
compartments differ in pH resulting in differing antigen processing (Brenner, 2003). 
Studies into the trafficking of CD1 during DC maturation have shown CD1a, CD1b and 
CD1c localization doesn’t change between the immature and mature form (Cao et al, 
2002, van der Wel et al, 2003). Human CD1d unlike its murine homologue does not 
bind AP-3 so can not access the lysosomal compartments. However studies by Kang et 
al (2002) reported that human CD1d can sometime associate with MHC II molecules 
and end up in the lysosomal compartments. After DC maturation CD1d molecules may 
lose access to these compartments, resulting in altered presentation (Gumperz, 2006).  
 
Understanding the processing of intracellular lipids onto CD1 molecules raises the 
question; how are extracellular glycolipids internalized and processed? Studies have 
shown that antigen presenting cells (APCs) such as DCs can internalize lipid antigen 
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using their mannose receptors, and these antigens are successfully delivered to the 
endosomal compartments for loading onto CD1b (Prigozy et al, 1997). Van der Elzen 
et al (2005) reported that apolipoprotein E (ApoE) is the serum factor that binds lipids 
and mediates their uptake by DCs through the lipoprotein receptor for presentation by 
CD1 molecules CD1b, CD1c and CD1d. This is a possible route for foreign lipid or 
extracellular self lipid uptake.  
 
 
1.7.6 Lipid antigens that bind to CD1 molecules 
 
The repertoire of lipids which can be loaded successfully onto the different CD1 
molecules is an expanding area of research. The lipid tails which are loaded deep into 
the groove of the CD1 molecule can be composed of mycolic acids (Beckman et al, 
1994), diacylglycerols (Sieling et al, 1995), ceramides (Kawano et al, 1997), 
polyisoprenols (Moody et al, 2004), polyketides (Matsunaga et al, 2004), 
phthioceranate (Gilleron et al, 2004) or fatty acid chains (Moody et al, 2004). The 
length of these chains varies greatly and sometimes exceeds the capacity of the CD1 
molecule antigen binding groove. The greatest mismatch is CD1b which can present 
diacylglycerols, sphingolipids and polyacylated carbohydrates ranging in length from 
C12 to C80 (Moody et al, 1997, Shamshiev et al, 1999, Gilleron et al, 2004). The 
identification of the crystal structure of CD1b loaded with a glucose monomycolate 
(GMM) antigen by Batuwangala et al (2004) showed the C56 long chain occupied 
almost the entire groove which could optimally accommodate a lipid length of C60-C64 
(Cheng et al, 2006). Studies by Ulrichs et al have shown CD1b loaded with antigen 
with lipid length of C80 which exceeds the predicted capacity of CD1b (Ulrichs et al, 
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2003). Following up on these reports Cheng et al demonstrated that the lipid chains 
aren’t trimmed but the excess carbons protrude through a portal acting as a “trapdoor” 
in the binding groove of the CD1b molecule. The studies also identified low pH as an 
important factor in the formation of CD1b antigen complexes (Cheng et al, 2006). The 
successfully loaded CD1 molecules are trafficked to the surface for recognition by CD1 
restricted T cells. 
 
1.7.7 Lipid antigens presented to CD1 restricted T cells 
 
Glycolipid antigens contain a hydrophilic head and hydrophobic tails. The molecular 
structure of the CD1 molecule reveals an Ag-binding superdomain that contains 2 
pockets (A' and F') lined by hydrophobic residues which bind the lipid tails (Zeng et al, 
1997). The T cells restricted by CD1a, CD1b and CD1c express various TCR 
arrangements (Grant et al, 1999, Shamshiev et al, 1999, Shamshiev et al, 2002). CD1d 
restricted T cells can express an invariant or semi-invariant TCR. It has been proposed 
that the CDR3 loop of the TCR is the point of contact between the lipid glycosyl group 
and the TCR. CDR3 residue mutagenesis has confirmed that CD1 restricted T cell 
TCRs are responsible for recognition of lipid antigens presented by the CD1 family of 
molecules. Minor changes in the CDR3 loop of the TCR abrogated the ability of the 
TCR to respond to CD1 bound lipid antigen (Grant et al, 1999, Grant et al, 2002). 
 
Several classes of lipid antigens have been shown to be presented by CD1 molecules to 
specific T cells; mycolates, glycosphinolipids, phospholipids, sulfoglycolipids and 
lipopeptides (Figure 1.8) (Lawton &  Kronenberg, 2004). The first lipids shown to be 
recognized by CD1-restricted T cells were mycobacterial lipids. CD1b presents 
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mycolic acids found in Mycobacterium tuberculosis and Mycobacterium leprae cell 
walls. These mycolic acids include glucose monomycolates and lipoarabinomanan 
(Figure 1.9) (Beckman et al, 1994, Sieling et al, 1995, Moody et al, 1997). CD1c was 
also reported to present lipids found in mycobacterial cell walls, such as mannosyl-
phosphopolyprenols (Figure 1.9) (Moody et al, 2000). Gilleron et al reported a CD1 
dependant T cell lipid Ag derived from mycobacteria called diacylated sulfoglycolipid 
(Ac2SGL). Ac2SGL was found to be presented by both CD1b and CD1c molecules. In 
CD1 blocking experiments, the blocking of CD1b using anti-CD1b antibodies resulted 
in 70% reduction in secreted IFN-γ and cytotoxicity whilst blocking of CD1c using 
mAb resulted in 35% reduction. CD1a blocking did not affect IFN-γ secretion and 
cytotoxicity against mycobacterium infected cells (Gilleron et al, 2004). CD1a can 
present lipids from mycobacterial cell walls such as lipopeptides. The lipopeptide 
didhydroxymycobactin (DMM) is thought to be an intermediate in mycobactin 
synthesis and structural studies have shown the T cell recognizes both the tail and head 
of the lipid (Moody et al, 2004) (Figure 1.9). 
 
Many CD1a, CD1b and CD1c restricted T cells do not require exogenous antigens for 
their activation. CD1 restricted T cells can also recognize “self antigen” presented by 
CD1 molecules such as the gangioside GM1 (Figure 1.9) (Shamshiev et al, 1999).  
 
Microbial lipid antigen presented by CD1d is not as well documented; several 
microbial lipids such as lipoarabinomannan (LAM) and glycosyl-phosphatidylinositols 
(GP1) bind CD1d but do not elicit T cell responses (Burdin et al, 1998, (Joyce et al, 
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1998, Molano et al, 2000 and Procopio et al, 2002). CD1d can also present the 
autologus disialogangalioside (GD3) to a subgroup of human CD1d restricted T cells 
however GD3 is not expressed on normal human tissues but only on tumours of 
neuroectodermal origin. The responding cells have invariant TCR α chains (Vα14 Jα18 
in mice and Vα24 Jα18 in humans) also respond to α-galactosylceramide and iGb3, and 
are denoted invariant NKT cells (iNKT). iNKT cells will be discussed in a separate 
section.  
 
1.8 Invariant natural killer T cells 
 
1.8.1 iNKT cell history 
 
The term NK T cell was first published in 1995 by Taniguchi et al and was used to 
define a subset of mouse T cells that shared some characteristics with NK cells, such as 
surface expression of NK1.1. The term NKT cell is now applied generally to CD1 
restricted T cells which express a TCR and NK cell associated receptors. 
The identification of murine Vα14+ NKT cells was first reported in 1986 when Imai et 
al isolated cDNA encoding the Vα14 TCR chain from a suppressor T cell hybridoma 
(Imai et al, 1986). Several groups published studies describing distinct subsets of αβ 
TCR+ T cells in mice which lacked the expression of CD4 and CD8 (Budd et al, 1987, 
Fowlkes et al, 1987, Newman et al, 1987). Other studies confirmed that this population 
of αβ T cells expressed NK1.1 (Sykes et al, 1990). NK1.1 had been previously thought 
to be expressed exclusively by NK cells. Vα14 Vβ8 T cell hybridomas which expressed 
CD4 or were double negative for CD4/CD8 and NK1.1 were made by Lantz and 
Bendelac (J Exp Med 1994). 
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Figure 1.9: Microbial and Self glycolipid antigens: Structures of Microbial and self 
gylcolipids described in the literature; including the iNKT agonist iGb3.  
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Subsequently Bendelac et al showed that the antigen presentation molecule for these T 
cells was CD1 not MHC class II (Bendelac et al, 1995). Murine Vα14 NKT cells make 
up ~0.5% of circulating T cells, 2.5% of T cells in the spleen and up to 30% of T cells 
in the liver (Bendelac et al, 2007). 
 
In 1993, while screening for anti cancer agents, Kirin Pharmaceuticals reported the first 
isolation of alpha galactosylceramide (αGalCer) from marine sponge Agelas 
mauritianus (Natori et al, 1993) (Figure 1.10). αGalCer was shown to have anti tumour 
properties. This resulted in the synthesis of KRN7000, an αGalCer analogue (Morita et 
al, 1995). KRN7000 demonstrated the ability to bind murine and human CD1d 
molecules. In 1997 it was shown that CD1d molecules present this glycolipid, to NKT 
cells, which resulted in their subsequent activation (Kawano et al, 1997). αGalCer and 
the related studies will be discussed in detail in section 1.7.5. 
 
1.8.2 NKT cells development 
 
Studies into the development of murine NKT cells revealed that they appear to be 
selected by bone marrow derived cells expressing β2M and CD1d, and are most 
probably CD4+CD8+ thymocytes. These thymocytes express NK1.1 and a restricted 
set of αβ TCRs. These cells were CD4+ and CD4-8- but never CD8+, because the 
presence of CD8 caused them to be negatively selected. Thus, neither CD4 nor CD8 
contributes signals that direct their maturation into the CD4+ and CD4-8- lineages 
(Bendelac et al, 1994, Taniguchi et al, 1995). This population of NKT cells in mice is 
characterised by its expression of the invariant Vα14 Jα18 TCR and NK markers. 
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Vα14+ iNKT cells arise in the thymus in the perinatal period and do not reach 
significant numbers until 3 weeks after birth. These cells are absent from nude mice 
and from thymectomized mice. (Gapin et al, 2001, Benlagha et al, 2002 and Matsuda et 
al, 2008).  
 
Several factors are essential for NKT development. Targeted disruptions in the NFκB 
subunits showed NFκB p50 activation to be required for the maturation of NK1.1 
positive precursors to mature Vα14+ NK1.1+ NKT cells (Sivakumar et al, 2003, Stanic 
et al, 2004). The expression of the gene which inhibits IKK2 kinase is also required for 
the development of iNKT cells (Schmidt-Supprian et al, 2004). Vα14 iNKT cells also 
require the expression of the transcrition factor Tbet (originally found to be required for 
the induction of IFN-γ synthesis and Th1 immunity by T cells), and mice with induced 
deletions of T-bet, showed a stem cell intrinsic defect in Vα14+ NKT generation 
(Townsend et al, 2004). Vα14 cell precursors express the GM-CSF receptor which is 
critical for the Vα gene rearrangement necessary for generating the Vα14 TCR. Mice 
negative for the GM-CSF receptor showed a significant reduction in mature Vα14+ 
NKT cells (Sato H et al, 1999, Taniguchi et al, 2003). 
 
1.8.3 Human  iNKT cells 
 
Following on from the identification of murine populations of invariant NKT cells, 
CD1d reactivity and potent cytokine secretion by T cells which express the 
homologous Vα24 Jα18 co-expressed with Vβ11 TCR have been described (Porcelli et 
al J Exp Med 1993) (Dellabona et al J Exp Med 1994). Other subsets of CD1 restricted 
T cells which can be positive or negative for the  invariant Vα24 Jα18 TCR chain and 
Chapter 1: Introduction 
 
 40 
CD161 have been identified in humans and are commonly referred as NKT cells. Some 
NKT cells have even been shown to express γδ TCR (Cardell et al Exp Med 1995). 
Advances in the development of CD1 tetramers have also lead to the discovery of a 
population of Vα24 Jα18 NKT cells that do not express CD161 and are CD1d 
independent (Hammond et al, 1999, Matsuda et al, 2000).  
 
To classify these various NKT and NKT-like subsets, the nomenclatures type 1 and 
type 2 are used. Type 1 NKT cells are classical invariant Vα24 Jα18 TCR positive cells 
that are reactive to CD1d in the absence or presence of αGalCer. These cells can be 
double negative for CD4/CD8, CD4+ and CD8+ and are classically potent secretors of 
the cytokines IFN-γ and IL-4. Mature type I NKT cells express CD161, but this is 
downregulated after activation. Type II NKT cells are CD1d reactive but not αGalCer 
reactive T cells, expressing semi invariant TCRs, can be CD161 positive or negative 
and are potent secretors of cytokines (IFN-γ and IL-4) (Godfrey et al, 2004). 
 
1.8.4 Antigens recognised by iNKT cells 
 
The lack of a known natural ligand for human iNKT cells led to a search resulting in 
some controversy, and the identification of an agreed natural ligand is still awaited. In 
2004 Zhou et al reported the identification of the mammalian lysosomal 
glycospingolipid, termed isoglobotrihexosylceramide (iGb3), which was recognized by 
iNKT cells and resulted in their activation, expansion and the secretion of both IFN-γ 
and IL-4. The authors also reported that mice deficient in β hexosaminidase b 
(necessary for iGb3 synthesis) showed a significant reduction in Vα14+ NKT numbers 
(Zhou et al 2004). The eligibility of iGb3 as the natural ligand was refuted in a series of 
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publications in which it was reported that iGb3 could not be detected in mammals. 
Using highly sensitive HPLC, the only iGb3 detected was in the dorsal root ganglion 
(DRG) of mice. This study was backed up with the finding of normal iNKT 
development in iGb3 deficient mice, indicating that iGb3 is not necessary for iNKT 
selection (Speak et al 2007, Porubsky et al 2007).  
 
1.8.5 α-GalCer 
 
Currently the gold standard of iNKT ligands is αGalCer. αGalCer bound to murine and 
human CD1d molecules stimulate type I NKT cells to secrete large amounts of Th1 and 
Th2 cytokines  (IFN-γ and IL-4 respectively) along with a milieu of other immune 
modulating cytokines. Therapeutic activation of iNKT cells in mice using α-GalCer can 
be used to treat many viral, bacterial and parasitic infections, and promote tumour 
reduction/protection in many tumour models such as B16 melanoma model (Kawano et 
al 1997).   
 
 
Figure 1.10: Structure of Alpha galactosylceramide: Diagram showing the structure 
of Alpha galactosylceramide. Reproduced from Kawano et al 1997. 
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1.9 iNKT cell function 
 
As previously described the innate immune system responds rapidly to infection. The 
effectors functions of iNKT cells, cytotoxicity and cytokine production, are thought to 
be of particular importance in containing pathogen spread during initial stages of 
infection and while recruiting other cells in the development of an adaptive immune 
response. As the name suggest, iNKT cells are efficient killers, however natural 
cytotoxicity does not seem to be their main effector function (Godfrey et al 2002).  
 
1.9.1 Cytotoxicity mediated by iNKT cells 
 
Exley et al (J Exp Med 1998) reported that cytotoxicity by human iNKT cells is CD1d 
restricted and enhanced in vitro in the presence of αGalCer. Later studies confirmed 
that iNKT cells mediate CD1d restricted lysis of several tumour cell types. Tumour 
cells negative for CD1d were not killed by iNKT cells but after transfection with 
CD1d, the same lines where rendered susceptible (Metelitsa et al 2001). Kawano et al 
(PNAS 1998) reported αGalCer treated mice exhibited iNKT cell-mediated tumour 
target lysis in a CD1d and NK1.1 independent mechanism. Cytotoxicity was reported 
to be non-specific NK cell like killing, mediated by perforin. Concanamycin A (CMA) 
which inhibits perforin abrogated killing but blocking antibodies against CD1d, NK1.1 
and FAS-L did not (Kawano et al 1998). Nicol et al reported that CD1d expression by 
target cells increased their susceptibility to lysis by human Vα24+ iNKT cells but was 
not essential as several CD1d negative targets were killed by Vα24+ iNKT cell lines. 
CD1d independent killing by human iNKT cells, suggested the lack of CD94 
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expression and co-stimulation as part of the CD1d independent cytotoxicity 
mechanism. (Nicol et al 2000), and indeed the subsets reported in CD1d dependant 
studies by Exley et al and Metelitsa et al both expressed CD94. This indicates different 
effector functions for different iNKT subsets, defined by surface marker expression.  
 
Perforin is a cytolytic protein found in granules in the cytoplasm of cytotoxic cells such 
as iNKT, NK and cytotoxic T cells (CTL). Upon degranulation it inserts into the target 
cell membrane creating tubules or “pores” leading to cell death. Perforin is found in the 
cytoplasm of iNKT subsets and experiments by Metelitsa et al (2001) and Nicol et al 
(2000) demonstrated a reduction in iNKT cytotoxicity through the addition of 
concanamycin A, an inhibitor of perforin. Invariant NKT cells also express FAS ligand 
(FAS-L) which upon binding to FAS on a target cell, a death inducing complex is 
formed leading to apoptosis induced cell death. Stenger et al reported CD4 CD8  CD1 
restricted T cell cytotoxicity against bacteria infected targets that was mediated by Fas-
FasL interaction, whereas CD8+ cells killed targets via FAS-L independent mechanism 
(Stenger et al, 1997), these findings indicate that different iNKT cell subsets have 
different effector functions.  
 
1.9.2 iNKT cell cytokine production 
 
Functionally iNKT cells are best known for their ability to rapidly produce and secrete 
large amounts of cytokines (Yoshimoto et al 1994, Matsuda et al 2000, Kronenberg, 
2005). The cytokine profile varies in different iNKT subsets but can include cytokines 
varying from the classical Th1, Th2 and Th17 cytokines IFN-γ and IL-4 to IL-2, IL-5, 
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IL-6, IL-10, IL-13, IL-17, IL-21 tumour necrosis factor (TNF) and GM-CSF 
(Kronenberg, 2005).  
 
Inavriant NKT cells are most notable for their ability to produce both IFN-γ and IL-4. 
This ability is expressed by both human Vα24+ iNKT cells and murine Vα14+ iNKT 
cells (Exley et al, 1997, Chen & Paul 1997). Studies on pre activated iNKT cells have 
found mRNA for IL-4 and IFN-γ, demonstrating iNKT innate configuration to rapidly 
produce both cytokines (Stetson et al 2003, Matsuda et al 2003). Crowe et al reported 
that iNKT cells can produce IL-4 two hours after stimulation, and production lasts for 
up to 16 hours. IFN-γ was also produced within hours and was produced for 72 hours 
post stimulation (Crowe et al 2003). Gumperz et al reported two subsets of CD1d 
restricted T cells which differ in cytokine production. One is a CD4 negative iNKT cell 
which produced Th1 cytokines (IFN-γ and TNF-α), the second was a CD4 positive 
subset which produced both Th1 and Th2 (IL-4) cytokines (Gumprez et al 2002). 
 
This milieu of cytokines allows the iNKT cells modulate an immune response through 
activation of other innate cells such as NK cells and DCs and, T cells and B cells of the 
adaptive immune response (Metelitsa et al 2001). TCR signalling influences the 
cytokine profile, the best evidence for this is provided by the studies using profile 
biasing αGalCer analogues such as OCH, C20:2 and α-C-GalCer (discussed in detail in 
section 1.10.1). Currently it is not known how a specific response is elicited after TCR 
activation, many hypotheses have been provided, the most probable are based around 
TCR signal strength based on the interaction between the TCR and CD1 molecule. 
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These depend on the bound lipid structure, avidity and association with lipid rafts 
which will be discussed in detail later. Another possible explanation is that the cytokine 
response depends on the subset and phenotype of the iNKT cell involved (Park et al 
2005, Crowe et al 2005). 
 
Reciprocal interactions between murine iNKT cells and DCs have shown that IL-12 
production by DCs is essential for triggering NKT cell activation (Kitamura et al  
1999). The same investigations showed αGalCer activation of iNKT cells resulted in 
the expression of IL-12R the IL-12 receptor on iNKT cells. In a series of blocking 
experiments these studies showed that anti-IL12, anti-CD40 and anti-CD40L mAb 
treatment resulted in the loss of IFN-γ production by iNKT cells.  
 
 
1.9.3 iNKT cell transactivation of other immune cells 
 
Many studies have demonstrated that iNKT cells interact with and can activate/recruit 
many immune cells such as NK cells, macrophages, DCs, B cells and cytotoxic T cells. 
Recently the transactivation of neutrophils, regulatory T cells and γδ T cells have also 
been reported (Matsuda et al  2008) (Figure 1.11).  
 
Mouse iNKT cells have been reported to have NK like cytolytic activity against tumour 
cells in several early studies (Cui et al 1997, Kawano et al 1998). Subsequently it was 
shown that murine iNKT cells can activate NK cell proliferation and cytotoxicity in an 
IFN-γ mediated manner (Nakagawa et al 1998, Carnaud et al 1999, Eberl & Mac 
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Donald 2000. Metelitsa et al showed that purified human iNKT cells could also 
activate NK cell cytotoxicity. In a transwell system they showed that iNKT cells 
activated with α-GalCer secreted IFN-γ and IL-2 which mediated the NK activation 
and this was abrogated by the depletion of these cytokines from the system (Metelista 
et al, 2001). 
 
iNKT cells can also interact with B cells and can influence antibody responses. 
Experiments which used α-GalCer as adjuvant to protein antigen showed 1-2 log higher 
levels of antibody and also increased the frequency of memory B cells in mice lacking 
MHC class II. This was mediated through cytokine and CD40-CD40L interactions, and 
suggests that iNKT can substitute CD4+ Th cell interactions with B cells (Galli et al 
2007). The expression of CD1d on B cells is also required to stimulate iNKT cell 
enhanced antibody production (Lang et al 2008).  
 
Recently cross talk between iNKT cells and CD4+ CD25+ regulatory T cells was 
investigated and it was reported that iNKT cells can modulate regulatory T cells 
function in an IL-2 mediated manner. In experiments inducing nickel tolerance, CD4+ 
NKT cells were required to induce the generation of regulatory T cells. NKT cell 
deficent mice did not induce tolerance and failed to generate regulatory T cells. In a 
reciprocal interaction regulatory T cells can suppress iNKT activation in a cell contact 
depentant mechanism, as shown by blocking of ICAM-1 or separation of cells into 
transwell system. (La Cava et al 2006). 
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In 2007 Jin et al reported that iNKT cells and γδ T cells interacted in a synergistic 
manner in an airway hyper-responsiveness (AHR) model but the mechanisms were not 
elucidated. AHR was induced in T cell-deficient mice by small numbers of co-
transferred γδ T cells and invariant NKT cells, whereas either cell type alone was not 
effective (Jin et al, 2007). 
 
1.9.4 iNKT cell interactions with dendritic cells 
 
Several studies have reported extensive cross talk between dendritic cells and NKT 
cells (Brigl et al, 2003, Fujii et al, 2004, Munz et al, 2005). Murine iNKT cells have 
the ability to fully mature myeloid iDCs into MHC, CD80/CD86 expressing DCs, 
which can produce bioactive cytokines (IL-12 and IL-10) (Fujii et al, 2005). iNKT 
cytokines can induce DC maturation but CD40-CD40L interactions via iNKT-DC 
crosstalk is crucial for full activation of the DC and subsequent linking of innate and 
adaptive immunity (Fujii et al, 2004, Sporri & Reise-Sousa, 2005). Studies by Tomura 
et al demonstrated dendritic cell maturation and IL-12 production in response to 
αGalCer activated CD40L expressing CD4+ murine iNKT cells. Anti CD40L mAb 
inhibited the production of IL-12 indicating the necessity of CD40L. The same study 
reported that IL-12 release preceded IFN-γ and that IL-12 was required for IFN-γ but 
not IL-4 production, suggesting IL-12 favours Th1 type response (Tomura et al 1999). 
Yang et al reported that human Vα24+ iNKT cells exhibited the same cross talk and 
these cells select for a Th1 response through the production of IL-12. The study also 
showed that DC were susceptible to lysis by iNKT cells and the authors suggested that 
this was a feedback mechanism Yang et al 2001). 
Chapter 1: Introduction 
 
 48 
 
In 2002 Vincent et al reported that human self reactive CD1 restricted T cells can 
promote dendritic cell maturation by recognizing CD1 in the absence of foreign 
antigen. T cells reactive against all CD1 isoforms; CD1a, CD1b, CD1c and CD1d, 
stimulated DC maturation but with distinct mechanisms of co-stimulation (CD1a, 
CD1b CD1c required LPS, whilst CD1d required lipid antigen and CD40L), all 
resulting in IL-12 production by the DC. (Vincent et al 2002). Following up on this 
knowledge, a mechanism reported for iNKT activation by dendritic cells showed weak 
responses to CD1d self antigen which was amplified by DC produced IL-12 in 
response to microbial infection resulting in potent IFN-γ secretion (Brigl et al 2003).  
 
In 2005 Yue et al reported that mAb ligation of CD1d in the absence of iNKT cells 
could rapidly stimulate monocytes and DCs to produce IL-12. Blocking of IFN-γ 
produced by iNKT cells and the transcription factor NFκB using mAbs, showed that 
IFN-γ from iNKT enhanced IL-12 production by APC but wasn’t essential but that the 
transcription factor NFκB was essential for IL-12 production (Yue et al 2005). The 
iNKT/DC interaction has the potential to skew subsequent immune responses and 
reiterates the powerful potential of this interaction for immunotherapy. 
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Figure 1.11: NKT cell transactivation: Diagrammatic representation of immune cells 
that NKT cells activate or interact with directly or by cytokine factors. Adapted from 
Matsuda et al 2008. 
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1.10 NKT cells in disease 
 
After the identification of Vα14 iNKT cells in mice and their human Vα24 iNKT 
counterparts, studies into the function and role of this T cell subset revealed their 
involvement in numerous diseases including infectious and autoimmune disease and 
tumour surveillance and rejection.  
 
1.10.1 Infectious Disease 
 
The involvement of Vα14 iNKT cells in immunity against bacterial infection was 
examined in several infection models. Control and clearance of Mycobacterium 
tuberculosis (mTB) involves the formation of a granuloma, a vital step in the control of 
the infection. Studies into the control of mTB showed IFN-γ is involved in the 
formation of the granuloma (Altare et al 1998). A murine model of mTB granuloma 
showed the presence of Vα14 iNKT cells within the granuloma and the recruitment of 
iNKT was attributed to the presence of iNKT ligands in the bacterial cell walls. iNKT 
cell knockout mice did not form the granuloma so the formation was attributed to iNKT 
cells and IFN-γ (Apostolou et al 1999). However the protection against mTB is not 
primarily due to iNKT cells. This was shown in studies using CD1d and β2 
microglobulin knockout mice, the KO mice showed no difference in infection 
compared to wild type mice (Behar et al 1999, Sousa et al, 2000). 
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Kawakami et al showed that protection against the fungal pathogen Cryptococcus 
neoforman was due to IFN-γ from Vα14 iNKT cells. In Vα14 iNKT knockout mice the 
infection was sustained longer due to the limited early IFN-γ attributed to iNKT cells 
(Kawakami et al 2001, Kawakami et al 2001). 
 
Gonzalez-Aseguinolala et al reported that αGalCer activated Vα14 iNKT cells display 
potent anti-malarial activity. Sporozoite inoculated mice were treated with αGalCer 
during the intrahepatic stages of infection and this inhibited disease development 
(Gonzalez-Aseguinolala et al 2000). The timing of NKT cell activation was critical in 
infection clearance, the iNKT cell target stage of the malarial life cycle was restricted 
to the intrahepatic stage of infection. Anti-malarial activity was due to IFN-γ and the 
activity was elicited in the absence of conventional T cells, NK cells and B cells. 
 
Vα14 iNKT cells have also been reported to play a role in viral infection. In 2000 
Kakimi et al reported a protective function of iNKT cell in a hepatitis B virus 
transgenic mouse model. 24 hours after a single injection of αGalCer, IFN-γ and IFN-
α/β release by intrahepatic iNKT cells was detected and hepatitis B virus (HBV) 
replication was abolished. The recruitment of NK cells was also reported. In IFN 
knockout mice the abolishment of HBV replication was lost (Kakimi et al, 2000). 
αGalCer injection as an adjuvant for vaccination with HBV antigen resulted in the 
induction and proliferation of HBV specific CTLs. Blocking of CD40-CD40L by 
antibody showed that this mechanism of HBV specific responses are dependant on this 
interaction and also IL-2 (Ito et al 2008) 
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Several publications have reported that NKT cells are targeted by HIV-1 (Van der Vliet 
et al, 2002, Motsinger et al 2002, Sandberg et al, 2002). NKT subsets which express 
the CD4 receptor (targeted by HIV-1) and the co-receptor CCR5 are highly susceptible 
to infection (Motsinger et al, 2002). 
 
1.10.2 Autoimmune disease 
 
The link between iNKT cells and autoimmunity was first observed with the reduction 
of iNKT numbers in a murine lupus model. It was shown the transfer of iNKT cells 
delayed the disease progression (Mieza et al 1996). In the non obese diabetic (NOD) 
murine model, a reduction in Vα14 cell numbers was associated with progression to 
type 1 diabetes (Gombert et al, 1996). Following up on this study, several groups using 
CD1d knockout NOD mice, showed that the transfer of Vα14 iNKT cells into NOD 
mice prevented disease development (Baxter et al 1997, Hammond et al 1998). Over-
expression of Vα14+ iNKT cells only partially corrected the disease so it was noted 
that the protection was due to iNKT functionality and not cell quantity (Lehuon et al 
1998). Laloux et al reported that the loss of iNKT cell derieved IL-4 is an important 
factor in diabetes development in NOD mice (Laloux et al, 2001). Naumov et al (2001) 
reported that in the NOD murine model iNKT cell numbers are decreased in the 
pancreatic islets of NOD mice at the time of progression from peri-insulitis to invasive 
insulitis and diabetes. Administration of αGalCer ameliorated the development of 
diabetes in NOD female mice, and resulted in an accumulation of iNKT cells and 
myeloid DCs in the pancreatic lymph nodes (PLNs) but not the inguinal lymph nodes. 
Transfer of DCs from the PLN but not the inguinal lymph nodes to NOD female mice 
completely prevented diabetes. The authors concluded the immunoregulatory role of 
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iNKT cells is manifested by the recruitment of tolergenic DC to the PLN and inhibition 
of autoimmune inflammation. A later study by Chen et al showed that in response to 
soluble factor produced by the iNKT cells, DC accumulated in the PLN, and 
subsequently recruited pathogenic T cells and tolerized them thus preventing β cell 
destruction (Chen et al, 2005). In a study of human type 1 diabetes, the Th1 cell 
mediated damage of pancreatic β cells, was initially reported to be regulated by iNKT 
cells. The authors report a correlation between T1D and the loss of IL-4 produced by 
iNKT cells, suggesting that iNKT cell derived cytokine has a role in T1D (Wilson et al 
1999). 
 
1.10.3 Cancer 
 
The ability of iNKT cells to respond rapidly, to secrete IFN-γ and to transactive NK 
cells and DCs has led to the hypothesis that iNKT cells could be important in cancer 
therapy. In 1997 Kawano et al and Cui et al investigated the role of iNKT cells in a 
murine B16 melanoma model which metalizes to the liver. Using NKT knockout mice, 
it was shown the activation of iNKT resulted in the clearance of the tumour in an IL-12 
dependant manner. The clearance of tumour in Vα14 transgenic RAG knockout mice 
(which have iNKT cells but do not have conventional T cells) identified iNKT cells to 
be the effector cell population responsible. The studies also showed iNKT cell 
cytotoxicity was dependant on direct contact with CD1d, and that this activity was 
abrogated with the addition of the perforin blocking agent CMA (Kawano et al 1997).  
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The anti-metastastic effect of αGalCer in mice was further investigated by Smyth et al 
in 2002. Using gene targeted mice and blocking antibody treatments these authors 
showed that IFN-γ from NKT cells and NK cells was essential for the anti-metastastic 
effect of αGalCer. The authors also showed that IL-12 and IL-18 were required for 
optimal IFN-γ production but IL-4 was not needed for the anti-metastastic activity. 
 
In 2002 Crowe et al reported that adoptive transfer of NKT cells from wild type mice 
into Jα281 KO mice with methylcholanthrene induced fibrosarcoma inhibited tumour 
growth in the absence of αGalCer stimulation. The NKT cells were reported to have an 
immunosurveillance role, and recruited NK and CD8+ T cells. The mechanism of 
protection was CD1d dependant and IFN-γ was found to be the protective cytokine, 
since IFN-γ KO mice failed to inhibit tumour growth. The IFN-γ was produced by 
NKT cells as well as NK and CD8+ T cells. Perforin produced by non-NKT cells was 
also critical in inhibition of tumour growth (Crowe et al, 2002). 
 
NKT cells are also implicated in immunity against tumours in humans. CD1d/αGalCer 
dependent anti-tumour cytotoxicity by human Vα24 iNKT has been reported (Brossay 
et al 1998, Spada et al 1998). In 1999 Kawano et al reported that Vα24 iNKT kill 
tumour cells in vitro and that Vα24 iNKT cell numbers are reduced in cancers. iNKT 
cells from patients with malignant melanoma killed several tumour cell lines in a 
perforin dependant manner when activated with αGalCer. It was thus speculated that 
the NKT cells, although reduced in number, where functionally normal in patients with 
malignant melanoma (Kawano et al, 1999).  
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Several studies followed reporting significant reductions of iNKT numbers in human 
cancers. Circulating iNKT numbers in prostate cancer were reduced 100 fold from 
0.21% in healthy controls to 0.02% in patients (Tahir et al, 2001). In contrast to the 
melanoma study from Kawano et al, the iNKT cells from prostate cancer patients 
showed a reduced in the production of IFN-γ, but normal levels of IL-4. Kenna et al 
reported that iNKT cell numbers are reduced in livers of patients with metastatic liver 
disease (Kenna et al 2001). Kenna et al later reported that CD1d expression and the 
level of CD1d T cell reactivity in tumour bearing livers to be unchanged in comparison 
to histologically normal livers (Kenna et al, 2007). The success in murine models 
coupled with reports of losses of Vα24 iNKT cell numbers and function in some human 
cancers, place iNKT cells as a potential targets for cancer therapy.  
 
1.11 NKT cells based immunotherapy for cancer 
 
Several approaches to iNKT based immunotherapy have entered clinical trial (Figure 
1.12). In 2002 Giaccone et al enrolled 24 patients with solid tumors into a phase I 
clinical trial. Patients received intravenous injection of αGalCer (50-4800 µg/m2) on 
days 1, 8 and 15 of a 4 weekly cycle. 24 hours post injection Vα24+ Vβ11+ iNKT cell 
numbers decreased in periphery, possibly due to activation induced down-regulation of 
TCR (Crowe et al 2003) and migration to the tissues. Increased serum levels of IFN-γ, 
IL-12 and GM-CSF was detected in several patients. The therapy was well tolerated 
with no adverse side effects, but no tumour regression was noted, although seven 
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patients displayed a prolonged period of stable disease with a median of 123 days 
(Giaccone et al 2002).  
 
Another approach to iNKT based cancer therapy was the intravenous injection of in 
vitro expanded and activated Vα24 iNKT cells. 6 patients with recurrent non small cell 
lung cancer were enrolled. Patients received 2 injections of up to 5x107/m3 autologous 
iNKT cells, which were expanded from PBMC using αGalCer and IL-2 in vitro (mean 
numbers of Vα24 iNKT cells increased from 0.06% up to 25%). The expanded iNKT 
cells showed good cytotoxic activity in vitro against K562 and PC-13 tumor cell lines. 
No adverse side effects were reported and increases in circulating iNKT number were 
reported in 2 cases. Increases in serum IFN-γ levels were also reported in 3 patients 
with NK cells identified as the main source. No regression or stabilization of disease 
was reported in any patients (Motohashi et al 2006). 
 
A third approach which has been the most widely investigated with several variations, 
uses infusions of dendritic cells pulsed with αGalCer. In 2004 Nieda et al enrolled 12 
patients with metastatic tumors. Patients received 2 intravenous and 2 intradermal 
injections of 5x106 autologus α-GalCer pulsed immature dendritic cells. The number of 
iNKT cells decreased 24 hours post injection again probably due to down-regulation of 
TCR and migration to the tissues. IFN-γ and IL-12 levels increased and activation of 
NK cells and T cells was also reported. The therapy was well received with reduction 
of tumor markers in 2 patients (Nieda et al 2004). 
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In 2005 Ishikawa et al enrolled 11 patients with non small cell lung cancer, and 
immunized intravenously up to 4 times with >5x107 immature dendritic cells/m2 of 
body mass pulsed with αGalCer. iNKT numbers increased in 1 patient after 2 
injections. Increases in mRNA encoding IFN-γ was reported in circulating iNKT cells. 
Again the therapy was well received and no adverse side effects were reported, but no 
regression was reported but disease progression stabilized in 2 patients (Ishikawa et al 
2005). 
 
Chang et al immunized myeloma patients 3 times with mature DCs; the first injection 
used unloaded DC and subsequent injections used dendritic cell pulsed with αGalCer. 
The injection of pulsed but not unpulsed dendritic cells led to the >100 fold increase in 
circulating iNKT numbers in all 5 patients, and these could be detected for up to 6 
months. IFN-γ and IL-12p40 levels increased and antigen specific CD8+ T cells were 
also reported. The therapy was well received and no adverse side effects were reported 
with one patients showing disease stabilization (Chang et al 2005).  
 
Recently Uchida et al enrolled 9 patients with head and neck cancer into a phase I 
clinical trial. Two injections of autologus αGalCer pulsed antigen presenting cells 
(APCs), were administered into the nasal submucosa. Each injection of 1x108 cells was 
separated by 1 week and consisted of PBMC stimulated with GM-CSF and IL-2 for 7 
days, then pulsed with αGalCer. The levels of DCs in the infusions ranged from 30-
55%. After the second injection increased iNKT numbers were observed in 4 patients 
and enhanced NK cell activity was detected in eight patients. The therapy was well 
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received and no adverse side effects were reported. No tumour regression was reported 
but disease progression stabilised in 5 patients (Uchida et al 2008). 
 
Motohashi et al conducted a follow up phase II clinical trial, enrolling 23 non small cell 
lung cancer patients (17 patients completed the trial). Patients received 4 intravenous 
injections of 1x109/m2 PBMC cultured with GM-CSF and IL-2 then pulsed with 
αGalCer, before administration. IFN-γ producing cells increased in 10 patients and this 
correlated with an increased survival time. 5 patients were reported to have stabilized 
disease (Motohashi et al 2009). 
 
Immunotherapy utilizing iNKT cells although well tolerated have been disappointing 
after the results observed in the murine models (Kawano et al 1997, Smyth et al 2002). 
There are several reasons for these disappointing results, (1) humans have different 
frequencies of iNKT cells compared to mice (2) the patients in the outlined human 
studies had advanced staged cancers, previous studies have reported the reduction in 
iNKT cells in cancers (Section 1.9.3). (3) The current therapies for human cancers are 
based on chemotherapy, radiation and surgery. The effects of these therapies on iNKT 
cell function are not well understood and could possibly effect immunotherapy. (4) The 
ligand for iNKT cells is unknown, currently αGalCer is the best know stimulator iNKT 
cells, however maybe an alternative glycolipid will result in optimal human iNKT cell 
activation. 
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Figure 1.12: NKT cell based immunotherapy: Schematics detailing the main 
approaches used in iNKT cell based immunotherapy. The intravenous injection of 
αGalCer (1), the infusion of αGalCer expanded iNKT (2), the infusion of monocytes 
derived DCs loaded with αGalCer (3), the infusion of GM-CSF and IL-2 cultured 
PBMC loaded with αGalCer (4). 
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1.11.1 iNKT cell activation by αGalCer analogues 
 
Miyamoto et al (Nature 2001) synthesised an αGalCer analogue termed OCH (Figure 
1.13). OCH was an altered ligand with shortened acyl chains and resulted in a Th2 bias 
with predominant IL-4 production when injected in to experimental autoimmune 
encephalomyelitis (EAE) mice. Injection of OCH resulted in increased serum IL-4 
levels and this was confirmed in an in-vitro assay using splenocytes. OCH activation of 
iNKT cells resulted in specific protection against EAE after a single intraperitoneal 
injection, whereas αGalCer stimulation of iNKT cells did not confer the same 
protection. OCH injection did not confer protection in Vα14+ knockout mice, IL-4 was 
speculated to be the protective cytokine, as EAE is thought to be a Th1/Th17 driven 
condition. OCH stimulation resulted in 5 fold lower proliferations of iNKT cells 
compared to αGalCer.  Schmieg et al (2003) synthesised another αGalCer analogue 
with a single change replacing the glycosidic O link of αGalCer with a CH2 link, 
named α-C-GalCer (Figure 1.13). Following up on previous studies showing that iNKT 
protected against hepatic stage malaria in mice (Gonzalez-Aseguinolasa, 2000) the 
authors reported 1000 fold more anti-malarial and 100 fold greater anti-metastatic 
activities than with αGalCer in an iNKT/CD1d dependant manner. To investigate the 
anti malarial effect of α-C-GalCer, the ability of either glycolipid to prevent blood 
stage malaria infection in mice challenged with live sporozoites was assessed. When 
given 3 days before challenge, α-C-GalCer completely protected 9 out of 10 mice from 
blood-stage malaria, whereas an identical dose of α-GalCer protected 0 out of 10 mice, 
the same as untreated controls. The results showed α-C-GalCer activation with 1 ng/ml 
led to a Th1 bias with increased IFN-γ and IL-12 and decreased IL-4 compared to 
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αGalCer stimulation with 100 ng/ml. The response to α-C-GalCer was also sustained 
longer and was detectable for 3 days longer than αGalCer.  
 
Porcelli et al reported that substituting the N-acyl chain of αGalCer with a shorter 
unsaturated fatty acid modifies the response by iNKT (Yu et al, 2005). C20:2 (Figure 
1.13) potently induced a Th2 biased cytokine response in serum. This was associated 
with diminished IFN-γ protection and Vα14+ NKT cell proliferation in splenocyte 
culture assay. In studies following up on this information Bittman et al reported a 
truncated nonisosteric C glycoside, termed α-1C-GalCer. These investigations used 
human DCs as antigen presenting cells for Vα24+ NKT cells and found that stimulation 
with α-1C-GalCer resulted in less IFN-γ than stimulation with αGalCer but higher 
Th1:Th2 ratios typical for Th1 response. (Lu et al, 2006).  
 
Recently Trappeniers et al reported another series of Th1 biased analogues, with 
structural modifications in the 6’OH group of the glycoyl moiety, after structural 
studies by Borg et al (2007). The Gal 6’OH sugar alcohol was identified as the only 
non involved moiety in the H-bond formation. The rational was that induction of 
changes at this point could induce further interactions between the ligand with CD1d. 
Several analogues were synthesized and tested. The immunoproperties of the resulting 
6’-derivatised αGalCer analogues, were investigated by examination of murine serum 
levels after treatment with the ligand. It was found that the 6’ derivatised αGalCer 
analogues resulted in a Th1 bias (Trappeniers, 2008). 
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Figure 1.13: αGalCer analogues: Schematic detailing the modifications made to KRN-
7000 in the derivation of OCH, C20:2 and α-C-GalCer (Reproduced from Wu et al 
2008) 
 
 
1.12 Hypothesis 
 
The above studies arguably show that two of the most important cellular links between 
the innate and adaptive immune responses are iNKT cells and the dendritic cell (DCs). 
As described iNKT cell activation using αGalCer can prevent and cure cancer in 
several murine models, but therapies using the same in humans have been 
disappointing (Section 1.9.3). Possible reasons for these results could be; (1) Lower 
NKT cell numbers in humans than mice both in the periphery and the liver, (2) Human 
NKT cells are functionally different to or have different subsets their murine 
counterparts, (3) Human iNKT cells react different to αGalCer than murine iNKT cells. 
The potential to manipulate the interaction between the iNKT cells and DCs is one that 
provides attractive potential for immunotherapy.  
 
The main aim of the proposed study was to investigate the reciprocal interactions 
between iNKT cells and DCs, and establish a system to test novel αGalCer analogues 
with proposed beneficial modifications for improved iNKT activation with the ultimate 
aim of therapeutic use.  
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1.12.2 Aims of present investigation 
 
• To investigate the extent of human CD1a-d reactivity in human peripheral 
blood 
• To test reactivity of human iNKT cells to αGalCer and other lipids in vitro 
• To optimize a method for the isolation and expansion of iNKT cells 
• To analyse the phenotype and function of iNKT cells 
• To establish a system to study DC-iNKT cell interactions in vitro 
• To test αGalCer analogue biological functionality 
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2.1 Materials 
 
2.1.1 Human Peripheral Blood Samples 
Human Peripheral blood mononuclear cells were obtained with permission from 
healthy donors in EDTA coated tubes or obtained from buffy coat packs supplied by 
the Irish Blood Transfusion Service, St James Hospital, Dublin 8, with the approval of 
the NUI Maynooth Ethical Committee. 
 
2.1.2 Reagents 
Reagents used in this project are shown in Table 1 below with the exception of 
monoclonal antibodies (mAb) which have a dedicated sub-section and table. 
 
Table 1: Reagents used in this thesis and their sources 
Product Company 
15 ml centrifuge tubes Sarstedt, Germany 
20 µm nylon mesh filter Falcon 2340, USA 
24-well tissue culture plate Nunc, Denmark 
3,3',5,5' tetramethylbenzidine (TMB) Sigma Aldrich, UK 
40 µm nylon mesh filter Falcon, USA 
50 ml centrifuge tubes Sarstedt, Germany 
6-well tissue culture plate Nunc, Denmark 
96-well flat bottomed tissue culture plate Nunc, Denmark 
96-well Maxisorp ELISA plates Nunc, Denmark 
96-well round bottomed tissue culture plate Nunc, Denmark 
α-galactosylceramide Kirin, Japan 
Anti-phycoerythrin microbeads Miltenyi Biotech, GmbH 
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Bovine serum albumin Sigma Aldrich, UK 
Brefeldin A Sigma Aldrich, UK 
Cell Trace CFSE proliferation kit Invitrogen, UK 
CD3 Microbeads Miltenyi Biotech, GmbH 
CD14 Microbeads Miltenyi Biotech, GmbH 
CD56 Microbeads Miltenyi Biotech, GmbH 
Cryovials Nagene, Denmark 
Dimethyl-sulfoxide (DMSO) BDH, USA 
Ethylenediaminetetraacetic acid (EDTA) Sigma Aldrich, UK 
Ethidium Bromide (EtBr) Sigma Aldrich, UK 
Flow Cytometry Tubes Falcon, USA 
Foetal Bovine Serum (FBS) Gibco, NZ 
Foetal Calf Serum (FCS) Gibco, NZ 
Fungizone Gibco, NZ 
Granulocyte Macrophage Colony Stimulating 
Factor (GM-CSF) R&D Systems, UK 
H2SO4  Sigma Aldrich, UK 
Hanks Buffered Salt Solutions Gibco, NZ 
HEPES Buffer Gibco, NZ 
HEK-Blue LPS detection kit InvivoGen, France 
Human IFN-γ DuoSet ELISA R&D Systems, UK 
Human IL-2 DuoSet ELISA R&D Systems, UK 
Human IL-4 DuoSet ELISA R&D Systems, UK 
Human IL-10 DuoSet ELISA R&D Systems, UK 
Human IL-12 DuoSet ELISA R&D Systems, UK 
Human IL-13 DuoSet ELISA R&D Systems, UK 
Hyclone Foetal Calf Defined Serum Hylclone, USA 
Isoglobotrihexosylceramide (iGb3)  Alexis, Switzerland 
Interleukin 2 (IL-2) R&D Systems, UK 
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Interleukin 4 (IL-4) R&D Systems, UK 
Ionomycin Sigma Aldrich, UK 
Lipopolysaccharide (LPS) Alexis, Switzerland 
LS Separation Columns Miltenyi Biotech, GmbH 
Lymphoprep Nycomed, Norway 
Normal Goat Serum Sigma Aldrich, UK 
Normal Mouse Serum Sigma Aldrich, UK 
Parafilm Fisher Scientific 
Paraformaldehyde (PFA) Sigma Aldrich, UK 
Pasteur Pipettes Sarstedt, Germany 
Penicillin Streptomycin Gibco, NZ 
Phorbol 12-myristate 13-acetate (PMA) Sigma Aldrich, UK 
Phosphate Buffered Saline Tablets Sigma Aldrich, UK 
Phytohaemagglutin (PHA) Sigma Aldrich, UK 
Poly I:C Invitrogen, UK 
Preseparation Filters Miltenyi Biotech, GmbH 
Roswell Park Memorial Institute  (RPMI) Gibco, NZ 
S-Monovette Vacutainers Sarstedt, Germany 
Saponin Sigma Aldrich, UK 
Sodium Azide Sigma Aldrich, UK 
T25 Tissue Culture Flasks Sarstedt, Germany 
T75 Tissue Culture Flasks Sarstedt, Germany 
Total cytotoxicity & apoptosis detection kit 
Immunochemistry Technologies, 
USA 
Tween 20 Sigma Aldrich, UK 
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2.1.3 Monoclonal Flow Cytometry Antibodies 
The monoclonal antibodies (mAb) used in this project are listed in table 2. The 
conjugated fluorochrome, supplier and catalogue number are also listed. Unconjugated 
CD1a, CD1b, CD1c, CD1d are non commercial and a kind gift from Prof. Steven 
Porcelli, Albert Einstein School of Medicine, NY, USA. 
 
Table 2: Monoclonal antibodies used in this thesis and their sources 
Antibody Fluorochrome Company 
Catalogue 
Number 
IFN-γ PE BD Biosciences 554552 
IL-4 PE BD Biosciences 554516 
IL-10 PE BD Biosciences 554498 
IL-13 PE BD Biosciences 559328 
CCR7 PE BD Biosciences 552176 
CD1a PE BD Biosciences  555807 
CD1a Unconjugated Non commercial   
CD1b FITC BD Biosciences 555969 
CD1b Unconjugated Non commercial   
CD1c FITC Miltenyi Biotech 130-090-507 
CD1c Unconjugated Non commercial   
CD1d PE BD Biosciences 550255 
CD1d Unconjugated Non commercial   
CD3 PE-Cy5 BD Bisosciences 555334 
Chapter 2: Materials & Methods 
 
 
69 
CD4 FITC BD Bisosciences 555346 
CD8 PE BD Bisosciences 555635 
CD11c PE BD Bisosciences 555392 
CD14 PE-Cy5 BD Bisosciences 550787 
CD19 APC BD Bisosciences 555415 
CD25 PE BD Bisosciences 555432 
CD28 FITC BD Bisosciences 555728 
CD40 PE-Cy5 BD Bisosciences 555590 
CD54 APC BD Bisosciences 559771 
CD56 FITC BD Bisosciences 345811 
CD69 PE-Cy5 BD Bisosciences 555532 
CD80 APC Immunotools 21270806 
CD83 PE BD Bisosciences 556855 
CD86 FITC BD Bisosciences 555657 
CD94 FITC BD Bisosciences 555888 
CD161 FITC BD Bisosciences 556080 
Goat Anti Mouse FITC BD Bisosciences 553443 
Goat Anti Mouse PE BD Bisosciences 550083 
HLA-DR FITC BD Bisosciences 555811 
Invariant NKT 
(6B11) PE BD Bisosciences 552825 
NKG2D APC BD Bisosciences 558071 
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Vα24 FITC Immunotech IM-1589 
Vβ11 PE Immunotech IM-2290 
 
 
2.1.4 Glycolipids 
The glycolipids used in this project are listed in table 4. The supplier and catalogue 
number are also listed.  
Glycolipid Supplier Cat Number 
αGalCer Enzo Life Sciences BML-SL232-0100 
iGb3 Enzo Life Sciences ALX-306-028-M001 
.  
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2.2 Cellular Preparation 
2.2.1 Generation of peripheral blood mononuclear cells (PBMC) 
Peripheral blood mononuclear cells were isolated from whole venous blood by 
lymphoprep gradient density centrifugation. Venous whole blood was taken into EDTA 
coated vaccutainers as an anticoagulant and diluted 1:1 with Hanks Buffered Salt 
Solution (HBSS) supplemented with 1% FCS. Buffy coat packs where mixed with 5 ml 
of 0.5% w/v EDTA and diluted 1:4 with HBSS supplemented with 1% v/v FCS. 
Carefully, 35 ml of diluted blood was layered onto 15 mls of Lymphoprep in a 50 ml 
centrifuge tube and centrifuged for 25 minutes at 400 g without accelerator or brake. 
The plasma layer was aspirated and discarded. The buffy coat was transferred into a 
clean centrifugation tube. The remaining Lymphoprep and red blood cell pellet were 
discarded. The buffy coats were diluted with 20 ml of HBSS containing 1% v/v FCS 
and centrifuged for 5 minutes at 800 g with accelerator and brake applied. The 
supernatants were aspirated and discarded; the cell pellet was resuspended by 
vortexing. The cells were again resuspended in 20 ml of HBSS supplemented with 1% 
v/v FCS and centrifuged for 10 minutes at 300 g. The supernatant was discarded and 
the cell pellet resuspended by vortexing and diluted in complete RPMI (RPMI 1640 
with Glutamax medium supplemented with 10% v/v FCS, 1% v/v penicillin-
streptomycin, 1% v/v fungizone and 25mM HEPES). 
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2.2.2 Enumeration of cells 
Cells in suspension were enumerated by UV microscopy using a haemocytometer. 
Briefly 20 µl of cell suspension was diluted with 380 µl of ethidum bromide acridine 
orange (EBAO) (0.8ml of 4mg/ml EB and 2 ml of 1mg/ml AO in 200 ml of 0.85% w/v 
NaCl) in a 0.5 ml tube and mixed by vortexing. Carefully 10 µl of the final dilution was 
applied to the haemocytometer and cells were counted in two opposing 1.0 mm x 1.0 
mm sections. Each of these squares accommodates 0.1 mm3 of liquid; therefore the 
number of cells in 1 ml is calculated and multiplied by the dilution factor. Live cells 
fluoresce green whilst dead cells appear orange under UV light after EBAO staining. 
 
Figure 2.1: Enumeration of cells using the haemocytometer. 2 grids of 16 squares 
are chosen and the number of live cells counted (green.) Each of these squares 
accommodates 0.1 mm3 of liquid; therefore the number of cells in 1 ml is calculated 
and multiplied by the dilution factor to give the final concentration of cells. 
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2.2.3 Cryopreservation and reconstitution of cells 
For long term storage, cells were cryopreserved in liquid nitrogen. Cells were pelleted 
by centrifugation for 7 mins at 400 g, the supernatant was discarded and the cells 
resuspended in freezing mixture (90% FBS and 10% DMSO, made freshly but in 
advance to allow exothermic heat produced from mixing to subside). Cells were 
immediately transferred to labelled cryovials and frozen at -80ºC for 24 hours before 
being transferred to liquid nitrogen stores. Cryopreserved cells were reconstituted by 
rapid thawing in a 37ºC water bath and transferring into universal tube containing pre-
warmed complete RPMI. Cells are centrifuged for 10 mins at 300 g, the supernatants 
are discarded and cell pellets resuspended in complete RPMI. Recently recovered cells 
were incubated at concentration of 1X106 cells/ml for 24 hours at 37ºC with 5% CO2 
before use. 
 
2.2.4 Cell lines 
Several cell lines were used in the studies within this thesis. The C1R lymphoblastoid 
cells which where stably transfected with CD1a, CD1b, CD1c or CD1d and a mock 
transfected C1R cell (A kind gift from Prof Steven Porcelli, Albert Einsten School of 
Medicine NY, USA). The NK sensitive tumour cell line K562 was also used as target 
cell for cytotoxicity. All cell lines were cultured in complete RPMI in T175 vented 
tissue culture flasks and maintained at a density of 5X105 cells/ml 37ºC with 5% CO2. 
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2.2.5 Magnetic bead separation of cells 
PBMC were separated into purified populations of monocytes (CD14+), T cells 
(CD3+) and iNKT cells (6B11+). PBMC were resuspended in 80 µl per 1X107 cells of 
cold Miltenyi Buffer (PBS supplemented with 0.5% BSA) by vortexing. Next 20 µl of 
magnetic anti-human marker Microbeads were added to each tube and incubated at 4ºC 
for 15 mins. Cells were diluted with 10 ml of buffer and centrifuged for 10 mins at 300 
g in a 4ºC centrifuge to remove excess Microbeads. Supernatants were removed by 
pipetting and discarded. Cell pellets were resuspended in 500 µl /1X107 total cells of 
cold Miltenyi Buffer and applied to pre-washed LS separation column and magnet. The 
cell suspension was washed through with five 3 ml washes of cold buffer into waste 
collection tube. The column was removed from the magnet and 5 ml of cold buffer was 
forcefully pushed through into a clean universal tube. Cells were centrifuged for 10 
mins at 300 g in a 4ºC centrifuge and resuspended in complete RPMI at concentration 
of 1X106 cells/ml. Cell purities were examined by flow cytometry and cell yields were 
determined by EBAO enumeration. 
 
2.3 Flow Cytometry 
Flow cytometry is a technique for rapidly analysing multiple parameters on large 
numbers of living (or dead) cells. Single cells suspended in a stream of fluid pass 
through a laser beam and interact with the light. Biochemical and biophysical 
characteristics of individual cells are quantified by measurement of visible and 
fluorescent light emissions.  
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A number of photodetectors are strategically placed inside the machine to detect 
transmitted and scattered light. One detector in line with the laser beam detects 
Forward Scatter (FSC) whereas another placed at 90º to it detects Side Scatter (SSC). 
There are also usually one or more fluorescent detectors (FL-1, 2, 3, 4) (Figure 2.2). 
Cell populations are distinguished on the basis of morphological differences as 
indicated by differences in their FSC and SSC. On this principle, larger and more 
granular cells such as macrophages are easily distinguished from smaller less granular 
lymphocytes. Flow cytometry also allows the detection of multiple fluorochrome-
conjugated mAbs bound to cells. Each fluorochrome when excited by the laser emits a 
different wavelength. The intensity of the emission is converted into a value, mean 
fluorescence intensity (MFI). 
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Figure 2.2: Schematic representing the principles of flow cytometry. Sample is taken 
into the sample inlet by suction or reverse pressure and forced into a single cell 
stream in sheath fluid. Cells pass through laser and the light emitted passes through 
filters and collected by photo multipliers which change signal from light into 
displayable signal. (Adapted from images at La Jolla Bioenginering Institute)
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2.3.1 Direct cell surface staining for Flow Cytometry 
Cells at a concentration of 1X105- 2X105 in single cell suspension were prepared for 
each control and sample tube. Cells were washed using 2 ml per 2X105 cells of PBA 
buffer (PBS with 1% v/v BSA and 0.02% w/v sodium azide), then centrifuged at 300g 
for 10 mins. Cells were resuspended in 80 µl of PBA per sample and stained with the 
appropriate amount of each required fluorochrome labelled mAb, cells were 
simultaneously stained with up to 4 mAbs, each with fluorochromes that emit light at a 
different wavelength, or relevant IgG isotype controls. Cell samples were also stained 
with single colour antibodies and stained as fluorescence minus one (FMO) controls (1 
colour is omitted, i.e PE FMO is FITC, PER-CP and APC).  Samples were vortexed 
and incubated away from light for 15 mins at room temperature to allow binding. Cells 
are then washed as before to remove any unbound mAb. Fluorochrome labelled cells 
were resuspended in 500 µl of PBA or 1% PFA, incubated at 4ºC and acquired within 1 
hour or 24 hours respectively. 
 
2.3.2 Indirect cell surface staining for Flow Cytometry 
As with direct staining 1X105- 2X105 cells in single cell suspension were prepared for 
each control and sample tube in 80 µl of PBA per sample and stained with 0.05-0.2 µg  
per 2X105 cells with primary unlabelled mAb. Optimal amounts of mAb were tested 
for each new lot of unlabelled mAb by comparing staining intensities of varying 
amounts (0.01-1µg) of mAb. Cells were incubated for 10 min at room temperature in 
the dark. Excess mAb was washed as previously described. Cells were resuspended in 
Chapter 2: Materials & Methods 
 
 
78 
80 µls of PBA and stained with 5 µl per 2X105 of fluorochrome labelled secondary 
mAb (anti-primary mAb) and incubated for 15 min at room temperature and washed to 
remove excess mAb. Cells were resuspended in 80 µl of PBA with 4% normal mouse 
serum to block non-specific binding sites for 10 min at room temperature. Cells were 
washed and resuspended. The cells were then stained with mAbs that were directly 
conjugated with fluorochrome as described above. 
 
2.3.3 Intracellular staining for Flow Cytometry  
1X106- 1.5X106 cells were prepared for each control and sample tube, and incubated 
for 24 hours with or without specific stimuli (i.e. αGalCer). Cells were stimulated for 4 
hours with medium alone, αGalCer (100 ng/ml), PMA (10 ng/ml) and ionomycin (1 
µg/ml). Brefeldin A (BFA prevents cytokine secretion) was added to each sample at 
concentration of 10 µg/ml. Cells were then washed using 2 ml per 1X106 cells of cold 
PBA, then centrifuged at 300 g for 10 mins. Cells were resuspened in 80 µl of PBA per 
sample. The appropriate amount of each surface staining mAb was added and 
incubated at room temperature for 15 min. Excess antibody was diluted with PBA and 
removed by centrifugation. Cells were resuspended in 80 µl of cold PBA. Next 500 µl 
of 4% paraformaldehyde was added to each sample for 10 mins at room temperature to 
fix cells (stops internalisation of mAb). Cells were washed with 2 ml per 1X106 cells of 
cold PBS with 1% v/v BSA (PBA), and then centrifuged at 300 g for 10 mins. Cells 
were permeabilised by adding 1 ml of 0.2% w/v saponin in PBA to each sample and 
incubating for 10 mins at room temperature in the dark. Excess saponin was removed 
by dilution and centrifugation. Cells were stained for the presence of intracellular 
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cytokine by adding the approriate amount of anti-human intracellular cytokine diluted 
in 50 µl of 0.2% w/v saponin or appropriate control antibody to each and sample and 
incubated for 20 mins at room temperature in the dark. Excess antibody was diluted 
and removed by centrifugation. Samples were resuspended in 500 µl of 1% PFA and 
acquired by flow cytometry.  
 
2.3.4 Flow Cytometry Analysis 
Post acquisition analysis was carried out using Cell Quest (BD). Briefly, analysis was 
based on the FSC and SSC of the total cell population, a single or series of electronic 
gates determining the population of cells analysed were set (Figure 2.3). Isotype 
controls are used to set the detectors and settings, allowing visualisation of a negative 
population. Isotype controls used in this study were all IgG (different isotypes) and 
matched to the corresponding specific labelling antibody; this allows detection and 
compensation for non specific binding (Figure 2.3). Flow cytometric histograms are 
used when analysing single staining, markers set according to isotype control determine 
positivity (Figure 2.3). Single stained cell and FMO sample dot plots were used for 
flourochrome compensation settings when analysing 2 or more staining mAb, 
quadrants determining positivity were set according to isotype controls (Figure 2.3). 
For analysis of lymphocytes, the following combinations of mAb were used; T-helper 
cells (CD3+, CD4+), CTLs (CD3+, CD8+), NK cells (CD56+, CD3-), CD56+ T cells 
(CD56+, CD3+),  iNKT cells (CD3+, 6B11+) (Analyse sample: Figure 2.4). Cell 
Quests inbuilt statistical program determined % of total cell, % of gated cells and the 
mean fluorescence intensity values. 
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Figure 2.3: Flow cytometry analysis and electronic population gating: A, Sample 
flow cytometric dot plots showing total PBMC. B, PBMC electronically gated into 
separate populations of lymphocytes (red), monocytes (orange) and residual 
granulocytes (green). C&D, Sample flow cytometric dot plots showing IgG isotype 
control staining and same plot showing relevant quadrant. E&F, Flow cytometric 
histogram showing IgG isotype and same histogram showing the relevant marker. 
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Figure 2.4: Flow cytometry dot plots showing, A, total electronically gated T cell 
lines. B, Parent population from (A) electronically gated into CD3+ cells. C, Dot plot 
showing CD4+ and CD8+ cells from the CD3+ parent population selected in (B). 
 
 
2.4 Enzyme linked immunosorbent assay (ELISA) 
ELISA paired antibody kits from R&D systems were used for identification of secreted 
cytokine in assay supernatants. Firstly, 96 well plates were coated with 100 µl per well 
of specific capture antibody against the target protein (e.g. IFN-γ, IL-4, IL-10, IL-12 
and IL-13) at concentration outlined in manufacturer’s protocol in PBS buffer 
overnight at room temperature, covered in film and kept away from direct light. Excess 
antibody was removed by washing 5 times with phosphate buffered saline and 
detergent and the plate was thoroughly dried. Non specific binding sites were blocked 
by adding 200 µl per well of PBS containing 1% v/v BSA (BSA acting as a non 
specific protein) and incubated at room temperature for 2 hours covered and kept away 
from light. The wash step outlined was repeated and the plate was dried by blotting. 80 
µl per well of sample supernatant was added to triplicate wells. A high standard was 
added in triplicate to each plate using recombinant cytokine (at given concentration) 
and serially diluted row by row to give a 7 point standard curve and an 8th triplicate was 
left blank. Samples and standards were incubated at 4ºC overnight covered in film and 
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away from direct light. Plates were washed as before and 100 µl of specific detection 
antibody (at manufacturers recommended concentration) was added to each well. Plates 
were incubated at room temperature for 2 hours covered in film and away from light. 
Excess detection antibody was washed away and 100 µl of Streptavidin/Horse Radish 
Peroxidise (HRP) was added to each well at concentration  outlined by manufacturer’s 
protocol. Plates were incubated for 20 minutes at room temperature covered in foil. 
Plates were again washed and 100 µl of 1:1 mix of substrate solutions A and B was 
added to each well and incubated at room temperature for 20 mins covered in foil. The 
enzyme reaction was stopped by adding 50 µl per well of 2N H2SO4. Plates were 
immediately read at 450nm using Tecan Sunrise plate reader (Figure 2.5).  
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Figure 2.5: Schematic representation of Enzyme Linked Immunosorbent Assay 
(ELISA) showing the major steps; from coating with capture anitbody, addition of 
samples, detection using biotin coated antibody, addition of streptavidin-HRP 
complex and final colourimetric step. 
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2.5 Human CD1 restricted T cells 
 
2.5.1 Preparation of iNKT cell ligands 
Glycolipid antigens; αGalCer, iGb3, SαGalCer, SαGalCer14 and Analogues W1-4 
(analogues described in chapter 6) were suspended in DMSO and vigorously vortexed 
for 10 minutes. Glycolipid stocks were then diluted to a concentration of 1 mg/ml in 
PBS containing 10% DMSO in PBS. The solution was split into 10 µl aliquots and 
frozen at -80°C. Several other solvents are recommended by manufactures for lipid 
solubility including; pyridine and 2:1 chloroform/methanol, however these solvents 
proved toxic to cells in culture and were not used. 
 
2.5.2 Isolation of 6B11 positive iNKT cells 
PBMC were isolated from whole blood by lymphoprep density gradient centrifugation 
and enumerated as described in previous sections. Cells were diluted with PBS to a 
density of 1X108 cells per 100 µl in a 15 ml Falcon centrifugation tube. Next 100 µl of 
mouse anti-human 6B11 mAb conjugated with PE was added to cell aliquots and 
incubated at room temperature, away from direct light for 15 minutes. Cells were 
diluted with 10 ml of PBS containing 1% v/v BSA and centrifuged for 10 minutes at 
300g to remove excess mAb. 6B11 positive cells were then magnetically separated 
using anti-PE Microbeads as previously described in section 2.2.5. The magnetically 
purified iNKT cells where subsequently expanded using three methods outlined in 
section 4.1. Each method is detailed in a dedicated sub-section below. Briefly the iNKT 
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cells where stimulated using; a mitogen, antigen or glycolipid and maintained in culture 
media containing IL-2. 
 
2.5.3 Generation of 6B11 positive iNKT cell lines: Method 1 
Magnetically isolated 6B11+ cells were plated in 24 well plates in 1 ml of cRPMI 
medium per well. Cells were stimulated with (1:1 cell ratio) irradiated (4000 RADS for 
11 minutes) PBMC feeder mix (2 different donors at concentration of 5X105 per 500 
µl) in cRPMI and 100 ng/ml of αGalCer.  24 hours after isolation, cells were 
supplemented with 50 U/ml of recombinant IL-2. Cell cultures are examined every 3 
days and supplemented with fresh medium containing 50 U/ml IL-2. When cells 
reached ~50% confluency, each well was split into 2 wells with the addition of 500 µl 
per well cRPMI and 50 U/ml IL-2. 
 
2.5.4 Generation of 6B11+ iNKT cell lines: Method 2 
As outlined in section 2.5.3, 6B11+ cells were plated with (1:1 cell ratio) irradiated 
PBMC feeder mix (2 different donors at concentration of 5X105 per 500 µl) in cRPMI 
and stimulated with 5 µg/ml of PHA. 24 hours after isolation cells were supplemented 
with 50 U/ml of recombinant IL-2. Cell cultures were examined every 3 days and 
supplemented with fresh medium containing 50 U/ml IL-2. When cells reached ~50% 
confluency, each well was split into 2 wells with the addition of 500 µl per well of 
complete RPMI and 50 U/ml IL-2. 
 
Chapter 2: Materials & Methods 
 
 
86 
2.5.5 Generation of 6B11+ iNKT cell lines: Method 3 
Isolated 6B11+ cells were plated at concentration of 1X106 cells/ml on 24 well plates 
coated with 10 µg/ml OKT-3 (wells coated with 10 µg in 1ml of PBS for 4 hours at 
room temperature or 4°C overnight). Irradiated feeder cells were not added. 24 hours 
post stimulation; medium was supplemented with 100 U/ml of IL-2. Cells were 
cultured for 7 days after which spent medium was replaced with cRPMI supplemented 
with 100 U/ml of IL-2. When cells confluency exceeded 50%, each well was split into 
2 wells (new well not coated with OKT-3) as described previously. 
 
2.5.6 Characterisation of 6B11+ iNKT cell lines 
After several rounds of stimulations, cell line purities were examined by flow 
cytometry. Briefly 2X105 cells were triple stained with Vα24 FITC, Vβ11 PE and CD3 
PE-Cy5 or CD161 FITC, 6B11 PE and CD3 PE-Cy5, CD8 FITC, CD4 PE and CD3 
PE-Cy5 or CD94 FITC, CD56 PE and CD3 PE-Cy5. Also 2X105 cells from 2 cell lines 
(due to budget restrictions) were stained with a CD1d PE tetramer (previously loaded 
overnight with αGalCer) and CD3 PE-Cy5. Cells were stained also for relevant IgG 
controls. Cells were acquired and analysed as described in section 2.3.4.  
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2.5.7 Analysis of T cell reactivity against CD1 transfected C1R cells 
PBMC or purified CD3+ T cells were prepared as described previously and cultured at 
a concentration of 0.2X106 cells per 100 µl of cRPMI. C1R cells expressing transfected 
CD1 were also cultured at 0.2X106 cells per 100 µl. PBMC or CD3+ cells (100 µl per 
well) were co-cultured with 100 µl per well of each CD1 isotype transfectant C1R cell 
line including the mock transfected C1R cell, as a negative control for 3 days at 37ºC 
with 5% CO2. PBMC or CD3+ T cells stimulated with 10 µg/ml of PHA served as a 
positive control. On day 3 supernatants were harvested and assayed for IFN-γ or IL-13 
by ELISA. C1R-CD1d cells were either unloaded or loaded for 24 hours with 100 
ng/ml of αGalCer, iGb3 or synthetic glycolipids. 
 
2.5.8 Analysis of iNKT cell reactivity against CD1d transfected C1R cells  
6B11+ iNKT cell line reactivity was examined against either mock transfected C1R 
cells or CD1d transfected C1R cells loaded or unloaded (2 hours prior to culture) with 
100 ng/ml of αGalCer, iGb3 or synthetic glycolipid. 2X105 6B11+ iNKT cells were co-
cultured with equal amounts of CD1d-transfectant cells, in the absence or presence of 
glycolipid, in round bottomed 96 well plates for 3 days at 37ºC with 5% CO2. On day 1 
& 3 supernatants were harvested and assayed for secreted IFN-γ and IL-4 by ELISA 
(Individual assay procedures are outlined within results chapters). 
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2.5.9 Analysis of iNKT cell cytotoxicity 
The total cytotoxicity and apoptosis detection kit provides a flow cytometry based 
method for the detection of cell lysis. Cytotoxicity by iNKT cell lines was examined 
against either K562 or C1R-CD1d target cells. Briefly target cells were incubated with 
1:250 dilution of stock carboxyfluorescein succinimidyl ester (CFSE) at 37ºC with 5% 
CO2 for 30 mins. The reaction was quenched by adding 10 mls of cold cRPMI. Target 
cells were pelleted by centrifugation for 10 minutes at 300g with no accelerator or 
break. Target cells were incubated with effector cells (6B11+ NKT cells) at ratios of 
1:1, 10:1 and 20:1 for 4 hours at 37ºC with 5% CO2. After incubation, cells were 
harvested and incubated on ice. 7-aminoactinomycin D (7-AAD) (1:10 dilution) stain 
was added immediately before acquisition by flow cytometry. An electronic gate 
selected the CFSE positive cells. CFSE positive cells which stain double positive for 7-
AAD have recently undergone apoptosis. 
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2.6. Dendritic Cells 
 
2.6.1 Generation of monocyte derived dendritic cells 
PBMC were isolated from whole blood and enumerated as described in previous 
sections. Cells were diluted with PBS containing 1% v/v BSA to a volume of 1X108 
cells per 100 µl in a 50 ml centrifugation tube and incubated with 100 µl of anti human 
CD14 Microbeads for 30 minutes at 4°C. Excess microbeads were removed by dilution 
with PBA and centrifugation at 300 g for 10 minutes. Cells were magnetically 
separated as described in section 2.5.2, washed and resuspended at a concentration of 
1X106 cells per ml in cRPMI containing defined Hyclone Foetal Calf Serum (dcRPMI). 
Hyclone defined FCS was used to prevent maturation of the DC due to endogenous 
endotoxins such as LPS (Figure 2.6). The endotoxin levels in batches of sera were 
tested using the invitrogen HEK-blue assay. CD14+ cells were plated on 6 well tissue 
culture plates, to give final concentration of 3X106 cells in 3 ml per well. Immature DC 
were generated from CD14+ monocytes by culture with 50 ng/ml of GM-GSF and 70 
ng/ml of IL-4. Cultures were incubated for 3 days at 37ºC with 5% CO2. On day 3 
medium was replenished by removing 1.5 ml per well of spent media and adding 2 ml 
per well of dcRPMI containing 50 ng/ml of GM-GSF and 70 ng/ml of IL-4. Cultures 
were incubated for a further 3 days at 37ºC with 5% CO2. On day 6, immature DC were 
carefully harvested from wells by gentle agitation and flushing using dcRPMI and a 
pasteur pipette. iDC were enumerated and fixed to a final concentration of  1X106 cells 
per ml in dcRPMI. 
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Figure 2.6: Detection of LPS using HEK Blue reporter cells. Bar graphs showing the 
levels of LPS in batches of FBS. LPS was used as positive control and PBS as 
negative control. HEK-Blue cells cultured in the presence of HEK-Blue selection mix 
are cultured in the presence of 20 µl of FBS for 24 hours. In the presence of LPS the 
reporter cells turn medium blue. Graphs are representative of 3 separate experiments 
 
 
2.6.2 Stimulation of dendritic cells with LPS and poly I:C 
Freshly isolated iDC were plated in triplicate in 96 well round bottom tissue culture 
plates at 1X105cells per 100 µl in dcRPMI. 100 µl of dcRPMI was added to the first 
triplicate (medium alone), 100 µl of dcRPMI and 1 µg/ml of LPS (final concentration) 
was added to the second triplicate (LPS) and 100 µl of dcRPMI and 7.5µg/ml of poly 
I:C was added (Poly I:C) to the final triplicate. Cultures were incubated for 24 hours at 
37ºC with 5% CO2. 
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2.6.3 Stimulation of dendritic cells with iNKT cells 
Freshly isolated iDC were plated in triplicate in 96-well round bottom tissue culture 
plates at 1X105 cells per 100 µl in dcRPMI. 100 µl of dcRPMI was added to the first 
triplicate (medium alone). iNKT cells; 1X105cells in 100 µl of dcRPMI were added to 
the second triplicate (iNKT), the same amount of iNKT cells were added to the third 
triplicate of iDC, along with 100 ng/ml of αGalCer or synthetic analogues (iNKT + 
αGalCer, analogues). PBMC were substituted as a non iNKT cell control into the 2nd 
and 3rd triplicates. The final triplicate was a lipid control to which 100 µl of dcRPMI 
was added with 100 ng/ml of αGalCer.  Cultures were incubated for 24 hours at 37ºC 
with 5% CO2. In some α-S-GalCer experiments, S-linked αGalCer replaced αGalCer. 
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2.6.4 Analysis of dendritic cell maturation 
After 24 hours stimulation, 180 µl of supernatant were removed from the plate for 
analysis of cytokine secretion by ELISA. 120 µl of PBA buffer was added to each well 
and cell triplicates were harvested into 3 tubes A, B and C.  Five micro-litre of mAb 
was added to each as out lined in table 6 below. Tubes were incubated for 15 minutes at 
room temperature in the dark to allow binding. Cells were then washed with 2 ml per 
tube of PBA to remove any unbound mAb and centrifuged at 300g for 10 minutes. 
Flourochrome labelled cells were resuspended in 500 µl of 1% PFA, incubated at 4ºC 
for 15 minutes and acquired on flow cytometer. As described in flow cytometry section 
an electronic gate was used to select the monocyte derived DC population, and the 
isotype controls (Figure 2.7) used to compensation for non specific binding before 
samples are acquired. 
 
Table 6: DC maturation staining panel of mAb 
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Figure 2.7: Flow cytometric analysis of DC: Flow cytometric histograms showing 
isotype controls used in DC maturation experiments. Purple histogram represents 
specific IgG isotype mAb compared to DC stained with specific mAb after stimulation 
with LPS. Plots are representative of 5 separate experiments. 
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2.6.5 Dendritic cell stimulation of allogeneic T cells 
After 24 hours stimulation with medium alone, LPS, iNKT cells or iNKT cells in the 
presence of 100 ng/ml of lipid antigen. 1X104 DC were incubated with 1X105 
allogeneic CD3+ T cells freshly isolated and labelled with CFSE (as described 2.5.9) in 
96 round bottomed plates for 3 and 5 days. Allogeneic T cell proliferation was analysed 
by flow cytometry, an electronic gate selected the CFSE positive cells, proliferative 
divisions where calculated by examining the fold reduction in CFSE intensity. 
Supernatant from the co-cultures were examined for cytokine production by ELISA 
 
2.7 Statistical Analysis 
Data was tested for normality using Graphpad Prism® statistical package. Normal data 
was analysed by Students T test (Graphpad Prism®). Data with non-normal distribution 
was analysed using a Mann Whitney U test (Graphpad Prism®). P values < 0.05 were 
considered as significant with 95% confidence. 
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Chapter 3: Investigation into CD1 
reactivity in human blood 
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3.1 Introduction 
 
The human immune system comprises of the innate immune system and the adaptive 
immune system. The innate immune system recognises conserved PAMPs and 
endogenous molecules, and responses rapidly. The adaptive response is antigen-
specific and requires time for the clonal expansion of cells before a response is 
elicited. Conventional T cells recognise peptide antigen presented by MHC 
molecules. T cells have the ability to generate a huge number of TCR structures to 
recognise the diverse antigen repertoire presented by MHC. A subset of T cells 
recognise conserved antigens, and are not restricted by MHC. These T cells are 
termed innate T cells. Some innate T cells recognise glycolipid antigen presented by 
CD1. CD1 molecules are a family of glycoproteins resembling major 
histocompatibility complex class 1 (MHC I) in overall structure (Gumperz 2006). 
Humans have 5 isoforms of CD1, CD1a-e (Martin et al 1986). CD1a, b, c and d 
function as antigen presenting molecules for T cells (Angenieux et al 2000). Mice 
have lost their group 1 CD1 molecules (CD1a, CD1b, CD1c) but have duplicated 
CD1d genes, CD1d1 and CD1d2 (Dascher & Brenner 2003). CD1 molecules are 
expressed in several tissues including intestine, thymus, liver, spleen, lung 
(Bradbury et al 1990, Bleicher et al 1990, Lacasse & Martin 1992, Bendelac et al 
1997). CD1 molecules are also expressed on many cell types, most notably  
monocyte, DCs and B cells (Bendelac et al 1997, Bendelac et al 2007). 
 
CD1 molecules present glycolipids to CD1 restricted T cells. In murine studies, the 
activation of CD1d restricted T cells resulted in the prevention and clearance of B16 
melanoma tumours (Kawano 1997, Cui et al 1997). In the succeeding years, 
activation of CD1d restricted T cells in mice was found to not only clear tumours 
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but prevent and clear multiple bacterial, viral and parasitic infections as well as 
ameliorate autoimmune disease (Smyth et al 2002, Apostolou et al 1999, Kawakami 
et al 2001, Gonzalez-Aseguinolala et al 2000 and Baxter et al 1997). Kawano et al 
(1999) subsequently investigated the role of human CD1d restricted T cells in 
cancer, and showed the in vitro cytotoxicity abilities of CD1d restricted T cells. 
However immunotherapy in human cancer using the CD1d ligand αGalCer based on 
the murine studies proved disappointing with no tumour regression or clearance 
(Giaccone et al 2002). It was noted that humans have significantly lower numbers of 
CD1d restricted T cells than mice (Wingender & Kronenberg 2008). In contrast to 
mice, humans have T cells restricted by CD1a, CD1b and CD1c (Gumprez & 
Brenner 2001). These CD1 restricted T cell subsets are not as well defined as their 
CD1d counterparts due to the lack of murine models. 
 
The majority of studies on human CD1a, b and c restricted T cells show they 
respond to exogenous mycobacterial glycolipids or endogenous glycolipids 
synthesised in response to bacterial infection (Gumprez & Brenner 2001, De Libero 
et al 2005). These studies outline the glycolipids from various microbes which are 
loaded onto group 1 CD1 molecules and elicit CD1 restricted T cells responses 
(Section 1.6.6). De Libero et al reported the APC upregulate endogenous GSL 
synthesis in the presence of bacterial infection and stimulate GSL specific T cells in 
and CD1 dependant manner (De Libero et al 2005, Muindi et al, 2010). 
 
The aim of this chapter was to investigate the expression of CD1 by PBMC subsets 
(monocytes, DCs, NK cells and T cells) to determine the cellular expression of 
CD1a, CD1b, C1Dc and CD1d in healthy human peripheral blood. Expression was 
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investigated by flow cytometry. We also aimed to establish a system to identify and 
quantify the levels of CD1 restricted T cells reactivity in human peripheral blood in 
the absence of exogenous or microbial antigen as previous studies had examined 
CD1 restricted T cells in the context of infection. Briefly CD1 transfected C1R cells 
expressing single isoforms of CD1 were co-cultured with freshly isolated human 
PBMC or enriched T cells. A mock transfected C1R cell was used as a negative 
control and the T cell mitogen PHA was used as a positive control. T cell reactivity 
against the four CD1 isotypes was measured using IFN-γ and IL-13 as readouts 
(Figure 3.1). The CD1d binding lipids αGalCer and iGb3 were used in the iNKT 
reactivity studies. Finally, we used flow cytometry to investigate the frequencies of 
iNKT cells in human blood.  
 
 
3.2 Objectives 
 
1. To examine CD1a, CD1b, CD1c, CD1d expression on circulating 
lymphocyte and monocyte populations 
2. To identify reactivity to CD1 isotypes a-d by human PBMC and enriched T 
cells 
3. To identify and characterise CD1 restricted T cell populations 
4. To enumerate human iNKT cells 
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Figure 3.1: Strategy for identification of human CD1 cell reactivity in human 
PBMC. Peripheral Blood Mononuclear Cells (PBMC) or CD3 +ve cells isolated 
from PBMC were incubated with mock transfected C1R cell or transfectant C1R 
cells expressing either CD1a, CD1b, CD1c or CD1d, loaded or unloaded with 
glycolipid. The mock transfectant C1R cell served as negative control. Reactivity 
was measured as amount of cytokine released on day 3.
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3.3.1 CD1 expression by PBMC subsets 
 
The expression levels of four CD1 isotypes; CD1a, CD1b, CD1c & CD1d, on 
PBMC subsets were investigated by flow cytometry, by co-staining PBMC for the 
four CD1 isotypes CD1a-d with either CD19 (B cells), CD14 (monoctyes), CD3 (T 
cells) or CD56 (NK and CD56+ T cells). PBMC were isolated using the lymphocyte 
density gradient centrifugation method described in chapter 2. The cells were co-
stained with the above mAbs and analysed by flow cytometry.  
 
Cell populations which stained positive for CD19 and a single CD1 isotype were 
deemed to be CD1 expressing B cells (Figure 3.2A). Of the four CD1 isotypes 
examined, CD1d was the most abundantly expressed with a mean of 70% expressed 
on B cells (Figure 3.2B), CD1c was expressed on 15% of B cells, while CD1a and 
CD1b were expressed by mean of 2% and 1% respectively (Figure 3.2B). Cells 
which stained positive for both CD14 and CD1 were identified as CD1 expressing 
monocytes (Figure 3.3A). CD1d was the most abundantly expressed, with a mean of 
90% of CD14 + cells expressing CD1d (Figure 3.3B). 15% of CD14 positive 
monocytes expressed CD1c (Figure 3.3B), while CD1a and CD1b was expressed on 
10-12% of monocytes respectively (Figure 3.3B). Cells which stained positive for 
CD56 were identified as CD1 expressing NK cells or NK-like T cells (Kelly-Rogers 
et al, 2006) (Figure 3.4A). Cells positive for CD1 and CD3 were identified as CD1 
expressing T cells (Figure 3.4B). CD1 isotype expression on NK cells and T cells 
was very sparse with less than 1% expressing each isotype. 
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Figure 3.2: Expression of CD1 isotypes by B cells. (A) Representative flow 
cytometric dot plots of PBMC co-stained for B cells (CD19) and CD1 isotypes a-d. 
Cells in the upper right quadrant are CD1 expressing B cells. (B) Scatter plot 
showing the percentage of B cells expressing individual CD1 isotypes. Black lines 
denote the means of 5 experiments.
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Figure 3.3: Expression of CD1 isotypes by CD14+ cells: (A) Representative flow 
cytometric dot plots of PBMC co-stained for monocytes (CD14) and CD1 isotypes 
a-d. Cells in the upper right quadrant are CD1 expressing monocytes. (B) Scatter 
plot showing the percentage of monocytes expressing individual CD1 isotypes. 
Black lines denote the means of 5 experiments. 
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Figure 3.4: Expression of CD1 isotypes by CD56+ cells (NK cells and CD56+ T 
cells) and CD3+ cells (T cells). (A) Flow cytometry dot plots of PBMC co-stained 
for CD56 and CD1 isotypes a-d. (B) PBMC co-stained for CD3 and CD1 isotypes 
a-d. Cells in the upper right quadrant are CD1 positive cells. 
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3.3.2 Verification of CD1 expression by CD1 transfected C1R cell lines 
 
C1R cell lines stably transfected with a single CD1 isotype (Exley et al 1997) were 
used to test for reactivity by CD1 restricted T-cells. Each C1R CD1 cell lines 
expressed a specific CD1 isotype, CD1a, CD1b, CD1c or CD1d and a mock 
transfected cell line served as a negative control. Flow cytometry was used to verify 
the expression of each CD1 isotype expression on each C1R CD1 cell line and the 
lack of any isotype expression on the mock transfected C1R cell line. The C1R 
mock cell line did not stain for the expression of any of the CD1 isotypes (Figure 
3.5). Examination of the C1R CD1a-d cell lines showed the CD1 transgene was 
stable and expressed on ~99% of the cells (Figure 3.5). Some cross reactivity was 
noted for mAb specific for CD1b and the CD1c and CD1d cell 
lines, and the CD1a mAb and the CD1d cell line. 
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Figure 3.5: Verification of CD1 isotype expression by transfected C1R cell lines; 
Mock, CD1a, CD1b, CD1c and CD1d. Each line was examined for the expression 
of CD1a (Blue histogram, CD1b (Green histogram), CD1c (Red histogram) or 
CD1d (Orange histogram). Isotype control staining is shown as purple filled 
histogram. Graphs are representative of 3 separate experiments. 
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3.3.3 PBMC responses to CD1a-d transfected C1R cells in the absence of added 
antigen 
In order to assess CD1 reactivity in human blood a functional assay was designed to 
measure responses of PBMC to the four CD1 isotypes CD1a, CD1b, CD1c and 
CD1d in the absence of added antigen. PBMC were co-cultured with mock 
transfected C1R cells (control) or C1R cells expressing single transfected CD1 
isotypes (CD1a-d) at 1:1 ratios for 3 days. The resulting reactivity was determined 
as the fold increases of measured cytokine (IFN-γ and IL-13), over the amount 
released in response to the mock (IFN-γ range 84-342 pg/ml, IL-13 range 5-25 
pg/ml). The mitogenic stimulator PHA was used as a positive control. Results from 
5 separate assays show 2-3 fold increases in reactivity of PBMC against CD1a (p 
=0.04) and CD1b resulting in IFN-γ release, and an ~1.5 fold increase in IL-13 
release in response to CD1a, CD1c (p =0.01) and d (Figure 3.6A and B 
respectively). 
  
3.3.4 CD3+ T cell responses to CD1a-d transfected C1R cells in the absence of 
antigen 
 
The experiments presented in section 3.3.3 used total PBMC as effector cells in the 
measurement of CD1 reactivity. However it is possible that the response observed 
includes non-T cell reactivity against C1R-CD1 cells and/or reactivity against CD1 
expressed by B cells and monocytes present in the PBMC. To eliminate this 
possibility magnetic bead enriched CD3+ T cells were used as effector cells. The 
resulting reactivity was determined by the fold increase of measured cytokine (IFN-γ 
and IL-13) over the levels released in response to the C1R mock transfected control 
(IFN-γ range 265-622 pg/ml, IL-13 range 26-31 pg/ml). Results from 5 assays 
showed that peripheral blood T cells exhibit significant reactivity against CD1d with 
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3.8 fold increase in IFN-γ (p =0.008) (Figure 3.7A) and 6 fold increase in IL-13 (p 
=0.04) (Figure 3.7B). Low level reactivity against CD1a was noted, with 2 fold 
increase in IFN-γ but not IL-13 secretion (Figure 3.7A&B).  
 
Figure 3.6: IFN-γ and IL-13 secretion by PBMC in response to CD1. (A) IFN-γ 
and (B) IL-13 release by PBMC in response to CD1a, b, c and d. PBMC were co-
cultured with CD1 transfected C1R cells at 1:1 ratios, the mock transfected C1R 
cell served as a control and T cell mitogen PHA as positive control. Cytokine 
levels are expressed as fold-increases in response to CD1-transfected cells 
compared to those released in response to the mock transfected control C1R cells. 
(IFN-γ range 84-342 pg/ml), (IL-13 range 4.5-25 pg/ml) measured by ELISA. 
Results are mean of 5 separate experiments. 
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Figure 3.7 IFN-γ and IL-13 secretion by CD3+ T cells in response to CD1. (A) 
IFN-γ and (B) IL-4 released by CD3+ T cells in response to CD1a, b, c and d. 
Magnetic bead enriched CD3+ T cells were co-cultured with CD1 transfected C1R 
cells at 1:1 ratios, the mock transfected C1R cell served as a control and T cell 
mitogen PHA as positive control. Cytokine levels are expressed as fold-increases 
in response to CD1-transfected cells compared to those released in response to the 
mock transfected control C1R cells (IFN-γ range 265-622 pg/ml), (IL-13 range 
26-31 pg/ml). Results are mean of 5 separate experiments. 
 
Chapter 3: Results 
 
 
109 
3.3.5 PBMC responses to CD1a-d transfected C1R cells in the presence of 
exogenous glycolipid antigen 
 
Since PBMC responses against CD1d were observed, we next examined the 
responses of PBMC to CD1d transfected C1R cells, in the absence and presence of 
100 ng/ml of two human CD1d binding glycolipid ligands, αGalCer & iGb3 
(Bendelac et al 2007). When PBMC were cultured with the mock transfected C1R 
cells, means of 220 ng/ml of IFN-γ and means of 14 ng/ml of IL-13 were detected in 
the supernatants 3 days after culture. These cytokine levels were 1.8 fold and 2 fold 
higher when CD1d transfected C1R cells were used as stimulators (Figure 3.8). In 
the presence of αGalCer loaded CD1d transfected C1R cells, a further increase in 
IFN-γ but not IL-13 secretion was observed. In the presence of iGb3 loaded CD1d 
transfected C1R cells, an increase in IFN-γ was observed but similar to αGalCer no 
increase in IL-13 release was observed compared to PBMC cultured with CD1d 
transfected cells (Figure 3.8). IFN-γ range 84-342 pg/ml, IL-13 range 5-25 pg/ml. 
These results suggest that a-GalCer and iGb3 
promote Th1 but not Th2 cytokine secretion by PBMC. 
 
 
3.3.6 CD3+ T cell responses to CD1a-d transfected C1R cells in the presence of 
exogenous glycolipid antigen 
 
We also examined the responses of magnetic bead enriched CD3+ T cells to CD1d 
in the absence or presence of αGalCer and iGb3. When enriched T cells were 
cultured with the mock transfected C1R cells, means of 220 ng/ml of IFN-γ and 
means of 14 ng/ml of IL-13 were detected in the supernatants 3 days after culture. 
These cytokine levels were 4 fold higher for IFN-γ secretion when CD1d transfected 
C1R cells were used as stimulators, but no increase in IL-13 was observed (Figure 
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3.9). In the presence of αGalCer loaded onto CD1d transfected C1R cells, an 11.6 
fold increase in IFN-γ (p =0.003) and 4.2 fold increase in IL-13 (p =0.03) secretion 
was observed. In the presence of iGb3 loaded onto CD1d transfected C1R cells, a 
6.1 fold increase in IFN-γ secretion and a 2.6 fold increase in IL-13 was observed 
when compared to CD1d transfected cells alone (Figure 3.9).  
 
 
Figure 3.8: (A) IFN-γ and (B) IL-13 secretion by PBMC in response to CD1 
loaded or unloaded with glycolipid. Graphs displaying CD1d reactivity by PBMC 
co-cultured at 1:1 ratios with CD1d transfected C1R cells in the absence or 
presence of 100 ng/ml of the exogenous lipid antigens αGalCer and iGb3. 
Cytokine levels are expressed as fold-increases in response to CD1-transfected 
cells compared to those released in response to the mock transfected control C1R 
cells (IFN-γ range 84-342 pg/ml, IL-13 range 5-25 pg/ml). Results are means of 5 
separate experiments. 
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Figure 3.9: CD1 reactivity by T cells in the presence of glycolipid: Graphs 
displaying CD1d reactivity by magnetically enriched T cells co-cultured at 1:1 
ratio with CD1d transfected C1R cells in the absence or presence of 100 ng/ml of 
the exogenous lipid antigens αGalCer and iGb3. Cytokine levels are expressed as 
fold-increases in response to CD1-transfected cells compared to those released in 
response to the mock transfected control C1R cells (IFN-γ range 265-622 pg/ml, 
IL-13 range 26-31 pg/ml). Results are mean of 5 separate experiments 
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 3.3.7 Invariant NKT cell populations in peripheral human blood 
 
Due to high levels of CD1d reactivity observed and significant responses to iNKT 
ligands αGalCer and iGb3 identified in previous experiments, enumeration of iNKT 
populations in human peripheral blood was determined by flow cytometric analysis. 
PBMC were co-stained using the invariant NKT mAb 6B11 and CD3 (Figure 
3.10A) or Vα24 and Vβ11 (Figure 3.10C). Using 6B11 co-stained with CD3 a mean 
of 0.05% cells stained positive for iNKT cells, from a cohort of 20 healthy donors 
with a range of 0.01% - 0.15% (Figure 3.10B). The co staining using Vα24 and 
Vβ11 resulted in a mean of 0.065% positive cells, from a smaller cohort of 7 healthy 
donors with a range of 0.02%  - 0.1% (Figure 3.10D). 
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Figure 3.10: Enumeration of iNKT cells in human blood: (A) Representative dot 
plot of cells expressing 6B11 and CD3, the upper right quadrant shows the iNKT 
cell population. (B) Invariant NKT frequency plot using 6B11 from 20 donors 
shows mean percentage of 0.05%. (C) Representative dot plot of cells expressing 
Vα24, Vβ11. Upper right quadrant shows the iNKT cells. (D) Frequency plot from 
7 donors using Vα24, Vβ11 shows mean of 0.06%. 
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3.4. Discussion 
 
CD1 expression has been described in many tissues, such as intestine, liver, spleen, 
thymus and lungs and on several populations of cells including monocytes, DCs and 
B cells. We examined human peripheral lymphocytes and monocytes from healthy 
donors for expression of CD1. In the investigation of CD1 expression, 4 subsets 
were examined; Monocytes (CD14+), B cells (CD19+), NK and NT cells (CD56+, 
(Natural T cells) CD56+ CD3+) and T cells (CD3+). Our findings showed that 
monocytes and B cells can express all isoforms, with CD1d being the most 
abundant. Little or no CD1 expression was found on NK, NT cells or T cells (Figure 
3.4). This study identifies CD1d as the most abundantly expressed isoform and 
monocytes as the major population of CD1 expressing cells in human peripheral 
blood. This is consistant with the CD1 expression levels described in previous work 
(Martin et al 1987, Porcelli 1995, Bendelac et al, 2007). CD1d is also expressed on 
epithelial cells and in several tissues including skin and adipose tissue. 
 
Due to the lack of CD1a, CD1b and CD1c in murine models, the majority of CD1 
restricted T cells described and studied are CD1d restricted T cells. T cells restricted 
by CD1a, CD1b or CD1c are reported in the context of microbial infection 
(Gumperz & Brenner 2001, De Libero et al 2005). Previously Kenna et al 
investigated CD1 group 1 and 2 reactivity by hepatic mononuclear cells and reported 
that reactivity was observed against CD1c and CD1d but not CD1a or CD1b. We 
aimed to test the CD1 reactivity to all 4 isotypes in healthy human peripheral blood 
with the aim of identifying populations of CD1 restricted T cells as this is not well 
defined in the literature. 
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 In the investigation of CD1 reactivity in human blood in the absence of added 
antigen, low level reactivity was observed against CD1a, b and d in the form of IFN-
γ secretion and CD1a, c and d in the form of IL-13 secretion (Figure 3.7). The 
cytokines detected might not be solely attributed to CD1 reactivity by T cells due to 
the mixed PBMC populations, so the study was repeated using magnetic bead 
enriched CD3+ T cells. Low level reactivity in the form of IFN-γ secretion was 
noted for CD1a but the majority of CD1 reactivity was observed against CD1d, in 
the form of both IFN-γ and IL-13 secretion (Figure 3.8). Reactivity to CD1a, b or c 
was not readily detected in healthy human peripheral blood. In discussion with Dr 
David Lammas, it was hypothesized that reactivity with CD1a, CD1b and CD1c is 
only observed in the presence of microbial infection (Personal communication with 
Dr David Lammas, University of Birmingham, UK). Previous studies describing 
CD1a, b and c reactivity was predominantly in the presence of microbial infection as 
described in section 1.6.6.  
 
Due to the predominant CD1d reactivity by human T cells, two human CD1d 
binding glycolipids were included in the reactivity assay; αGalCer and iGb3. Several 
groups have reported CD1d restricted T cell reactivity to these ligands (Kawano et al 
1997, Zhou et al 2004). In the PBMC reactivity assay, a response comparable to that 
of PHA was observed with the addition of both ligands (Figure 3.9), and as before 
CD1d reactivity in the form of cytokine secretion was increased with the substitution 
of PBMC with purified CD3+ T cells. The literature describes this subset of CD1d 
restricted T cells which respond to αGalCer and iGb3 as invariant iNKT cells 
(Bendelac et al, 1997).  
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In the final study of this section we investigated the frequency of iNKT cells in 
human peripheral blood. The range of peripheral human iNKT cells is reported in 
several studies as 0.01-1% of lymphocytes (Prussin & Foster 1997, Exley et al 1998, 
Kronenberg et al 2005). It has also been reported that iNKT cell numbers in the 
periphery is changed in cancer (Kawano 1999). We examined the range of iNKT 
cells in healthy human peripheral blood using 2 different staining patterns, the mAb 
pairings of Vα24, Vβ11 and 6B11, CD3 a mean of 0.05% iNKT cells was observed 
in human peripheral blood, this is within the ranges reported in the literature of 
0.01%-1% (Prussin & Foster 1997, Exley et al 1998, Kronenberg et al 2005). It is 
well established that iNKT vary in frequency between peripheral blood and tissues 
in both humans and mice, with mice having significantly more iNKT cells than 
humans (Bendelac et al 1997, Kronenberg et al 2005). NKT cells comprise 0.5% of 
hepatic T cells compared to 50% in murine liver (Kenna et al 2007). Recently Lynch 
et al reported the presence of a significant population in the human omentum, the 
highest frequency reported in humans to date (Lynch et al, 2009). The presence of 
more significant populations of iNKT cells in humans, such as those in the omentum 
suggests new roles for iNKT cells in immunity and regulation. In this chapter we 
investigated the expression of CD1 on PBMC and found that monocytes and B cells 
but not T cells or NK cells express all isoforms with CD1d being the most 
abundantly expressed. We aimed to identify populations of CD1 restricted T cells in 
peripheral blood and found that the majority of CD1 restricted T cells in healthy 
human peripheral blood are CD1d restricted. 
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3.5 Conclusions 
• CD1 is predominantly expressed in human peripheral blood by the 
professional antigen presenting cells, monocytes and B cells 
• CD1d is most abundantly expressed CD1 molecule on human PBMC 
• CD1a, b and c reactivity is very weak in healthy human peripheral blood 
• CD1d restricted T cell activity is the most abundant in healthy human 
peripheral blood 
• iNKT cells comprise ~0.05% of peripheral human PBMC and react to the 
CD1d antigens αGalCer and iGb3 
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4: Results: Expansion and 
Characterisation of Human NKT cells 
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4.1 Introduction 
Invariant natural killer T (iNKT) cells are a rare subset of human innate T cells 
(0.01-1% of PBMC), which express an invariant TCR (Vα24 Jα18) and NK cell like 
surface molecules (e.g. CD56, CD94, CD161). The invariant TCR recognises 
glycolipid antigen presented by CD1d molecules. The natural ligand is currently 
unknown but several iNKT agonists have been identified. The glycolipid αGalCer, 
derived from marine sponge is the best defined agonist and the current “gold 
standard” for iNKT activation (Kawano et al, 1997, Kronenberg, 2005).  
 
Invariant NKT cells vary in their surface phenotypes and functionally distinct 
subsets (CD4+ subsets, DN subsets, CD94+ iNKT cells) (Bendelac et al, Exley et 
al, 1998, Nicol et al, 2000). Some subsets of iNKT cells display potent cytotoxic 
ability but classically iNKT cells are best described as prolific cytokine producers 
(Yoshimoto et al 1994, Matsuda et al, 2000, Godfrey et al 2002, Kronenberg, 
2005). The simultaneous secretion of both IFN-γ and IL-4 is a defining factor of 
some iNKT cells (Exley et al 1997, Chen & Paul, 1997). iNKT cells can however 
secrete a wide range of immunomodualtory cytokines, such as; GM-CSF, IL-2, IL-
5, IL-6, IL-10, IL-13, IL-17, IL-21, TNF-α (Matsuda et al, 2008). 
 
The small numbers of iNKT cells (~0.05%) present in human peripheral blood 
(Figure 3.11), provide a difficult obstacle in the functional study of iNKT cells. The 
most efficient way to study circulating human iNKT cells is to isolate and expand 
them in vitro. Several methods are described in the literature (Porcelli et al 1996, 
Exley et al, 1997, Tahir et al 2001, Exley et al, 2003). In this body of work we 
aimed to investigate and optimize 3 methods to obtain highly pure populations of 
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iNKT cells. We also aimed to test the functional capabilities of the resulting iNKT 
cell lines for cytokine production and cytotoxic activity in response to αGalCer. A 
method for the isolation and expansion of functional iNKT cells from human 
peripheral blood will provide a tool for use in a series of assays for testing novel 
αGalCer analogues (Chapter 6) and the reciprocal interactions between iNKT cell 
and peripheral blood DCs (Chapter 5). 
 
Three methods were tested for the isolation and expansion of iNKT cells from fresh 
healthy human blood. Method 1 (Figure 4.1) was adapted from a method described 
in 1997 by Exley et al. PBMC were stained using mAb 6B11 PE as previously 
described in chapter 2, and positively stained cells were magnetically separated 
using anti-PE magnetic Microbeads. The purified iNKT population was cultured 
with irradiated PBMC from two donors acting as feeders and accessory cells. 
Glycolipid (αGalCer) was added at 100 ng/ml along with 50 U/ml of IL-2 on day 1. 
The cultures where then cultured in a CO2 incubator and fresh IL-2 added every 3 
days.  
 
Method 2 was adapted from method described by Tahir et al (Tahir et al, 2001). 
The iNKT cell isolation procedure was repeated for Method 2 and isolated cells 
were again cultured with irradiated PBMC from 2 donors but PHA stimulation was 
substituted for glycolipid stimulation on day 1. Cells were cultured with IL-2 and 
the stimulations were repeated on day 14 and subsequently every 14 days.  
 
The third method was adapted from a protocol outlined in 2003 by Exley et al. This 
method differed from method 1 and 2 only in the stimulation steps. The protocol 
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describes the stimulation of purified iNKT cells with irradiated feeders and 
αGalCer, then the transfer of expanding iNKT cells to anti-CD3 mAb coated plates. 
After personal communications with Prof Mark Exley, the purified iNKT cells 
where cultured on day 1 in wells coated (4 hours prior to use) with 1 µg/ml of the 
anti-CD3 monoclonal antibody OKT-3. No irradiated feeder cells were used. This 
simplified the protocol. On day 2, 50 U/ml of IL-2 was added to the culture. IL-2 
medium was replenished every 7 days (Figure 4.1).   
 
After the expansion and development of iNKT cell lines, we phenotyped expanded 
iNKT cell lines by flow cytometry to confirm their identity as iNKT cells, to 
determine iNKT cell purities and to determine their surface phenotypes.  These 
lines were then used for functional studies. 
 
4.2 Objectives 
1. To optimize a method for the isolation and expansion of iNKT cells from 
human peripheral  blood 
2. To phenotypically characterise expanded iNKT cell lines 
3. To functionally characterise iNKT cell lines 
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Figure 4.1: Strategy for the expansion and generation of NKT cell lines: Three 
methods (1-3) were employed. Each method was based on the same isolation 
method of staining with 6B11 PE mAb and the magnetic removal of PE stained 
cells using anti-PE Micro-bead. The 6B11+ cells were then stimulated by 1 of 3 
methods; (1) culture with irradiated feeders and 100 ng/ml αGalCer, (2) culture 
with irradiated feeders and 10 µg/ml PHA or (3) incubation on anti-CD3 OKT-3 
coated plates. All cultures were maintained in the presence of IL-2 from day 2 
onwards. 
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4.3.1: Optimization of iNKT cell expansion  
PBMC were prepared from a total of 35 buffy coat packs, before being used for 
magnetic bead separation of iNKT cells. Because of the low frequencies of iNKT 
cell in peripheral human blood the yields and purities were not determined in order 
to maximise the starting numbers of iNKT cells in the expansion phase. iNKT cells 
isolated from peripheral human blood were expanded in vitro using 3 methods. The 
yields and purities of iNKT cells were then determined by EBAO cell counting and 
flow cytometry. Ten lines were generated using Method 1. This method resulted in 
minimal expansion of iNKT cells, and low purities ranging from 0.8% to 2.1% with 
a mean of 1.5% of cells expressing the iNKT marker 6B11. Method 1 also yielded 
low numbers of cells (Figure 4.2A, 4.3A). Five lines were established using method 
2 and yielded cell lines with purities of iNKT cells ranging from 1% to 25% of 
cells. Although significant expansions were achieved, numbers of iNKT cells 
remained modest with yields reaching 5x106 of cells expressing the iNKT marker 
6B11 (Figure 4.2B, 4.3B). 7 lines were established using method 3.  The purities of 
iNKT cells in these lines ranged from 15 to 99% with the average purity of 57% 
(Fig 4.4, 4.5A-B). Numerically, yields were also high with total cell numbers 
reaching <50x106 cells total. iNKT cells were detected by staining aliquots of each 
cell line with 3 different combinations of mAb and analysis by flow cytometry. 
Interesting to note is the variation in iNKT cell frequencies determined when three 
different types of flow cytometry stainings were used. Staining of the same lines 
with Vα24 and Vβ11, 6B11 and CD3, or the CD1d tetramer with CD3 (Figure 
4.5A-D) resulted in different estimates of iNKT cell purity. The CD1d tetramer 
loaded with αGalCer was used to verify several of the lines but was not routinely 
used due to budget and time restrictions. 
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Method 3 was the choice of method used for development of further iNKT lines. In 
total 20 iNKT cell lines were established using Method 3. Of the 20 lines, 7 lines 
successfully expanded to purities of over 30%, the remaining lines either failed to 
expand or never reached purities in excess of 30% (Figure 4.7). 
 
 
Figure 4.2: Expansion of iNKT from human blood: Line graphs displaying the 
percentage of iNKT cells over time from isolation (1) to post expansion (2). Time 
point 1 represents the % of iNKT in PBMC from each donor before isolation. (A) 
Method 1, (B) Method 2 and (C) Method 3. iNKT cells were isolated from 
peripheral blood using magnetic Microbead separation, and expanded using 
either 100 ng/ml αGalCer and irradiated feeders (Method 1), PHA and irradiated 
feeders (Method 2) or plate bound OKT3 anti CD3mAb in the absence of 
irradiated feeders (Method 3).  
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Figure 4.3: iNKT cell expansion. Representative flow cytometry dot plots of 
expanded iNKT populations using (A) Method 1 and (B) Method 2. Cells in the 
upper right quadrants are positive for 6B11 and CD3. 
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Figure 4.4: Expansion of iNKT cells. Flow cytometry dot plots of five different 
iNKT cell lines generated using Method 3. Cells in the upper right quadrant are 
positive for CD3 and 6B11 and deemed to be iNKT cells (dot plots are 
representative of 20 iNKT cell lines). Only lines with purities in excess of 30% 
purity were used in subsequent experiments. 
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Figure 4.5: Flow cytometric detection of iNKT cells.  Three different staining 
procedures were used to detect iNKT cells by flow cytometry. iNKT cell line 
number 3 was stained with mAbs specific for the Vα24 and Vβ11 TCR chains (A), 
CD3 and a CD1d tetramer loaded with αGalCer (B) or 6B11 and CD3 (C). Cells 
in the upper right quadrants are iNKT cells. (D) Scatter plot displaying the 
difference in % purity determined for 2 iNKT lines using the 3 staining methods. 
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4.3.2: iNKT cell phenotyping  
Seven iNKT cell lines expanded from human blood with purities of over 30% were 
characterised by flow cytometric analysis of iNKT cell surface marker phenotypes. 
Electronically gated iNKT cells where analysed for the expression of CD4, CD8, 
CD94 and CD161 by co-staining with mAbs specific for these molecules and mAbs 
specific for CD3 and 6B11. Phenotypic profiles of two iNKT cell lines are shown in 
figure 4.6 and 4.7. The percentage of gated iNKT cells that expressed CD4, CD8, 
DN, CD94 and CD161 on iNKT cell line generated from 7 donors are shown in 
figure 4.8. CD4 was expressed by a mean of 48% of iNKT cells (Figure 4.8) with a 
range of expression from 31% to 75% (Figure 4.8). CD8 was expressed by a  mean 
of 11% of iNKT cells (Figure 4.8) with a range of 5 to 15 % expression. iNKT cells 
double negative for CD4 and CD8 (DN) comprised 40% of iNKT cells examined 
with range varying from 14% to 63% (Figure 4.8).  The co-stimulatory/inhibitory 
molecule CD94 was expressed on a mean of 13% of iNKT cells with a range of 
expression from 1% to 33% (Figure 4.8). CD161, another stimulatory/inhibitory 
molecule had mean expression of 40% on the lines examined with a range of 13.3% 
to 69% (Figure 4.8). These results show that iNKT cells are phenotypically 
heterogeneous. 
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Figure 4.6: Phenotypic characterisation of iNKT cell line Number 3 by flow 
cytometry. Flow cytometric dot plot showing expression of Vα24 and Vβ11 TCR 
chains (A) and  6B11 and CD3 (B). C-F, flow cytometry dot plots showing the 
expression of CD4, CD8, CD94 and CD161 by electronically gated iNKT cells.  
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Figure 4.7: Phenotypic characterisation of iNKT cell line number 7 by flow 
cytometry. Representative flow cytometric dot plot showing expression of Vα24 
and Vβ11 TCR chains (A), and 6B11 and CD3 (B). C-F, flow cytometry dot plots 
showing the expression of CD4, CD8, CD94 and CD161 by electronically gated 
iNKT cells
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Figure 4.8: iNKT cell line phenotypes: Scatter plot showing the mean frequencies 
(horizontal line) of surface marker expression by iNKT cells in cell lines 
established using Method 3. Cell markers are shown as percentage of the 6B11 
positive cells. Results are based on 7 iNKT cell lines from different donors. 
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4.3.3: Investigation into iNKT cell cytokine secretion in response to CD1d and 
exogenous glycolipid αGalCer 
 
CD1d reactivity and glycolipid specificity of iNKT cell lines were assessed in 
functional assays. iNKT cells were expanded from human peripheral blood using 
Method 3 (described in section 4.3.1) and were co-cultured with the stably 
transfected C1R CD1d cell line, loaded or unloaded with 100 ng/ml of αGalCer, 
using mock transfected C1R cells as negative control and the T cell mitogen PHA 
as positive stimulus. Reactivity was measured by quantifying secreted IFN-γ and 
IL-4 in cell culture supernatants using ELISA. Small amounts of IFN-γ (112 pg/ml) 
and IL-4 (58 pg/ml) were released by iNKT cell lines cultured with mock-
transfected C1R cells. iNKT cells co-cultured with CD1d transfected C1R cells 
released means of 4.5 and 3 fold more IFN-γ and IL-4 respectively. The levels of 
both cytokines were increased with the addition of iNKT ligand αGalCer with 8 
fold more IFN-γ (p =0.01) and a 7 fold increase in IL-4 secretion (p =0.04) 
compared to the levels released in response to mock transfected C1R cells (Fig 4.9 
A&B). To confirm that this cytokine secretion required CD1d, CD1d molecules on 
C1R CD1d cells were blocked using anti-CD1d mAb and iNKT cell reactivity 
against CD1d transfected C1R cells in the presence or absence of αGalCer was 
tested as before. This resulted in 4 fold reductions in both IFN-γ and IL-4 secretion 
in comparison to the CD1d loaded with αGalCer (Figure 4.9 A&B). These results 
indicate that the iNKT cell lines respond to αGalCer in a CD1d dependant manner, 
releasing IFN-γ and IL-4. 
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Figure 4.9: iNKT cell responses to CD1d: Bar graphs showing the fold increase 
in levels of secreted (A) IFN-γ and (B) IL-4 by iNKT cells in response to mock 
transfected C1R cells or CD1d transfected C1R cells in the presence or absence of 
αGalCer. Block denotes the blocking of loaded CD1d with an anti-CD1d mAb as 
a control for specificity. PHA was used as a positive stimulus. Results are a mean 
of 5 separate experiments. 
 
 
 
4.3.4: Investigation into iNKT cell cytotoxicity against CD1d transfected C1R 
target cells  
iNKT cell cytotoxic capabilities were assessed using the total cytotoxicity and 
apoptosis assay (Chapter 2). C1R cells stably transfected with CD1d were labelled 
with CFSE and were incubated with iNKT cells in the presence or absence of 
αGalCer for 4 hours at effector target ratios of 10 to 1. After incubation cells were 
co stained with 7-AAD, a marker of recent apoptosis and double positive cells 
staining for CFSE and 7-ADD represented apoptotic target cells. C1R CD1d target 
cells incubated with no effector cells resulted in a mean of 3% apoptotic target cells 
(Figure 4.10A, 4.11), Addition of iNKT cells resulted in a mean lysis of 9% of 
target C1R CD1d cells (p =0.03) (Figure 4.10B, 4.11). The further addition of 
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αGalCer resulted in an increase in lysis to 13% of the target cells (p =0.002) (Figure 
4.10C, 4.11). These results indicate that the iNKT cell lines are capable of killing 
CD1d expressing target tumour cells and this cytotoxicity is enhanced with 
αGalCer. 
 
 
Figure 4.10: iNKT cell cytotoxicity against CD1d transfected C1R cells. Flow 
cytometric dot plots representative of iNKT target cell lysis. C1R-CD1 cells 
labelled with CFSE stain were cultured with iNKT cells in the absence or 
presence of αGalCer. A, Target cells alone. B, Target cells co cultured with iNKT 
cells. C, Targets co cultured with iNKT in the presence of 100ng/ml of αGalCer. 
Cells in the upper right quadrant represent apoptotic target cells. Results are 
representative of 3 different experiments. 
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Figure 4.11: iNKT cell cytotoxicity against CD1d+ target cells. CFSE labelled 
CD1d transfected C1R target cells were incubated either alone, with iNKT cells in 
the presence or absence of 100 ng/ml of αGalCer for 4 hours at 10:1 ratios. The 
induction of apoptosis was identified using the apoptotic stain 7-AAD. Results are 
mean of 3 separate experiments. 
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4.3.5: Investigation into iNKT cell cytotoxicity against K562 targets 
Natural cytotoxicity by iNKT cells against the CD1d-negative NK sensitive human 
cell line K562 was also assessed using the CFSE incorporation cytotoxicity assay 
(Figure 4.12). K562 target cells stained with CFSE were incubated with iNKT cells 
in the absence or presence of αGalCer for 4 hours at effector target ratios of 1:1, 
10:1 and 20:1 (Figure 4.13). After incubation cells were co-stained with 7-AAD. 
Double positive cells (CFSE and 7-AAD) represented apoptotic target cells. K562 
target cells incubated in the absence of effector cells resulted in 3% apoptotic cells 
(Figure 4.12A). Addition of iNKT cells resulted in mean lysis of 19% of target cells 
(p =0.0001) (Figure 4.12B & 4.13). Addition of αGalCer resulted in an increase in 
lysis to 26% of target cells (p =0.0035) (Figure 4.12C, 4.13 & 4.14). These results 
indicate that the iNKT cell lines are capable of killing CD1d negative target tumour 
cells and this cytotoxicity is enhanced with αGalCer. H&E staining of iNKT cell 
and K652 co-cultures show that cell to cell contact occurs in the co-cultures (Figure 
4.15). 
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Figure 4.12: iNKT cell cytotoxicity against K562 cells. Flow cytometric dot plots 
representative of iNKT target cell lysis. K562 cells labelled with CFSE were 
cultured with iNKT cells in the absence or presence of αGalCer. (A) Target cells 
alone. (B) iNKT co cultured with targets . (C) iNKT co cultured with targets in the 
presence of 100 ng/ml of αGalCer. Cells in the upper right quadrant represent 
apoptotic target cells. Results are representative of 3 different experiments. 
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Figure 4.13: iNKT cell cytotoxicity against K562 target cells. CFSE labelled K562 
target cells incubated either; alone, with iNKT in the presence or absence of 
100ng/ml of αGalCer at 10:1 ratios. The induction of apoptosis was identified 
using the apoptotic stain 7-AAD. Results are the mean of 3 separate experiments 
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Figure 4.14: Killing of K562 target cells by iNKT cell lines. Line graph displaying 
lysis of CFSE labelled K562 cells by iNKT at 3 effector target ratios, 1:1, 10:1 and 
20:1. CFSE labelled K562 target cells were incubated with iNKT cells at different 
ratios for 4 hours. The induction of apoptosis was identified using the apoptotic 
stain 7-AAD. 
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Figure 4.15: iNKT tumour cell cytotoxicity. Histology picture showing a H&E 
stained (A) K562 tumour cell in contact with (B) 3 iNKT cells.  The identity of the 
cells is achieved by comparison with H&E stained K562 and iNKT cells cultured 
alone. K562 targets cells were incubated for 4 hours with iNKT cells then 
smeared on a microscope slide, dried for 24 hours and stained using hematoxylin 
and eosin. The slides were dried for 24 hours and a covered with a cover slip.
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4.4 Discussion 
Several investigators have described the expansion of iNKT cells using αGalCer 
stimulation in the presence of irradiated feeder cells and IL-2 (Tahir et al 2001, 
Exley et al, 2003). We used this expansion method (Method 1) starting with 
magnetic bead enriched iNKT cells cultured with irradiated PBMC from 2 separate 
donors, 100 ng/ml of αGalCer and 50 U/ml of IL-2. Method 1 resulted in very weak 
expansion with low purities of iNKT cells. The highest yield achieved after 3 
rounds (6 weeks) of stimulation was 2x106 cells of which iNKT purity was 1.5%. 
This is not concurrent with Tahir et al (2001) who obtained pure populations of 
iNKT cells with good yields. 
 
In Method 2, the T cell mitogen PHA was substituted for the specific iNKT agonist 
αGalCer as used in Method 1. Stimulated iNKT cells were cultured the presence of 
irradiated feeder cells and IL-2 (Exley et al 1997). Method 2 resulted in higher 
yields of cells and better iNKT purities. The highest yield achieved by Method 2 
was 5x106 cells, with a purity of 25% iNKT cells from 5 lines plated (Figure 4.2B). 
Again this method was reported in the literature as a procedure for the expansion of 
highly pure iNKT cell lines (Exley et al 1997). 
 
After personal correspondence with Prof Mark Exley, Harvard Medical School, 
Method 3 using plate bound anti-CD3 mAb clone OKT-3 was used to expand iNKT 
populations. Method 3 resulted in good yields, with up to 5x107 cells with purities 
ranging from 30% up to 97% (Figure 4.5). Method 3 was used as the optimal 
technique for iNKT expansion, however the failure rate of lines as with Methods 1 
and 2 remained high with only 1 line from every 3 expanding. The reason for this 
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“failure” of cells to expand could be attributed to low responding individuals. 
Croudace et al (2008) reported that healthy PBMC donors could be divided into 
those who responded to αGalCer stimulation and those who responded poorly or not 
at all, These authors observed that these good and weak responder phenotypes 
remained stable over time and upon restimulation, only the individuals who 
responded initially showed a secondary response to αGalCer stimulation (Croudace 
et al 2008).  
 
As outlined above, Methods 1 and 2 have been successfully used to expand human 
iNKT cells in vitro (Tahir et al 2001, Exley et al 1997, Exley et al 2003). Several 
reasons could explain the failure of Method 1 and 2 to expand iNKT cells; (1) It is 
possible that the iNKT cells were overstimulated.  In Methods 1 and 2, cells were 
re-stimulated every 14 days, whereas the authors of the previous studies stimulated 
their cells every 3-6 weeks.  Method 3 only used a single stimulation and expanding 
cells where maintained with IL-2. iNKT cells upon stimulation internalise their 
TCR to avoid overstimulation (Crowe et al 2002), therefore it is possible that iNKT 
cells are not detected by surface mAb staining. (2) iNKT cell purities or yields were 
not assessed after magnetic bead separation, to maximise the number of iNKT cells 
used. It is possible that low yields and purities were obtained using this procedure 
and this could explain the low rates of expansion and the proliferation of non-iNKT 
CD3+ cells. Importantly, the authors of the above-mentioned papers sorted their 
cells using a high speed flow cytometric cell sorter. (3) Non-optimal cell densities: 
purified iNKT cells where cultured with irradiated PBMC, the presence of which 
made it difficult to assess the levels of iNKT cells microscopically, cell cultures 
may have been overcrowded or split before full proliferation was induced. Method 
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3, because of the lack of feeder cells, allowed easier maintenance and visualisation 
of cell densitiy of 1X106 iNKT cells/well. (4) The reagents may not have been 
optimal: after lengthy discussions with several collaborators, the question of 
reagents was raised (FBS, PHA, αGalCer, OKT-3 anti CD3 mAb) and differences 
between sources could explain why the Methods outlined worked for the original 
authors but failed in this body of work. 
 
During identification of iNKT cells it was noticed that the numbers of iNKT cells 
within each line differed depending on the mAb used for their detection by flow 
cytometry. A sample of each iNKT cell line was stained using either; Vα24 and 
Vβ11 mAbs, CD3 and 6B11 mAb or αGalCer loaded CD1d PE tetramers with CD3 
mAb. In one iNKT cell line, αGalCer loaded CD1d PE tetramers and CD3 mAb 
stained 97% of cells, while 65% of the same population stained with 6B11 and CD3 
mAb, and the mAb pairs Vα24 and Vβ11 stained 43%. Possibly the staining of the 
iNKT TCR with multiple mAbs versus a single mAb or CD1d tetramer could 
explain the difference in cell number between methods, where one mAb could 
partially block the second directed against the same receptor. Also noted in the 
iNKT line dot plots was a perception of streaking populations, initially flow 
cytometric compensation settings where adjusted but the numerous “streaking” 
populations did not change. Godfrey et al previously reported that iNKT cell 
internalize their TCR upon TCR stimulation to prevent over activation and the 
iNKT cells then re-introduce the receptor to the surface as they become rested 
(Crowe et al, 2003). This could explain the differential expression of the TCR by 
the iNKT cell lines as they were stimulated using plate bound OKT-3 anti CD3 
mAb and IL-2 during culture. 
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Expanded iNKT cells were characterised by flow cytometry to determine the iNKT 
surface molecule phenotypes. Of 20 iNKT cell lines generated we phenotypically 
assessed 7 lines, each which had a purity in excess of 30% 6B11 positivity. 
Previous studies have described subsets of CD4+, CD4-CD8- in mice and humans 
and CD8+ iNKT cells in humans but not mice (Bendelac et al, 2007, Matsuda et al 
2008). Analysis of our iNKT lines showed mixed populations with ~50% cells 
expressing the CD4+ phenotype, 43% expressing the DN phenotype and 7% 
expressing CD8.  
 
Different subsets of iNKT cells which express different surface marker repertoires 
have previously been described (Bendelac et al 2007, Exley et al 1997, Exley et al 
1998). The iNKT cell lines generated in the present work consisted of mixed 
subsets. The generation of iNKT clones or homogenous iNKT cell lines was not 
attempted, due to time/equipment limitations. Furthermore we aimed to minimize 
the protocol for the generation of iNKT cell lines so that the method could be used 
in future iNKT cell based immunotherapy. Thus minimization of time and in vitro 
procedures would be beneficial. The surface phenotype of iNKT cells can 
determine their function. Exley et al (1997) reported that cytotoxicity by iNKT cells 
is CD1d restricted, but later Nicol et al showed that cytotoxicity by iNKT cells can 
occur independently of CD1d. These authors suggested that the expression of CD94 
by the iNKT cell lines may facilitate TCR-independent cytotoxicity (Nicol et al, 
2000). We assessed our lines for 2 inhibitory/stimulatory molecules, CD94 and 
CD161 expression by flow cytometry. CD94 was expressed at low frequencies 
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(<10%) whilst CD161 was expressed by ~50% of the iNKT cells examined (Figure 
4.7).  
 
iNKT cells are well described as potent cytokine producers, with the ability to 
simultaneously secrete IFN-γ and IL-4  in response to αGalCer stimulation (Exley 
et al, 1997, Chen and Paul 1997). We examined our iNKT cells’ ability to produce 
cytokine by co-culturing at 1:1 ratio with CD1d transfected C1R cells in the 
absence or presence of 100 ng/ml αGalCer. Optimal IL-4 secretion was observed 24 
hours after stimulation and optimal IFN-γ secretion was observed after 72 hours as 
described previously and in personal correspondence with Prof Mark Exley. In 
earlier cytokine experiments with PBMC and purified CD3+ populations, IL-4 was 
not readily detectable so IL-13 was substituted in its place.  In hindsight the time 
point of 72 hours was probably too long for the optimal detection of IL-4 in our 
assay supernatants. Addition of CD1d mAb partially blocked both IL-4 and IFN-γ 
secretion, verifying the role of CD1d in the activation of the iNKT cell lines (Figure 
4.8). The secretion of both cytokines could be due to the presence of a mixed iNKT 
cell subset population in our lines, previous studies have described different subsets 
preferentially secreting either both IFN-γ and IL-4 (CD4+ iNKT cells) or IFN-γ 
alone (DN iNKT cells) (Gumperz et al 2002, Lee et al 2002, Chen et al 2007). 
 
iNKT cells have been reported to lyse tumour cells in vitro (Exley et al, 1997, Nicol 
et al, 2000). We tested the cytotoxic abilities of our iNKT cell lines using CFSE 
labelled tumour cells as targets, we can report that our iNKT cell lines can 
efficiently lyse the CD1d transfected C1R cell line and the NK sensitive K562 
tumour cell line in the absence of αGalCer. The percentage specific lysis of both 
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targets was increased with the addition of αGalCer. iNKT cell lines efficiently lysed 
targets at effector target ratios of 1:1, 10:1 and 20:1, with 10:1 chosen as the 
optimum ratio due to cell number restraints. Activation of the iNKT cells in the 
absence of αGalCer in the cytokine and cytotoxicity assays may be influenced by 
their previous expansion and culture with IL-2. To reduce the possibility of 
activation by IL-2 cells where rested for 24 hour before use in assays. The lysis of 
the CD1d negative NK sensitive K562 tumour cell line by the iNKT cell lines 
shows the CD1d independent cytotoxic capabilities of iNKT cells, which may be 
mediated by surface receptors such as the NKG2 family of stimulatory/inhibitory 
molecules. Microscopic examination of the lysis cultures between K562 tumour 
cells and iNKT cell shows cell to cell contact, indicating this may be necessary for 
CD1d independent killing. Unexpectedly, the addition of αGalCer resulted in an 
increase in K562 killing. Cross presentation of the glycolipid by other CD1d 
expressing iNKT cells or other contaminating CD1d-positive cells, could be a 
explanation for this contribution of αGalCer to CD1d-independent cytotoxicity. The 
thorough examination of the killing mechanism was limited by the number of iNKT 
cells available.  
 
This chapter of work has optimized a previously described method for the isolation 
and expansion of human iNKT cells from peripheral blood.  Furthermore it 
examined the subsets within the cell lines established. The functional ability of the 
iNKT cell lines to produce cytokine and lyse tumour target cells was also 
investigated. We aimed to optimize and establish a method of expanding functional 
iNKT cells which provide a essential tool in subsequent chapters. 
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4.5 Conclusions 
• Purified iNKT cells expanded in response to the plate bound anti-CD3 mAb 
OKT-3 and IL-2 in the absence of irradiated feeder cells. 
• iNKT cell lines expressed phenotypes of mixed subsets (CD4+, CD4-CD8-, 
CD8+) 
• iNKT cell lines secreted IFN-γ and IL-4 in the presence of CD1d and 
αGalCer 
• iNKT cell lines efficiently lysed tumour cell targets in vitro in the absence 
of αGalCer, however the % specific lysis was increased in the presence of 
αGalCer 
• The iNKT cells expanded from human peripheral blood were both 
phenotypically and functionally concurrent with the literature (potent 
cytokine secreting cells with the ability to lyse target cells) and provided a 
valuable asset in the following body of work 
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5: Results: Reciprocal interactions 
between Human iNKT cells and 
Dendritic cells 
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5.1: Introduction  
Dendritic cells (DCs) are a population of cells which act as sentinels for the immune 
system, surveying the local environment, capturing and processing Ag for 
presentation to T cells. Thus DCs provide a link between the innate and the adaptive 
immune systems (Banchereau et al 2000). DCs exist in two main states with 
numerous intermediates; the Ag capturing and processing immature DC (iDC) and 
the Ag presenting and co-stimulatory mature DC (mDC). DCs are classed as 
professional antigen presenting cells (APCs) due to their ability to sample, capture 
and present a large antigenic load and their ability to provide both TCR stimulation 
(signal 1) and co-stimulation (signal 2) and the release of cytokines that polarize T 
cell responses (Signal 3) (Blanko et al 2008, Banchereau et al 2000). The provision 
of signal 1, 2 and 3 results in full activation of naïve T cells, and thus elicits a full 
and effective adaptive immune response (Banchereau & Steinman1998, Figor et al 
2004).  
 
Full maturation of the iDC is required for the provision of signal 2. Maturation is a 
process whereby the iDC encounters a maturation stimulus such as various pathogen 
products, inflammatory cytokines or TLR agonists. In this body of work the TLR 
agonists; LPS and poly I:C where used as maturation stimuli. LPS binds to cell 
surface TLR 4, while poly I:C binds to TLR3 found within intracellular vesicles. 
Upon binding a cascade of intracellular signals is initiated leading to the 
transcription of maturation associated genes. This leads to the upregulation of cell 
surface expression of MHC and co-stimulatory molecules such as CD40, CD80 and 
CD86. Other receptors induced on mature DC include CCR7, a chemokine involved 
in cell migration, CD40 which binds its ligand CD40L on T cells and augments the 
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co-stimulatory signal. CD54 is an adhesion molecule which binds LFA-1 on T cells 
and increases the avidity of the interaction between the DC and the T cell allowing 
ultimately T cell activation. CD80 is a co-stimulatory molecule expressed on DCs 
and binds CD28 expressed on T cells. CD83 is a classical maturation molecule, 
whose function or ligand is unclear. CD86 is a co-stimulatory surface molecule 
similar to CD80 and also binds CD28 on T cells. The resulting activation varies 
depending on which molecule CD28 binds. HLA-DR is human MHC II and is 
presentation molecule found on DCs and interacts with T helper cells (Banchereau et 
al 2000). 
 
The maturing DC leaves the tissue and migrates to the peripheral lymph nodes. The 
DC morphology changes and it develops the dendritic like structures to which it 
owes its name. Some DC reside in the lymph nodes but the subset detailed in this 
study are peripheral DC. The mature (mDC) can also produce cytokines such as IL-
12 and IL-10, which polarize adaptive immune responses. Once the mDC reaches 
the lymph node it encounters naïve T cells and presents the antigenic peptide bound 
to MHC molecules to T cells. The responding T cell receives co-stimulation signals 
via the CD80/CD86-CD28 interaction. This activates the naïve T cell to proliferate 
and respond in a specific manner. In the absence of co-stimulation the T cell 
becomes anergic and does not respond to the Ag presented, thus resulting in 
tolerance (Banchereau et al 2000, Figdor et al 2004). 
 
Due to the powerful abilities of DCs to elicit and skew a T cell response, they are 
now widely manipulated for therapeutic use. For successful elicitation of an 
effective T cell response the DC vaccine must be a fully mature DC providing both 
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signal 1 and 2. Adjuvants such as LPS can be used to mature the DC in conjunction 
with the target Ag (e.g. tumour Ag) (Steinman & Banchereau 2007, Figdor et al 
2004, Dubsky et al 2005) Another adjuvant used in DC vaccine studies is 
tocotrienol-rich fraction (TRF). TRF is a non-toxic natural compound, which has 
been shown to enhance the effectiveness of DC vaccines in murine models, with 
inhibition of tumour growth and increased IFN-γ and IL-12 (Hafid et al 2010). 
 
The reciprocal interactions between DCs and innate T cells (iNKT cells and γδ T 
cells) have been previously described in murine models (Brigl et al 2003, Fujii et al 
2004, Munz et al 2005, Ishikawa et al 2005). Murine iNKT cells have the ability to 
fully mature myeloid iDCs into antigen presenting cells expressing MHC, 
CD80/CD86, which produce bioactive cytokines (IL-12 and IL-10) (Munz et al, 
2005). Cytokines released by iNKT cells, and signals mediated by CD40-CD40L 
interactions achieved through direct contact between the DC and the iNKT cell are 
required for full activation of the DC and subsequent linking of innate and adaptive 
immunity (Fujii et al, 2003, Sporri & Reise-Sousa 2005). Vincent et al reported the 
interactions between self reactive human CD1 restricted cells and DCs in the 
absence of antigen result in DC maturation, they also report that distinct 
mechanisms of costimulation lead to profound differences in concomitant 
interleukin 12 p70 production (Vincent et al 2002). Yang et al reported that human 
Vα24+ NKT cells exhibited the same cross talk with monocyte derived DCs as their 
murine counterparts, and that iNKT cells select for a Th1 adaptive response through 
the production of IL-12 by DCs. The authors also described specific lysis of DCs by 
this NKT subset, and concluded this is a possible feedback control mechanism 
(Yang et al 2001). Ishikawa et al compared the interactions between Vα24 iNKT 
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cells and either monocyte derived DC and IL-2/GM-CSF cultured PBMC. The 
authors concluded the interactions resulted in the expansion of iNKT cells and the 
production of IFN-γ. PBMC cultured in the presence of IL-2/GM-CSF exhibited the 
better stimulatory effect compared to monocyte derived DCs (Ishikawa et al 2005). 
The study of the interactions between human iNKT cells and monocyte derived DC 
is not as extensively studied their murine counterparts, which highlights the need for 
in-depth studies of the reciprocal interactions between the two. 
 
This influence of iNKT cells on DC could possibly be harnessed as a cellular 
adjuvant for cell based therapies. Another benefit for using iNKT cell mediated 
maturation of DC is that, iNKT cells have direct anti-tumour effects and can 
mobilize an innate immune response (NK cells) and an adaptive response via B & T 
cell activation (Munz et al 2005). Nieda et al demonstrated that iNKT activated by 
αGalCer loaded DC induced NK and T cell expansion in cancer patients (Nieda et al 
2004). 
 
DCs are rare in human peripheral blood, therefore the study of DCs therefore 
requires the in vitro generation of DC from precursors. The method most widely 
used for the generation of monocyte derived DCs was first published in 1994 by 
Sallusto & Lanzavecchia. 
 
In this body of work we aimed to thoroughly investigate the reciprocal interactions 
between human monocyte derived DCs and iNKT cell in vitro. We aimed to 
establish a system to test novel αGalCer analogues potential for therapeutic use. 
Using the method described by Sallusto and Lanzavecchia we derived DCs from 
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monocytes and examined their immature phenotype, and determined if the TLR 
agonists LPS and poly I:C could induce phenotypic and functional DC maturation 
for use as positive controls. We investigated the ability of human iNKT cell and 
non-iNKT cells in the absence or presence of αGalCer to mature iDC into fully 
functional mDCs with the ability to elicit a T cell response (Figure 5.1). 
 
5.2: Objectives  
1. Establish a DC maturation system 
2. Investigate iNKT ability to activate immature DC 
3. Examine the reciprocal functional interactions and responses of iNKT and 
DC 
4. Investigate the T cell maturating capabilities of iNKT activated DC 
Chapter 5: Results 
 
 
154 
 
 
Figure 5.1: Strategy for the investigation of interactions between human iNKT 
and dendritic cells: Monocyte derived immature DC were cultured in the presence 
or absence of αGalCer. LPS or poly I:C were included as positive control for DC 
maturation whilst non iNKT cells or culture medium serve as negative control. 
After stimulation DCs were examined for surface marker expression, cytokine 
production and their ability to activate naïve T cells. 
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5.3.1: Effect of LPS and Poly I:C on dendritic cells.  
Monocyte-derived dendritic cells (DC) were cultured from human peripheral blood 
as described in chapter 2. The starting number of PBMC and the purities of isolated 
monocytes were assessed over 8 experiments. The average starting number of 
PBMC was 4.96 x 108 and after magnetic bead separation the average number of 
CD14+ monocytes retrieved was 1.67 x 107. Monocyte purities were examined by 
flow cytometry and are shown table 5.1. The generation of immature DC from 
monocytes resulted in the downregulaton of CD14 so expression of CD14 was 
analysed in order to assess DC maturation (Figure 5.2).  
 
The effects of LPS and poly I:C on iDC maturation was investigated by examining 
changes in cell surface marker repertoires by flow cytometry (Figure 5.3) and by 
quantification of secreted cytokines by ELISA (Figure 5.4). iDC were incubated for 
24 hours in medium alone (control) or in the presence of LPS or poly I:C. The levels 
of expression of seven surface molecules were investigated for each set of DC, 
namely CCR7, CD40, CD54, CD80, CD83, CD86 and HLA-DR.  
 
CCR7 was undetectable on iDC having similar fluorescence intensities to iDC 
stained with isotype control antibodies. Stimulation with LPS or Poly I:C resulted in 
mean inductions of 1.7 and 2 fold (p =0.03) increases in fluorescence intensities of 
CCR7 surface expression respectively. CD40 was also expressed on iDC at low 
levels and the mean surface expression was increased 7 fold (MFI) with LPS 
stimulation (p =0.003) and 5.5 fold with poly I:C stimulation (p =0.008). CD54 was 
expressed at moderate to high levels on iDC, and the mean expression levels were 
increased 3 and 2 fold with LPS (p=0.008) and poly I:C (p=0.015) respectively. 
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CD80 was expressed at low levels on iDC (compared to isotype control staining 
intensities), and this was not increased by LPS or Poly I:C stimulation within 24 
hours. CD83 was expressed at very low levels on iDC, with intensities similar to 
those of the isotype control. LPS stimulation induced a (mean 3.5 fold) increase in 
expression (p =0.002), whilst poly I:C resulted in smaller (mean 1.7 fold) increase in 
surface CD83. CD86 was expressed at low levels by iDC, stimulation with LPS and 
poly I:C resulted in (4.5 and 3.7 fold respectively) increases in surface expression( 
p= 0.0007 and p =0.02). HLA-DR was expressed at moderate levels on iDC with 
fold increases in expression of 2 and 1.6 with LPS and poly I:C stimulation 
respectively (Figure 5.3). These results show that LPS and poly I:C treatment of iDC 
result in the upregulation of Ag presentation and co-stimulation molecules. This 
confirms that iDC could be obtained from healthy human peripheral blood and 
matured using the TLR ligands LPS and poly I:C.  
 
Cytokine secretion by DC incubated with LPS or poly I:C was examined by ELISA. 
Levels of IL-10 and IL-12 were compared to those released by iDC incubated in 
medium alone (control). Cytokine secretion was quantified from 5 experiments and 
expressed as fold increases over the levels released by iDC cultured in medium 
alone (IL-12 range 41-88 pg/ml, IL-10 range 54-108 pg/ml). Stimulation of iDC 
with LPS resulted in a mean 5 fold increase in IL-12 (p =0.041) (Figure 5.4A) and 8 
fold increase in IL-10 secretion (p =0.007) (Figure 5.4C). Poly I:C stimulation 
resulted in 2.5 fold increase in IL-12 secretion (p =0.001) (Figure 5.4B) and ~1.5 
fold increase in IL-10 (p =0.04) (Figure 5.4D). These results show that iDC can be 
isolated from healthy human peripheral blood and that the TLR agonists LPS and 
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poly I:C can induce DC maturation and cytokine production. For maturation 
purposes LPS was better than poly I:C and thus selected for use in later experiments.   
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Table 5.1: Yields and purities of CD14 magnetic bead enrichment of monocytes 
from PBMC 
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Figure 5.2. Downregulation of CD14 during the generation of iDC from 
monocytes. A & B, Flow cytometry dot plots showing the expression of (A) CD14 
and CD11c by monocytes sorted by magnetic-bead separation and (B) the CD14 
negative fraction. C & D, Flow cytometry histograms showing that CD14+ 
monocytes cultured with GM-CSF and IL-4 downregulate CD14 during the 
transition from (C) monocytes to (D) immature DC. Purple histsograms 
respresents isotype control staining. Results are representative of 8 donors. 
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Figure 5.3. LPS and Poly I:C induce DC maturation.  Flow cytometric histograms 
showing the intensities of CCR7, CD40, CD54, CD80, CD83, CD86 & HLA-DR 
expression by iDC cultured for 24 hours in medium alone (Purple), iDC cultured 
with LPS (Green) or  iDC cultured with Poly I:C (Blue). Bar charts showing 
average mean fluorescence intensity (MFI) of surface molecule expression 
observed in 5 independent experiments.  
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Figure 5.4: LPS and Poly I:C induce cytokine production by DC. Supernatants 
from iDC cultured with LPS or poly I:C for 24 hours were examined for levels of 
secreted IL-10 and IL-12 by ELISA. Bar charts show the fold increase in cytokine 
levels over those from unstimulated DC which released 41-88 pg/ml IL-12 and 54-
108 pg/ml IL-10 respectively. Results show levels of IL-12 (Purple) in response to 
LPS (A) and Poly I:C (B) and IL-10 (Blue) in response to LPS (C) and poly I:C 
(D) Results are mean of 5 independent experiments. 
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5.3.2: Effect of co-culturing iNKT cells with dendritic cells.  
Monocyte derived dendritic cells (DC) were incubated in medium alone (control) or 
co cultured with equal numbers of iNKT cells expanded from human peripheral 
blood (using Method 3, described in chapter 4) with or without the addition of 100 
ng/ml of αGalCer. Expression of seven surface molecules was investigated for each 
set of DC.  
 
The MFI of CCR7 expression on DC was increased 1.7 fold with iNKT cell co-
culture compared to DC cultured in media alone. CCR7 expression was further 
increased (final 2.5 fold) with the addition 100 ng/ml of αGalCer to the co-culture. 
CD40 surface expression was increased 1.5 fold with iNKT cell co-culture and 2.5 
fold with addition of αGalCer to the co-culture. CD54 expression was increased 3 
and 5 fold with co-culture of iNKT cells (p= 0.07) in the absence or presence of 
αGalCer (p =0.003) respectively. CD80 was expressed at low levels on iDC (similar 
to the isotype control), this was not increased by either co-culture after 24 hours. 
iNKT cell co-culture induced a 2 fold increase in CD83 expression, whilst co-
culture with iNKT cells and 100 ng/ml of αGalCer resulted in 4 fold increase in 
surface CD83 on DCs (p =0.01). Co-culture with iNKT cells resulted in a 2.5 fold 
increase in CD86 expression compared to iDC alone (p =0.03), whilst co-culture in 
the presence of αGalCer resulted in increase of 5 fold (p =0.01). HLA-DR 
expression was increased 1.25 fold and 1.5 fold on DC co-cultured with iNKT cells 
and iNKT cells in presence of αGalCer respectively (Figure 5.5). 
 
Cytokine secretion by DC incubated with medium alone or co-cultured with iNKT 
cells in the presence or absence of 100 ng/ml of αGalCer was examined by ELISA. 
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Culturing DC with αGalCer resulted in a 7 fold increase in IL-12 secretion 
compared to iDC cultured in medium alone (range 41-88 pg/ml). Levels of IL-10 
released by DC cultured in medium alone (range 54-108 pg/ml) were not altered in 
response to the same stimulus of culturing with 100 ng/ml of αGalCer (Figure 5.6). 
Co-culture of DC with iNKT cells resulted in an average 12 fold increase in IL-12 (p 
=0.0001), a 1.5 fold increase in IL-10 and 2.5 fold increase in IFN-γ release 
compared to the levels released by iDC alone (Figure 5.7). It should be noted that  
The cellular origin of the IFN-γ was not tested but is likely to be the iNKT cells.  
The co-culture of DC loaded with 100ng/ml of αGalCer with iNKT cells resulted in 
further increases of IL-12 (p =000.1) and IFN-γ (p =0.0079) (23 and 6.2 fold 
respectively) but no increase of IL-10 were recorded for 3 individual experiments 
(Figure 5.7). These results show that iNKT cells can induce DC maturation and 
cytokine production and that the maturation and cytokine production was 
significantly increased with the addition of 100 ng/ml of αGalCer. 
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Figure 5.5. iNKT cells induce DC maturation. A, Flow cytometric histograms 
showing the intensities of CCR7, CD40, CD54, CD80, CD83, CD86 & HLA-DR 
expression by DC cultured in medium alone (Purple), DC co-cultured with iNKT 
cells (Blue), and DC loaded with 100 ng/ml of αGalCer and co-cultured with iNKT 
(Red). B, Bar charts showing average mean fluorescence intensity (MFI) observed 
in 5 independent experiments. 
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Figure 5.6: Effects of αGalCer on cytokine production by monocyte derived DC. 
Bar graphs show fold increases in levels of IL-12 (purple), IL-10 (blue) and IFN-γ  
(green) released by iDC cultured in the presence of 100 ng/ml of αGalCer 
compared with those released by iDC alone. Results are a mean of 5 separate 
experiments. 
 
 
 
 
Figure 5.7: Effects of iNKT cells cytokine production by DC. Bar graphs show 
fold increases in levels of IL-12 (purple), IL-10 (blue) and IFN-γ  (green) released 
by iDC cultured in the presence of iNKT cells in the absence or presence of 100 
ng/ml of αGalCer compared with those released by iDC alone. Results are a mean 
of 5 separate experiments. 
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5.3.3: Effect of co-culturing non-iNKT on dendritic cells 
To investigate the specificity of the observed iNKT induction of iDC maturation, 
non purified iNKT cells consisting of total PBMC stimulated with PHA and cultured 
in the presence of IL-2, were co-cultured as previously described with DC in 
medium alone or in the absence or presence of 100 ng/ml of αGalCer. As previously 
observed, iDC incubated in the presence of αGalCer and expanded iNKT cells 
upregulated CCR7, CD40, CD54, CD83, CD86 and HLA-DR (Figure 5.8). However 
when PHA/IL-2 expanded PBMC were substituted for iNKT cells, no upregulation 
of these markers was observed. This data indicates that iNKT cells are required for 
the induction of DC maturation and that total non-iNKT cells do not have the same 
ability.  
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Figure 5.8: iNKT cells are required for αGalCer induced DC maturation. iDC 
were cultured in medium alone (purple histograms) with PBMC expanded with 
PHA and IL-2 in the presence of αGalCer (pink histograms) or iNKT in the 
presence of αGalCer (Red). Flow cytometry histogram showing the expression of 
CCR7, CD40, CD54, CD80, CD83, CD86 or HLA-DR. Bar charts show average 
MFI. Results are a mean of 5 separate experiments 
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5.3.4: Effects of dendritic cells matured with iNKT cells on allogeneic T cell 
proliferation proliferation and cytokine production 
The capacity of DC matured with iNKT cells in presence or absence of 100 ng/ml of 
αGalCer to activate naïve allogeneic T cells was investigated in T cell proliferation 
and cytokine release assays. DC were cultured in medium alone, in the presence of 
the TLR agonist LPS, or with equal numbers of iNKT cells or stimulated PBMC in 
the presence or absence of the iNKT stimulant αGalCer for 24 hours. The DCs were 
then diluted and co-cultured with purified peripheral naïve T cells at 1:10 ratios for 
72 hours. The naïve T cells were stained with CFSE prior to the addition of the DC 
in order to distinguish them from the DC and iNKT cells. The CFSE proliferation 
assay was used to investigate T cell proliferation after co-culture with DCs under the 
various conditions. The parent population has highest intensity of CFSE and this is 
reduced with each round of daughter cells, resulting in populations of decreasing 
CFSE intensities.  
 
In the experiment shown in Figure 5.9, CFSE labelled T cells incubated in medium 
alone did not divide with a single parent population detected on day 3 (Figure 5.9A). 
CFSE labelled T cells incubated with DCs cultured in medium alone proliferated 
with 3 daughter populations detected (Figure 5.9B). CFSE labelled T cells incubated 
with DCs cultured in presence of LPS resulted in > 4 daughter populations (Figure 
5.10C). CFSE labelled T cells incubated with DCs co-cultured with iNKT cells 
resulted in 4 daughter populations (Figure 5.9D). CFSE labelled T cells incubated 
with DCs loaded with 100 ng/ml αGalCer co-cultured with iNKT cells also resulted 
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in >4 daughter populations (Figure 5.9E). The results were similar for 3 independent 
experiments. 
 
The supernatants of 3 day co-cultures of T cells and DCs were assessed for the T 
cell cytokines IFN-γ and IL-4 by ELISA (Figure 5.10). T cells cultured with DC that 
were matured with LPS, iNKT cells or iNKT cells in the presence of 100 ng/ml 
αGalCer produced higher levels of IFN-γ (2000-2320 pg/ml) in comparison to T 
cells incubated with immature DC (Figure 5.10A).  However the quantities of IL-4 
(58-65 pg/ml) released by T cells cultured with iDC were similar to those released 
by T cells cultured with DC that had been matured with LPS, iNKT cells and iNKT 
cells in the presence of 100 ng/ml αGalCer (Figure 5.10B). These results show that 
iNKT cells matured DC can induce T cell proliferation and Th1 biased cytokine 
production and αGalCer compliments this effect. 
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   CFSE fluorescence 
 
Figure 5.9: DC matured by co-culture with iNKT cells induce proliferation of 
allogeneic T cells. Allogeneic T cells were labelled with CFSE and incubated with 
DC cultured under various conditions A-E. Representative flow cytometric 
histograms show CFSE positive T cells, cultured  alone (A) or  with DC previously 
cultured with medium alone (B), LPS (C), iNKT cells (D) or iNKT cells in the 
presence of 100 ng/ml αGalCer (E). Results are representative of 3 separate 
experiments. 
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Figure 5.10: DC matured using iNKT cells stimulate IFN-γ  and IL-4 production 
by naïve allogeneic T cells. iDC were cultured in medium alone, with LPS, iNKT 
cells, iNKT cells in the presence of 100 ng/ml αGalCer or expanded PBMC in the 
presence of 100 ng/ml αGalCer. After 24 hours the cells were washed, diluted and 
co-cultured at 10:1 ratios with naïve allogeneic T cells. After 3 days levels of 
secreted IFN-γ  and IL-4 were measured by ELISA. Bar charts show the levels of 
(A) IFN-γ (2000-2320 pg/ml) and (B) IL-4 (58-65 pg/ml) secreted by allogeneic T 
cells incubated in the presence of DCs stimulated as aforementioned. Results are 
means of 3 separate experiments. 
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5.4: Discussion 
 
In the investigation into the reciprocal interactions between iNKT and DCs we 
optimized a technique for the generation of DCs from monocyte precursors 
described previously by Sallusto and Lanzavecchia (1994). On average the yields of 
CD14+ cells isolated from a mean of 496 x106 PBMC by magnetic bead separation 
was 16.7 x106 CD14 positive cells. The purities ranged from 81.6% to 98.6%. 
CD14+ monocytes were cultured with GM-CSF and IL-4 for 6 days. On day 6 
CD14 was downregulated indicating the transition from monocytes to immature DC 
as described by Sallusto and Lanzavecchia (1994). The DCs where classed as 
immature due to their low expression of the DC surface molecules; CD40, CD54, 
CD80, CD83 and CD86 (Banchereau et al 2000). We used 2 TLR agonists, LPS and 
Poly I:C to mature our DCs and investigate the phenotype and function of a mature 
DC (Rescigno et al 1998, De Jong et al 2002). As described in studies by Rescigno 
et al (1998) and De Jong et al (2002), LPS and Poly I:C induced the upregulation of 
the surface molecules, CD40, CD54, CD83, CD86, HLA-DR and the chemokine 
receptor CCR7. Interestingly the expression of surface molecule CD80 was not 
upregulated in response to LPS or poly I:C after a 24 hour stimulation. Maerten et al 
(2003) reported that the expression of various surface markers occurs at different 
time points after stimulation, and thus later time points could see the up regulation 
of CD80. A time curve study was beyond the scope of this project due to time and 
budget restrictions. Both LPS and poly I:C stimulation resulted in the secretion of 
IL-10 and IL-12 by DCs indicating a functionally mature DC. 
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The main aim of this body of work was to investigate the interactions between iNKT 
cells and monocyte derived DCs in order to establish a system of DC maturation by 
iNKT cells activated by novel antigens (Chapter 6). The co-culturing of iNKT cells 
and iDC resulted in the maturation of the iDC into APCs expressing the maturation 
molecules CD40, CD54, CD83 and CD86. The addition of αGalCer resulted in an 
increase in upregulation of these maturation molecules.  
 
We also examined the effects of αGalCer on cytokine production by DC and found 
that this glycolipid on its own induced the production of IL-12 but not IL-10. The 
cytokine produced can not be atttributed solely to the glycolipid, since it is possible 
the αGalCer was contaminated with endotoxin. However Yue et al recently showed 
that CD1d ligation on DC with multiple CD1d mAbs resulted in the secretion of IL-
12 (Yue et al 2010). Next we co-cultured iDC in the presence or absence of αGalCer 
with iNKT cells, and examined the surface phenotype of the DCs and the cytokine 
production by the co-cultures. iNKT cells in the absence of αGalCer induced the 
upregulation of DC surface markers associated with maturation and this 
upregulation was significantly increased in the presence of αGalCer. It is a point to 
note that the iNKT cell lines were cultured in the presence of IL-2 and thus were 
previously activated. The maturation in the absence of glycolipid could be due to 
CD40-CD40L interaction as described by Fujii and colleagues (2003) or the 
presentation of unknown endogenous glycolipid in the system. However the 
interactions between DC and iNKT cells in the absence of αGalCer resulted in 
significantly less IL-12 and IFN-γ than in its presence. This round of experiments 
was repeated but the PBMC were substituted for the highly pure iNKT cell line. 
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PBMC in the absence or presence of αGalCer failed to mature the immature 
monocytes derived DCs. 
 
The interactions between iNKT cells and DC resulted in a Th1 biased cytokine 
profile with increased IL-12 and IFN-γ but no IL-10 produced. This is concurrent 
with previous studies in both mice and humans (Yang et al 2000, Fujii et al 2003). 
Other groups have reported increased or decreased secretion of IL-12 by DCs in 
response to interactions with iNKT cells, depending on the experimental conditions 
and whether they were carried out in vivo or ex vivo. (Naumov et al 2001, Vincent et 
al 2002). This indicates that iNKT cells have differential abilities to drive a response 
in different ways i.e Th1 or Th2.  
 
Next we investigated if the interaction between the iNKT cells and DCs was 
sufficient to elicit T cell responses. Fujii et al reported that elicitation of a T cell 
response via DC and iNKT cell interactions requires TCR/CD1/Ag complexing, 
CD40-CD40L interactions (Fujii et al 2003). To examine the elicitation of human T 
cell responses we co-cultured iNKT matured DC with CFSE labelled allogeneic 
CD3+ T cells and examined T cell proliferation and their cytokine profiles after 3 
and 5 days. CD3+ allogeneic T cells were stained with CFSE and cultured alone as a 
control. The parent population did not divide after 3 or 5 days. Allogeneic CFSE 
stained T cells co-cultured with iDC proliferated after 3 and 5 days. Culturing 
allogeneic T cells with LPS matured DC resulted in greater T cell proliferation, 
exhibiting 4 divisions after 3 days. Co-cultures of iNKT cells and iDC in the 
absence of αGalCer resulted in comparable proliferation of allogeneic T cells to 
those of LPS matured DC. This could be due the slightly activated iNKT cell and the 
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milieu of pro-inflammatory cytokines detected in the supernatant of the cultures in 
the absence of αGalCer, this mode of activation is described previously by Blanko et 
al (2008). The addition of αGalCer resulted in increased T cell proliferation but this 
increase was not significant. The supernatants of the cultures were examined for the 
presence of Th1 and Th2 cytokines to determine the type of response elicited, IFN-γ 
was produced in large quantities by allogeneic T cells incubated with DCs matured 
in the presence of LPS, iNKT cells and iNKT cells and αGalCer. IL-4 was also 
produced but at low levels in cultures of DCs matured in the presence of LPS, iNKT 
cells and iNKT cells and αGalCer. (58-65 pg/ml).  
 
The results described in this chapter show that co-culturing of iNKT cells and iDC 
resulted in the maturation of the iDC into APCs that produced abundant IL-12 but 
little or no IL-10. The addition of αGalCer resulted in an increase in upregulation of 
maturation molecules and IL-12 secretion. These iNKT cell matured iDC drove a 
pro-inflammatory response with abundant IFN-γ and IL-12, which induced 
proliferation of allogeneic circulating T cells and skewed them to produce high 
levels of  IFN-γ but low IL-4. This body of work mirrors murine work by Munz et 
al, which described the resultant Th1 response from the culture of iNKT cells with 
iDCs (Figure 5.13) (Munz et al 2005). The understanding of the interactions 
between iNKT cells and DC and the resulting T cell response is essential for the 
design of immunotherapies. We have established a platform for the analysis of 
human iNKT cell/DC interactions which can be effectively used to test novel 
glycolipid antigens with the ultimate aim of tailoring T cell responses for 
immunotherapy.  The application of this system for the testing of synthetic 
glycolipids is the subject of Chapter 6. 
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5.5 Conclusions 
• Immature DCs can be generated in vitro from monocytes isolated from 
human peripheral blood 
• LPS and poly I:C stimulation induce DC maturation and production of DC 
derived cytokine 
• iNKT cells can induce DC maturation and DC derived cytokine secretion  
• DCs matured in the presence of iNKT cells and αGalCer can induce 
proliferation and cytokine secretion by allogeneic T cells 
• The use of iNKT cells as a DC adjuvant results in a Th1 biased immune 
response 
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6: Results: Investigations into the 
biological activity of novel αGalCer 
analogue glycolipids 
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6.2: Introduction 
In 1997 Kawano et al and Cui et al reported that Vα14 iNKT cells activated using 
αGalCer, a glycolipid derived from marine sponge, cleared B16 melanoma in mice 
(Kawano et al 1997, Cui et al 1997). Smyth et al subsequently reported that IFN-
γ from iNKT cells and from NK cells was essential for the anti-metastatic effect of 
αGalCer (Smyth et al 2002). In 1999 Kawano et al reported that human Vα24 iNKT 
cells could kill tumour cells in vitro and were reduced in number in human cancers 
(prostate, melanoma and liver). These studies highlighted the possible potential of 
iNKT cells for cancer immunotherapy. Since 2002 numerous clinical trials have 
attempted to harness the anti-tumour ability of iNKT cells in human cancer patients. 
Several approaches have been applied in phase I and II trials including, the injection 
of the iNKT stimulating ligand αGalCer into patients with solid tumours (Giaccone 
et al 2002), infusion of in vitro expanded iNKT cell into patients with recurrent non 
small cell lung cancer (Motohashi et al 2006) or infusions of dendritic cells pulsed 
with αGalCer into patients with non small cell lung cancer, myeloma, or head and 
neck cancer (Nieda et al 2004, Ishikawa et al 2005, Chang et al 2005, Uchida et al 
2008, Motohashi et al 2009) (Figure 1.12) The studies were well received with low 
toxicity but overall they proved disappointing with regard to tumour 
regression/clearance. 
 
The failure of iNKT cells to induce tumour regression in clinical trial directed 
studies towards development of synthetic analogue ligands, which could potentially 
increase the anti-tumour effect of human iNKT cells. In 2002, Miyamoto et al 
synthesised an analogue of αGalCer, named OCH (Figure 1.13). OCH differs from 
αGalCer in that it has a truncated sphingosine chain. OCH was found to skew a Th2 
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like response with predominant IL-4 production. OCH activation of iNKT cell 
resulted in specific protection against EAE, whilst αGalCer failed to induce 
protection. The development a Th1 biased analogue followed in 2003 with the 
synthesis of α−C-GalCer by Schmieg et al (Figure 1.13). α−C-GalCer replaces the 
O glycoside bond found in αGalCer’ with a C glycoside bond. The authors reported 
1000-fold increase in anti malarial activity and 100-fold anti metatastic activity 
compared to αGalCer in murine models. Responses using α−C-GalCer resulted in a 
Th1 biased response with increased IFN-γ and IL-12 and decreased IL-4 compared 
to αGalCer. The development of αGalCer analogues with structural changes to 
increase/skew activity is a very attractive concept for immunotherapy. 
 
Colleagues from University College Dublin synthesised several analogues with 
small structural changes predicted to increase either stability or affinity with respect 
to TCR-CD1d-lipid contact. α-S-GalCer was synthesised by the group of Dr. 
Xiangming Zhu et al and replaced the glycosidic oxygen atom link with a sulfur 
atom link (Figure 6.1). Thioglycosides are very attractive substitutes for O-
glycosides as it is well known that they are much less susceptible to enzymatic 
cleavage as well as chemical degradation, moreover, their anomeric sulphur may 
interact with CD1d through hydrogen bonding. Thus authors proposed the structural 
changes would increase the stability of the linkage and thus increase the presentation 
time of the glycolipid (Dere et al 2008). This lipid was kindly provided by Dr Zhu 
for testing in our biological assays along with a truncated version α-S-GalCer-14, 
which differs in the length of the acyl chains. Four αGalCer analogues (W1-W2) 
were synthesised by the group of Professor Paul Murphy at the National University 
of Ireland Galway (Figure 6.2). The analogues W1-W4 had trucated sphingosine  
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Figure 6.1: Structures of the synthetic analogue α-S-GalCer glycolipid and the 
truncated α-S-GalCer Structures provided by Zhu et al. 
 
 
 
 
 
Figure 6.2. Structures of the synthetic αGalCer analogues glycolipids W1-W4.  
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chains. W1-W4 contained several structural changes to the carbohydrate head and in 
analogue W4 the O-glycoside was replaced with O2S-glycoside. The authors 
proposed these analogues would have biological activity. 
 
In this body of work we aimed to investigate the biological activity of these six 
novel αGalCer analogues. We aimed to test the functional responses (cytokine 
production and cytotoxicity) of our human iNKT cell lines expanded from 
peripheral blood to the novel analogue glycolipids. The analogues were also used in 
the DC-iNKT system established in chapter 5 to test both the reciprocal interactions 
between iDC and iNKT and the subsequent T cell responses to the novel analogues. 
The results obtained with the novel analogues are compared to αGalCer throughout 
(Figure 6.3). 
 
6.2: Objectives  
1. To test the iNKT stimulatory ability of novel αGalCer analogues 
2. To investigate ability of the glycolipid analogue activated iNKT to activate 
immature DC 
3. To examine the reciprocal functional interactions and responses by the 
glycolipid analogue activated iNKT and DC 
4. To investigate the T cell maturating and activating capabilities of the 
glycolipid analogue activated iNKT activated DC 
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Figure 6.3: Strategy for investigation of biological activity of synthetic αGalCer 
analogue glycolipids. Analogues were tested for iNKT cell stimulatory capabilities 
using the C1R reactivity, cytotoxicity and DC activation assays optimized and 
described in previous results chapters. The analogues were compared to the 
current gold standard of iNKT cell activation, αGalCer in all assays. 
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6.3.1: Investigation of iNKT cell cytokine responses to novel synthetic αGalCer 
analogues 
Currently αGalCer remains the “gold standard” ligand for the activation of iNKT 
cells. αGalCer stimulates potent cytotoxicity and the early release of both IFN-γ and 
IL-4 by iNKT cells. As discussed previously clinical trial therapies using αGalCer 
have resulted, in at best modest successes, and new analogues provide the best 
chance of improved iNKT activators. In response to this, the iNKT stimulating 
properties of 6 novel αGalCer analogues, differing in small structural changes were 
investigated. iNKT cell reactivity to six novel αGalCer analogues was assessed 
using functional assays. iNKT cells expanded from human peripheral blood using 
Method 3 (described in chapter 3) were co-cultured with CD1d transfected C1R 
cells loaded or unloaded with αGalCer or single analogues for 24 or 72 hours (100 
ng/ml). The mock transfected C1R cells were used as a negative control and T cell 
mitogen PHA was used as positive control. Reactivity to the lipid ligands was 
measured by quantifying secreted IFN-γ and IL-4 in the culture supernatants by 
ELISA. 
 
Six analogues were tested (W1, W2, W3, W4, S-α-GalCer & S-α-GalCer14). Of the 
six analogues tested for iNKT cell cytokine secretion, only one analogue showed 
biological activity which justified further investigation with none of the remaining 
analogues stimulating IFN-γ or IL-4 release by iNKT cells over and above the 
amounts released by unloaded CD1d transfected C1R cells (IFN-γ (311-480 pg/ml) 
and IL-4 (152.3-164.2 pg/ml) (Figure 6.4 and 6.5).  
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The reactive analogue termed α-S-GalCer, differs from αGalCer in the bond which 
links the carbohydrate head to the fatty acid chain, glycosidic S link replaces 
glycosidic O link in αGalCer. Stimulation of iNKT cells with α-S-GalCer-pulsed 
CD1d+ C1R cells resulted in a mean 7 fold increase in levels of IFN-γ over the 
levels released in response to mock transfected C1R cells (p =0.001). This compared 
to a 5 fold increase with αGalCer stimulation (Fig 6.5A). α-S-GalCer stimulation of 
iNKT cells resulted in a mean 9.5 fold increase in levels of IL-4 compared to the 
levels released in response to mock transfected C1R cells (p =0.01). This compared 
to 11 fold increase with αGalCer stimulation (Fig 6.5B). There was no significant 
difference between the cytokine produced by α-S-GalCer stimulated iNKT cells and 
the that produced by αGalCer stimulated iNKT cells.  To ensure the specificity of α-
S-GalCer, CD1d was blocked using a blocking mAb. The blocking of CD1d on the 
C1R transfected C1R cells resulted in a 4.2 fold reduction in IFN-γ compared to α-
S-GalCer stimulation and 1.8 fold reduction in IL-4 secretion (Fig 6.6 A & B).  
These studies show that of the 6 analogues test only 1, α-S-GalCer stimulated 
cytokine production by iNKT cell lines in a CD1d dependent manner. 
 
 
 
Results: Chapter 6 
 
 
185 
 
Figure 6.4: Analogues W1-W4 and α-S-GalCer 14 failed to induce cytokine 
secretion by iNKT cells. iNKT cells were co-cultured with CD1d transfected C1R 
cells unloaded or loaded with either αGalCer or αGalCer analogues. 
Supernatants were examined for IFN- γ after 72 hours (A) and IL-4 after 24 
hours (B). Bar graphs display the mean fold increase over in cytokine levels 
compared to those released in response to mock transfected C1R cells (IFN-γ 
100.1-124.3 pg/ml & IL-4 40-62.7 pg/ml). Results are means from 5 independent 
experiments. 
 
 
Figure 6.5: S-α-GalCer induces IFN-γ  and IL-4 secretion by iNKT cells. iNKT 
cells were co-cultured with CD1d transfected C1R cells unloaded or loaded with 
either 100 ng/ml of αGalCer or α−S-GalCer were examined for IFN- γ  after 72 
hours (A) and IL-4 after 24 hours (B) by ELISA. Bar graphs display the mean 
fold increase in cytokine secretion compared to those released in response to 
mock-transfected C1R cells (IFN-γ 100.1-124.3 pg/ml & IL-4 40-62.7 pg/ml). 
Results are means of 5 independent experiments. *P<0.01; **P<001. 
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Figure 6.6 Monoclonal antibody blocking of CD1d reduces α-S-GalCer induced 
cytokine secretion by iNKT cells. iNKT cells were co-cultured with CD1d 
transfected C1R cells unloaded or loaded with 100 ng/ml of α−S-GalCer in the 
absence or presence of CD1d mAb were examined for IFN- γ after 72 hour (A) or 
IL-4 after 24 hours (B) ELISA. Bar graphs display the mean fold increase in 
cytokine levels over those released by mock transfected C1R cells (IFN-γ 100.1-
124.3 pg/ml & IL-4 40-62.7 pg/ml).  Results are from 5 independent experiments. 
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6.3.2: Investigation into α−S-GalCer induced cytotoxicity of CD1d transfected 
C1R cell lines by iNKT cells 
 
The ability of α-S-GalCer to prime CD1d+ targets for cytotoxicity by iNKT cells 
cytotoxic capabilities were assessed using the CFSE incorporation cytotoxicity 
assay. C1R cells stably transfected with CD1d were labelled with CFSE and were 
incubated with iNKT cells in the presence or absence of αGalCer or α-S-GalCer for 
4 hours at effector target ratio of 10 to 1. After incubation cells were co stained with 
7-AAD, a marker of recent apoptosis. Double positive cells staining for CFSE and 
7-AAD represented apoptotic lysed target cells. C1R CD1d target cells incubated in 
the absence of effector cells contained a mean of 3% apoptotic cells (Figure 6.7A, 
6.8). Addition of iNKT cells resulted in mean lysis of 7% of target C1R CD1d cells 
(p =0.03) (Figure 6.7B, 6.8). The further addition of αGalCer resulted in a mean 
increase in lysis to 13% of the target cells (p =0.002) (Figure 6.7C, 6.8). Addition of 
α-S-GalCer resulted in mean lysis of 18% of CD1d transfected target cells (p 
<0.0001) (Figure 6.7D, 6.8). These studies show that of the α-S-GalCer stimulated 
iNKT cell can lyse CD1d transfected target cells. 
 
Figure 6.7: α-S-GalCer primes CD1d transfected C1R tumour cells for lysis by 
iNKT cells. Representative flow cytometric dot plots showing iNKT cytotoxicity of 
CFSE labelled CD1d transfected target cells incubated with, iNKT cells alone (B), 
iNKT cells with αGalCer (C) or iNKT cells with s-αGalCer (D). Target cells alone 
(A) act as negative control. Lysed cells stained positive with the apoptotic stain 7-
AAD so cells in the upper right quadrants represent lysed cells. Results are 
representitive of 3 independent experiments. 
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Figure 6.8: α-S-GalCer primes CD1d transfected C1R tumour cells for lysis by 
iNKT cells. iNKT cells were co-cultured at 10:1 ratio with CFSE labelled CD1d 
transfected C1R  target cells in the absence or presence of 100 ng/ml of αGalCer 
or α-S-GalCer. Lysed cells stained positive with the apoptotic stain 7-AAD. Bar 
chart showing the mean of 3 separate cytotoxicity assays, target cells alone act as 
negative control. *P=0.03; **P=0.002; ***P=0.0001. 
 
 
6.3.3: Investigation into α−S-GalCer induced iNKT cell cytotoxicity of K562 
cell lines  
 
To further assess the biological activity and iNKT cell stimulatory properties of s-α-
GalCer; iNKT cell cytotoxicity was examined against the NK cell sensitive K562 
cell line, in the presence of s-α-GalCer. iNKT cells were co-cultured with either 
K562 at 10:1 effector to target ratio in the presence or absence of either 100 ng/ml of 
αGalCer or α-s-GalCer. iNKT cells stimulated with α-S-GalCer lysed a mean of 
30% of target cells (p =0.0002) (Fig 6.9D & 6.10).  This was an increase over 
αGalCer stimulated iNKT cells which lysed a mean of 23% (p =0.003) (Fig 6.9C & 
6.10) and over iNKT without additional exogenous ligand which lysed 19% (p 
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<0.0001) (Fig 6.9B & 6.10). These studies show that of the α-S-GalCer stimulated 
iNKT cell can lyse CD1d negative target cells. 
 
Figure 6.9: S-αGalCer induces K562 tumour cell lysis by iNKT cells.  
Representative flow cytometric dot plots showing iNKT cytotoxicity of CFSE 
labelled K562 target cells incubated with, iNKT cells alone (B), iNKT cells with 
αGalCer (C) or iNKT cells with s-αGalCer (D). Target cells alone (A) act as 
negative control. Lysed cells stained positive with the apoptotic stain 7-AAD in the 
upper right quadrants represent lysed cells. Results are representative of 3 
independent experiments. 
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Figure 6.10: S-αGalCer induces K562 tumour cell lysis by iNKT cells.  iNKT cells 
were co-cultured at 10:1 ratio with CFSE labelled K562 target cells in the absence 
or presence of αGalCer or α-S-GalCer. Lysed cells stained positive with the 
apoptotic stain 7-AAD. Bar chart showing the mean percentage of killed target 
cells from 3 separate cytotoxicity assays. Target cells alone act as negative control.  
**P=0.003 ***P=0.0002. 
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6.3.4: Effect of s-α GalCer stimulated iNKT on monocyte derived dendritic 
cells. 
Monocyte derived dendritic cells (DC) were incubated in medium alone (control) or 
co cultured with equal numbers of iNKT cells expanded from human peripheral 
blood (using Method 3, described in chapter 4) with or without the addition of 100 
ng/ml of αGalCer or s-α-GalCer for 24 hours. Expression of seven surface molecules 
was investigated for each set of DC as outlined in chapter 5.  
 
Co-culture of iDC with iNKT cells in the absence of glycolipid antigen resulted in a 
1.7 fold upregulation of CCR7 expression by DC. CCR7 expression was increased 
2.5 fold with the addition 100 ng/ml of αGalCer to the co-culture (p =0.008) and 
2.35 fold with 100 ng/ml α-S-GalCer (p =0.008) compared to iDC cultured in 
medium alone. The surface expression of the co-stimulatory molecule CD40 was 
increased 1.9 fold upon co-culture with iNKT cells with 100 ng/ml of αGalCer (p 
=0.009) and 1.6 fold with the addition of α-S-GalCer (p =0.02). Surface expression 
of the adhesion molecule CD54 was increased 2.1 fold with co culture with iNKT 
cells and 100 ng/ml of αGalCer and 1.6 fold with addition of α-S-GalCer. CD80 was 
expressed at low levels on iDC with MFI comparable to that of iDC stained with 
isotype control mAbs. This was not increased by co-culture with iNKTs in the 
presence or absence of either αGalCer or α-S-GalCer. Surface expression of the 
classical DC maturation marker CD83 was increased 3.4 fold upon co-culture with 
iNKT cell of 100 ng/ml of αGalCer (p =0.002) and 2.7 fold with addition of α-S-
GalCer to the co-culture (p =0.004). Surface expression of CD86 was increased 1.5 
2.5 fold upon co-culture with iNKT cell of 100 ng/ml of αGalCer (p =0.01) and 2.15 
fold with addition of α-S-GalCer (p =0.03) to the co-culture. Expression of HLA-DR 
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was increase 1.25 fold upon co-culture with iNKT cell of 100 ng/ml of αGalCer and 
1.2 fold with addition of α-S-GalCer to the co-culture (Figure 6.11). The effects of 
iNKT in the absence of glycolipid on DC maturation is detailed in chapter 5. There 
was no significant difference between the maturation induced by α-S-GalCer 
stimulated iNKT cells and the maturation induced by αGalCer stimulated iNKT 
cells. 
 
Cytokine secretion from co-culture supernatants of DCs incubated with iNKT cells 
in the presence or absence of 100 ng/ml of αGalCer or α-S-GalCer were examined 
by ELISA. Levels of IL-10 and IL-12 secreted by DC were compared to those 
released by iDC incubated in medium alone (control). Cytokine secretion was 
quantified in 3 experiments by ELISA. Co-culture of DC with iNKT cells resulted in 
an average 2 fold increase in IL-12 (p =0.04) and 1.26 fold increase in IL-10 over 
that released by the iDC alone (54-66 pg/ml IL-12, 79-84 pg/ml IL-10) (Figure 
6.12). The co-culture of DC loaded with 100 ng/ml of αGalCer with iNKT cells 
resulted in 16 fold increase of IL-12 (p =0.002) (Figure 6.12) and 2.26 fold increase 
in IL-10 production (p =0.0007). DC loaded with 100 ng/ml of α-S-GalCer and co-
cultured with iNKT cells resulted in 10 fold increase of IL-12 release (p =0.002) 
(Figure 6.12) and 1.7 fold increase in IL-10 production (p =0.0001). These results 
indicate that iNKT cells stimulated with αGalCer and α-S-GalCer have similar 
adjuvant effect on cytokine production by monocyte derived DC. 
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Figure 6.11. α-S-GalCer stimulated iNKT induce DC maturation comparable to 
αGalCer. A, Flow cytometric histograms showing intensities of CCR7, CD86, 
CD83, CD40, CD54,  HLA-DR & CD80 expression by iDC cultured alone 
(Purple), cultured with iNKT in the presence of αGalCer (Red) or cultured with 
iNKT in the presence of α-S-GalCer (Orange). Bar charts showing the average 
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mean fluorescence intensities (MFI) observed in 3 independent experiments. iDC 
(Purple), iNKT + αGalCer (Red) and iNKT + α-S-GalCer (Orange). *P<0.03; 
**P<0.009. 
 
 
Figure 6.12.: α-S-GalCer stimulated iNKT cells induce cytokine secretion by DC 
that is comparable the levels released by DC cultured with to αGalCer stimulated 
iNKT cells. iDC were cultured in medium alone, co-cultured with iNKT cells in 
the absence or presence of 100 ng/ml αGalCer or α-S-GalCer and cytokine 
production measured by ELISA. Bar graphs show the fold increase in the 
secretion of IL-12 (green) and IL-10 (blue) compared to iDC cultured in medium 
alone (54-66 pg/ml IL-12, 79-84 pg/ml IL-10). Results are the means of 3 separate 
experiments. *P<0.04; **P=<0.002; ***P<0.0007 
 
 
 
 
6.3.5: DC matured with iNKT cells in the presence of α-S-GalCer can stimulate 
the proliferation and activation of allogenic T cells 
 
The capacity of DC matured with iNKT cells in presence or absence of either 100 
ng/ml of αGalCer or 100 ng/ml of α-S-GalCer to activate naïve allogenic T cells was 
investigated in T cell proliferation and cytokine release assays as previously 
described in chapter 5. DCs were cultured in medium alone, in the presence of the 
LPS or with equal numbers of iNKT cells or PHA stimulated PBMC (non-iNKT cell 
control cells) in the presence or absence of αGalCer or its analogue α-S-GalCer for 
24 hours. The DCs were then co-cultured with CFSE labelled purified peripheral 
Results: Chapter 6 
 
 
195 
naïve T cells at 1:10 ratio for 72 hours. CFSE proliferation assay was used to 
investigate T cell division after co-culture with DCs cultured matured under the 
various conditions. The parent population of T cells had highest intensity of CFSE 
stain and this was reduced with each round of daughter cells, resulting in 
populations of decreasing CFSE intensities. 
  
In the experiment shown in figure 6.11, CFSE labelled T cells incubated in medium 
alone did not divide with a single parent population present after 72 hours culture 
(Figure 6.13A). CFSE labelled T cells incubated with DCs cultured in medium alone 
proliferated with 3 daughter populations detected (Figure 6.13B). CFSE labelled T 
cells incubated with DCs cultured in presence of LPS resulted in 5 daughter 
populations (Figure 6.13C). CFSE labelled T cells incubated with DCs co-cultured 
with iNKT cells resulted in 5 daughter populations (Figure 6.13D). CFSE labelled T 
cells incubated with DCs loaded with 100 ng/ml αGalCer and co-cultured with 
iNKT cells resulted in 5 daughter populations (Figure 6.13E). or DC loaded with 
100 ng/ml α-S-GalCer and co-cultured with iNKT cells resulted in 5 daughter 
populations (Fig 6.13F). Similar results were obtained in 2 other separate 
experiments. 
 
The supernatants of T cell and DC 3 three  day cultures where assessed for levels of 
the T cell cytokines IFN-γ and IL-4 by ELISA (Figure 6.14). T cells cultured in the 
presence of DC that were matured with LPS, iNKT cells or iNKT cells in the 
presence of 100 ng/ml αGalCer or α-S-GalCer produced high levels of IFN-γ (1918-
2154 pg/ml) in comparison to T cells incubated with immature DC, but produced 
small quantities of IL-4 (36-57pg/ml) (Figure 6.14). Addition of αGalCer and or α-
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S-GalCer to the DC-iNKT cell co-cultures did not lead to increased secretion of 
IFN-γ or IL-4 by the allogeneic T cells. 
 
              
 
Figure 6.13: DC matured with αGalCer and α-S-GalCer stimulated iNKT cells 
induce proliferation of allogeneic T cells. Representative flow cytometric 
histograms showing CFSE positive T cells cultured in medium alone (A) or with 
DC previously cultured with medium alone (B), LPS (C), iNKT cells (D), iNKT 
cells in the presence of 100 ng/ml αGalCer (E) or iNKT cells in the presence of 
100 ng/ml α-S-GalCer (F). Results are representative of 3 separate experiments 
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Figure 6.14: DC matured with iNKT cells in the absence and presence of  
αGalCer and α-S-GalCer stimulated iNKT cells induce IFN-γ and IL-4 release by 
allogeneic T cells. Bar graphs show secretion of IFN-γ (A) and IL-4 (B) by 
allogeneic T cells incubated for 72 hours in the presence of DCs that were 
previously cultured for 72 hours in medium alone, with LPS, with iNKT cells in 
the presence or absence of 100 ng/ml αGalCer or α-S-GalCer. Results are means 
of 3 separate experiments.  
 
 
6.4: Discussion 
iNKT cells are a rare subset of innate T cells which express an invariant TCR and 
NK cell like surface molecules. iNKT cells have potent cytotoxic capabilities and 
can rapidly release cytokines that activate, polarise and regulate adaptive immune 
responses. iNKT cell cytokines include GM-CSF, IL-2, IL-5, IL-6, IL-8, IL-10, IL-
17 and TNF-α, although their simultaneous production of IFN-γ and IL-4 is most 
noteworthy (Exley et al 1997, Gumperz et al 2002, Kronenberg 2005) (Chapter 4). 
iNKT cells are also widely reported to activate other immune cells and skew the 
subsequent immune responses (Nakagawa et al 1998, Carnuad et al 1999, Fujii et al 
2004, Munz et al 2005). 
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In 1997 Cui et al, and Kawano et al reported the identification of a glycolipid 
isolated from the marine sponge Agelas mauritianus whilst screening for anti cancer 
agents, called αGalCer. αGalCer activated iNKT cells and cleared B16 melanoma in 
murine models (Cui et al 1998, Kawano et al 1997). Subsequent studies highlighted 
the potent anti-tumour ability of murine iNKT cells activated with αGalCer (Smyth 
et al 2002, Crowe et al 2002).  
 
iNKT cells are also implicated in immunity against tumours in humans, with 
reduction in iNKT numbers in several human cancers (Kawano et al 1999, Tahir et 
al 2001, Kenna et al 2003). Human iNKT cells are reported to kill iNKT cells in 
vitro and activate potent anti-tumour innate and adaptive immune responses 
(Brossay et al 1998, Kawano et al 1999, Metelista et al 2001, Fujii et al 2004). 
However clinical trials based on iNKT immunotherapy in various cancers have 
proved disappointing compared to the results observed in murine models.  iNKT cell 
based immunotherapies have frequently been based on the activation of peripheral or 
infused iNKT cells with αGalCer pulsed DC (Section 1.10, Figure 1.12).   
 
As mentioned in section 6.2, several investigators have designed and synthesised 
modified αGalCer analogues in improving and skew iNKT cell function.  Thus, 
while αGalCer stimulates the simultaneous production of Th1 and Th2 cytokines 
(Exley et al 1997, Prussin & Foster 1997), analogue glycolipids have been 
synthesised that polarise cytokine production by  iNKT cells towards Th1 or Th2  
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(Franck et al 2003, Miyamoto et al 2001, Schmieg et al 2003). The analogues are 
based on small structural changes to αGalCer, aimed to improve affintiy, stability 
and contact between CD1d, glycolipid and the TCR.  
 
In this body of work we tested the iNKT stimulatory capabilities of 6 novel αGalCer 
analogues, W1-W4, α-S-GalCer and α-S-GalCer14 (Figure 6.1, Figure 6.2).   
CD1d transfected C1R cells were pulsed with the glycolipids and then used as 
stimulators of iNKT cell lines generated using Method 3 and described in chapter 4. 
Of the analogues tested only α-S-GalCer stimulated iNKT cells to induce cytokine 
production at levels comparable to αGalCer (Exley et al 1997, Gumperz et al 2002). 
α-S-GalCer stimulation resulted in greater IFN-γ but less IL-4 production compared 
to αGalCer (Figure 6.4, Figure 6.5). This augmented IFN-γ/IL-4 ratio suggests a Th1 
bias which could be beneficial in therapy for viral infection and cancer. Mab 
blocking of CD1d on the CD1d transfected C1R cells, used as stimulators, caused 
inhibition of cytokine secretion by iNKT cells in response to α-S-GalCer. This 
provides compelling evidence  that α-S-GalCer is loaded onto CD1d.  We also found 
that iNKT cells killed CD1d expressing and CD1 negative tumour cell lines. α-S-
GalCer activated iNKT cells lysed more tumour cells than αGalCer stimulated iNKT 
cells, again suggesting that α-S-GalCer may have superior anti-tumour properties 
(Figure 6.7-6.10).  
 
In chapter 5 we described the ability of iNKT cells in the presence of αGalCer to 
mature iDC and stimulate them to produce IL-12 in vitro. Here, we investigated the 
ability of α-S-GalCer to mature iDC (Figure 6.11). The maturation of monocyte 
derived DC by iNKT cells stimulated with α-S-GalCer was comparable to the DC 
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maturation of iDC by αGalCer stimulated iNKT cells, when upregulation of cell 
surface molecules involved in cell adhesion, antigen presentation and costimulation 
were examined.  Furthermore, the ratio of IL-12 to IL-10 released by the DC was 
similar for αGalCer and α-S-GalCer activated iNKT cells (Figure 6.12). Indeed α-S-
GalCer resulted in comparable allogeneic T cell proliferation and cytokine 
production to that observed with αGalCer (Figure 6.13, Figure 6.12). These data 
suggests that α-S-GalCer has a similar adjuvant effect to that of αGalCer and could 
be a candidate for immunotherapy.  
 
Previous studies have reported the lack of stimulatory effect by similar α-S-GalCer 
analogues (Blauvent et al 2008). The methods used to derive these α-S-GalCer 
analogues are reported as different to those used for the synthesis of the α-S-GalCer 
used in the present study (Dere et al 2008). The study by Blauvent and co-workers 
investigated the stimulatory properties of αGalCer and α-S-GalCer in mice, in vivo 
and in vitro. The failure of α-S-GalCer to induce cytokine production by mouse 
splenocytes [is that correct?] was reported as lack of a stimulatory effect. In 
collaboration with Professor Padraic Fallon at Trinity College Dublin, we tested our 
α-S-GalCer analogue in wild type and CD1d knockout mice. Concurrent with the 
study by Blauvent and co-workers, no stimulatory effect was observed with α-S-
GalCer in mice, while injection of mice with αGalCer resulted in increased levels of 
IFN-γ and IL-4 in serum and stimulated recall responses of splenocytes. We propose 
that α-S-GalCer is only stimulatory in humans and therefore merits further 
investigation in vitro and in primates as an anti-tumour agent. 
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6.5 Conclusions 
• α-S-GalCer induces cytokine production by iNKT cells, with a Th1 biased 
ratio 
• α-S-GalCer induces the lysis of CD1d positive and CD1d negative cells by 
iNKT cells 
• iNKT cells stimulated with α-S-GalCer can induce DCs maturation and 
cytokine secretion  
• DCs matured in the presence of iNKT cells and α-S-GalCer can induce 
proliferation and cytokine secretion by allogeneic T cells 
• α-S-GalCer to stimulation of iNKT cells as a DC adjuvant results in a Th1 
biased immune response 
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7. Discussion 
Although current treatment modalities for malignant tumours, such as surgery, 
radiation and chemotherapy have been improved markedly in the past three decades, 
the prognosis for these neoplasms remains poor (Soling & Rainov 2001). Alternate 
treatments such as immunotherapy, are gaining more momentum, with some 
immunotherapies in phase II/III clinical trials. Immunotherapy is the use of the 
bodies natural defence system, the immune system, in the treatment of a variety of 
human diseases. Cellular immunotherapy has focused on the concept of eliciting a 
specific T cell response. The cells of the innate immune system such as DCs and 
innate T cells have been widely used in many immunotherapy trials against cancer to 
date (Banchereau 2007, Bennouna 2008, Fujii 2009). Cancer immunotherapy has 
been well tolerated and specific but it’s efficacy remains variable.  
 
Invariant Natural Killer T cells are a subset of innate T cells and unlike conventional 
T cells they are restricted by the MHC like molecule CD1d and respond to 
glycolipids (Bendelac 2007). As the name suggests iNKT cells express an invariant 
TCR (Vα24 Jα18) and NK like molecules on their surface. iNKT cells are present at 
very low frequencies in human peripheral blood (0.01%-1%). However humans have 
T cells restricted by the CD1a, CD1b and CD1c as well as non iNKT cells restricted 
by CD1d. Due to the lack of the group 1 CD1 molecules (CD1a, CD1b and CD1c) in 
mice, T cells restricted by CD1 are poorly defined in the absence of microbial 
infections (Vincent et al 2003). In our studies we aimed to investigate the CD1 
reactivity in human peripheral blood. We established an assay using CD1 transfected 
C1R cells co-cultured with PBMC from healthy donors, we examined the culture 
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supernatants by ELISA for the classical Th1 and Th2 cytokines, IFN-γ and IL-4 
respectively after 72 hours. We failed to detect IL-4 in the supernatants of the PHA 
stimulated positive controls. We substituted IL-4 with another Th2 cytokine IL-13. 
We tested for IFN-γ and IL-13 in subsequent experiments. No significant reactivity 
was observed in the PBMC cultures so purified CD3+ T cells from peripheral blood 
were substituted for PBMC. Reactivity in the form of IFN-γ and IL-13 production 
was observed for CD1d but not for the group one CD1 molecules (CD1a, CD1b and 
CD1c). Previous studies in the literature describing CD1 group 1 reactive T cells 
from peripheral blood have described the presence of microbial lipids (Kronenberg 
2005, Wingender & Kronenberg 2006, Ulrichs et al 2008). We can hypothesize that 
CD1a, CD1b and CD1c reactive T cells are only found in the presence of a microbial 
infection. With the identification of CD1d reactivity, we repeated the C1R assay with 
the addition of the CD1d binding glycolipids αGalCer and iGb3. The addition of the 
glycolipids resulted in increases in both Th1 and Th2 cytokines in culture 
supernatants. This indicated that the major group of CD1 restricted T cells in human 
peripheral blood are iNKT cells.  
 
iNKT cells due to their low frequency in human peripheral blood, are difficult cells 
to study in vitro. Studies described in the literature used expanded iNKT cell lines 
and clones (Exley et al 1997, Tahir et al 2001, Exley et al 2003). In order to study 
the biology of iNKT and DC interactions we aimed to establish iNKT cell lines from 
human PBMC. We tested 3 methods described previously. Expansion of iNKT 
proved difficult, and several problems were identified. (1) The failure to isolate a 
pure population of iNKT cells from peripheral blood resulted in the expansion of non 
iNKT cells. Other groups use high speed fluorescence assisted cell sorting (FACS) 
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(Exley et al 2003), this equipment was not available during this section of work. (2) 
The variability amongst donors resulted in some lines failing to expand and others 
expanding at different rates, this variability was also observed by Croudace et al, 
who noted that iNKT cells from some donors fail to respond to stimulation. (3) The 
quality of reagents can affect iNKT cell expansion, (personal communications with 
Prof Mark Exley and Prof Steve Porcelli). A method described by Exley et al which 
utilizes a plate bound anti-CD3 mAb OKT-3 as a stimulus proved to be the best of 
the methods tested for the expansion of iNKT cells. This method resulted in highly 
pure iNKT cell lines with good numerical yields after 4-6 weeks of culture. We 
phenotyped the expanded iNKT cells to compare to those described in the literature. 
iNKT cells are predominately described as either CD4+ or double negative (DN) for 
CD4 and CD8 (Dellabona et al 1994, Exley et al 1997, Gumperz et al 2002). The 
iNKT cell lines established in this body of work had mixed populations of CD4+ 
iNKT cells and DN cells. Functionally iNKT cells are described as potent cytokine 
producers, with the unique ability to produce IFN-γ and IL-4 simultaneously (Chen 
and Paul 1997, Exley et al 1997). We examined the ability of the expanded iNKT 
cells to produce cytokine upon stimulation with αGalCer, and consistant with the 
literature, the cells produced both IFN-γ and IL-4 simultaneously. This data shows 
that our adapated method of purifying iNKT cells from human peripheral blood, 
results in functional iNKT cells as described previously by Exley et al (1997). iNKT 
cells as the name indicates are also effective cytotoxic cells. iNKT cell cytotoxicity 
has been described in both CD1d dependant and CD1d independent manner (Exley 
et al 1997, Nicol et al 2000). We tested the ability of our iNKT cell lines to lyse 
CD1d transfected C1R target cells in vitro, iNKT cells in the absence αGalCer could 
lyse significant numbers of target cells, the number of cells lysed was increased with 
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the addition of αGalCer. We also tested the ability of our cells to lyse the NK cell 
sensitive cell line K562 which is CD1d negative. iNKT cells lysed significant levels 
of the K562 target cells, the addition of αGalCer resulted in an increase in the lysis 
levels. Interestingly as mentioned previously K562 cells are CD1d negative, in 2000 
Nicol et al reported iNKT lyses of the CD1 negative U937 cell line. The authors 
outlined the invariant Va24+T-cell lines used in the studies by Exley et al which 
indicated the necessity of CD1d for cytotoxic activity, co-expressed CD94, whereas 
their iNKT cells did not. They further implicated that the different results can be 
resolved if CD94/NKG2 inhibits CD1d-TCR-independent cytotoxic activity against 
otherwise sensitive CD1d-negative targets. This hypothesis can explain the lysis of 
our K562 cells as our cell lines had variable levels of CD94 expression. The increase 
in lysis with the addition of αGalCer suggests that either the iNKT cell lines or the 
K562 cell line expresses very low levels of CD1d, due to cell number restraints, the 
expression of CD1d was not tested on either line. These results show that functional 
iNKT cells can be readily expanded from human peripheral blood in vitro but the 
success of expansion can be attributed to the donor “response”, reagent grade and the 
stimulation time and frequency. 
 
iNKT cells are attractive candidates for cancer immunotherapy due to their potent 
adjuvant ability (Fujii et al 2009). In murine models, activation of iNKT cells  using 
αGalCer resulted in the clearance and prevention of tumours (Cui et al 1997, 
Kawano et al 1998, Smyth et al 2000). iNKT cell based immunotherapies have 
under gone several phase I and phase II clinical trials, and whilst specific and well 
tolerated, results have been mediocre (Giaccone et al 2002, Nieda et al 2004, 
Motohashi et al 2006, Motohashi et al 2009). The basis of the most recent set of 
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clinical trials is the infusion of monocyte derived DC primed with a glycolipid, with 
or without an infusion of in vitro expanded iNKT cells. In order for immunotherapy 
to be successful, the DC must be fully matured and provide the correct signals to T 
cell populations. This has proven one of the biggest challenges in DC based 
immunotherapy (Banchereau and Steinman 1998, Figdor et al 2004). The interaction 
between the iNKT cell and the DC has been well established in murine models but 
only a few studies have examined these interactions in humans (Vincent et al 2002, 
Munz et al 2005, Yang et al 2005). We aimed to address this and our studies have in 
detail studied the reciprocal interactions between iNKT expanded from peripheral 
blood and monocyte derived DC. Our data shows that iNKT cells can induce 
maturation of DCs, the maturation was stronger with the addition of αGalCer. 
Maturation of the DC was determined by the upregulation of the maturation marker 
CD83, the co-stimulatory molecules CD40 and CD86, the adhesion molecule CD54, 
the antigen presentation molecule HLA-DR and the chemokine receptor CCR7 after 
24 hours co-culture. The maturation induced was comparable to maturation induced 
by the TLR agonists LPS and poly I:C, which have been previously described 
(Rescigno et al 1998, De Jong et al 2002). This data shows that iNKT can 
pheotypically mature human DCs, this has been reported previously, but our studies 
have more extensive in the investigation of the effects of iNKT cells on the 
expression of, co-stimulation molecules (CD40, CD80, CD86), adhesion molecules 
(CD54), antigen presentation molecules (HLA-DR) and chemokine receptors 
(CCR7) than the previous studies (Munz et al 2005, Yang et al 2005) We 
investigated the functional properties of iNKT cell matured DC. iNKT cell matured 
DC produced significant levels of IL-12 p70 and also produced levels of IL-10. The 
interaction in turn resulted in significant levels of IFN-γ produced by the iNKT cells. 
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The production of cytokine revealed a Th1 bias (IL-12/IFN-γ) this has been 
described previously by Vincent et al. Next we investigated if this bias resulted in a 
Th1 response by allogeneic naïve peripheral T cells. iNKT cell matured DC induced 
the proliferation of allogenic peripheral T cells again with comparable results to the 
proliferation induced by LPS. The proliferated T cells secreted large amounts of 
IFN-γ and small amounts of the Th2 cytokine IL-4. These results also show that 
iNKT have a strong adjuvant effect, resulting in a Th1 bias immune response and 
correlates with the clinical trial data which showed increases in IFN-γ producing 
cells after iNKT/DC immunotherapy. This body of work is also the most 
comprehensive study of the interactions between iNKT and monocyte derived DC 
and the subsequent T cell response. 
 
The natural ligand for iNKT cells remains to be elucidated but αGalCer a glycolipid 
isolated from marine sponge is currently the best known stimulator of iNKT cell in 
both mice and humans. With the disappointing clinical results observed with iNKT 
immunotherapy, many research teams aimed to produce a synthetic ligand with the 
hope of improving iNKT activation. In 2002 Miyamoto et al synthesised OCH, a 
αGalCer analogue, with truncated fatty acid chains. Stimulation of iNKT cell with 
OCH resulted in a Th2 bias, and the prevention of encephalomyelitis in mice. In 
other murine models OCH provided protection against other Th1 driven autoimmune 
disease such as collagen induced arthritis (Chiba et al 2004), insulitis and diabetes 
(Mizuno 2004 et al).  In 2003 a Th1 biased αGalCer analogue was reported by 
Schmieg and colleagues. α-C-GalCer had a C-glycoside as opposed to the O-
glycoside found in αGalCer. Stimulation of iNKT cells with α-C-GalCer resulted in 
a Th1 biased ratio of cytokine and 1000 fold increase in anti-malarial activity and 
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100 fold increase in anti-tumour activity compared to αGalCer (Schmieg et al 2003). 
The same group are currently investigating the use of α-C-GalCer as an adjuvant in a 
attenuated live influenza vaccine (Kopecky-Bromberg et al 2009). With the potential 
of analogues for immunotherapy reported, we tested the biological activity of several 
novel αGalCer analogues. Of the 6 tested only one, α-S-GalCer, stimulated iNKT 
cell lines. The ability of α-S-GalCer to induce cytokine production by human iNKT 
cells was tested in the CD1d transfected C1R assay described previously. α-S-
GalCer induced the production of both IFN-γ and IL-4 by iNKT cell lines, however 
exhibited a greater Th1:Th2 ratio compared to αGalCer. α-S-GalCer induced greater 
iNKT cell lyses of both CD1d transfected C1R targets and CD1d negative K562 
cells compared to αGalCer. In keeping with the iNKT based immunotherapy 
investigation, we investigated the ability of α-S-GalCer stimulated iNKT cells to 
mature monocyte derived DC and their ability to subsequently elicit a T cell 
response. α-S-GalCer stimulated iNKT cells induced DC maturation and the 
production of high levels of IL-12 but low levels of IL-10. The α-S-GalCer 
stimulated iNKT cell matured DC also proliferated allogeneic T cells and stimulated 
the same to produce high levels of IFN-γ and low levels of IL-4. Previously Blauvelt 
et al investigated the biological activity of their own α-S-GalCer. In contrast to our 
findings, the authors reported the α-S-GalCer had no biological activity. This study 
was in conducted in mice and examined proliferation of iNKT cells and production 
of cytokine, both in vivo and in vitro. The activity was not examined in a human 
system. In collaboration with Prof P Fallon (TCD) we repeated these murine studies 
and found that our α-S-GalCer also failed to induce iNKT activation in mice. The 
authors proposed that α-S-GalCer did not bind the CD1 molecule. To note, α-S-
GalCer was first synthesised and described by Xhu et al, the method to synthesize 
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this α-S-GalCer varies from the method used by Blauvelt and colleagues (Dere et al 
2008, Blauvent et al 2008). The data from the human studies using α-S-GalCer 
shows it stimulates iNKT cells in vitro with a Th1 bias. The conflicting murine data 
suggest that further investigations into both the stimulatory and structural properties 
of α-S-GalCer are necessary. However the success of tailoring iNKT responses via 
novel analogues provides strong evidence that iNKT cell therapy could be ultilized 
as specific immunotherapy adjuvants in the fight against human disease in the future. 
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